



6th Schizophrenia International Research Society Conference

***Integrated Prevention and Treatment:
Shifting the Way We Think***

**FLORENCE, ITALY
4 – 8 APRIL 2018**





6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Opening Letter

Dear Attendees,

It is our great pleasure to welcome you to the 6th Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The fifth congress in 2016 was a major success for the field attracting more than 1800 attendees from 52 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia.

The focus of the 6th Biennial Conference is 'Integrated Prevention and Treatment: Shifting the Way We Think'. Under the outstanding leadership of Program Committee Chairs, Paola Dazzan, Bitá Moghaddam, and Eóin Killackey, we have an exciting scientific program planned for this year. The Program Committee selected thirty-five outstanding symposia sessions out of 103 submissions. They also put together a Pharmaceutical Pipeline session and selected ninety-six superior oral presentations to be presented on Tuesday from more than 650 abstracts submitted. Plan to visit the poster sessions during lunch on Thursday, Friday, and Saturday to see the over 1,000 posters.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers

President: Patrick McGorry, FRCP, M.D., Ph.D.

President-Elect: Lynn DeLisi, M.D.

Past President: René S. Kahn, M.D., Ph.D.

Secretary: Til Wykes, DBE, MPhil, Ph.D.

Treasurer: Shitij Kapur, M.D., Ph.D.

Program Committee Chair: Paola Dazzan, FRCPsych

Program Committee Co-Chair: Bitá Moghaddam, Ph.D.

Program Committee Co-Chair: Eoin Killackey, Ph.D.

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



SAVE THE DATE!



The Schizophrenia International Society's (SIRS) Board of Directors enthusiastically announces that beginning in 2019 they will host annual meetings alternating between Europe on even years and North America on the odd years. The society is working to create a cohesive balance incorporating key elements from both the legacy of the former International Society on Schizophrenia Research (ICOSR) and SIRS. SIRS is excited to bring together scientists from around the world to further its mission to exchange the latest advances in biological and psychosocial research in schizophrenia. It is hoped that moving to an annual meeting will facilitate further progress toward developing international collaborations for the discovery of causes and better treatments for schizophrenia and related disorders.

We hope that moving to an annual meeting will continue to develop international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders.

The 2019 Conference will be held at the Hyatt Regency in Orlando, Florida from 10-14 March 2019. The Program Committee is being led by Professors Paola Dazzan and Raquel Gur.

Registration and abstract submissions will open in mid-July 2018. For more information, please refer to Schizophreniaresearchsociety.org under the 2019 conference tab.

We look forward to seeing you in Orlando in 2019!

For any questions, please contact the SIRS Executive Office at info@schizophreniaconference.org.



Table of Contents

General Information	Page 2	
Wednesday, 4 April	Page 22	
Thursday, 5 April	Page 24	
Friday, 6 April	Page 34	
Saturday, 7 April	Page 44	
Sunday, 8 April	Page 62	
Thursday Posters	Page 68	
Friday Posters	Page 95	
Saturday Posters	Page 122	
Index of Presenters and Authors	Page 149	
Notes	Page 159	



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Disclosures

Disclosures for 2018 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research society appreciates the generous support of the Society from our 2017-2018 Supporting Corporations.

Gold



Silver



Other Sponsorships



Educational Grants:

The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

- Alkermes
- Sunovion

The Junior Travel Award Fellowship Program is partially sponsored by a grant from the U.S. National Institute Drug Abuse to Harvard Medical School (Lynn DeLisi, PI).



General Information

General Information

OFFICERS:



Patrick McGorry
FRCP, M.D., Ph.D.
President




Lynn DeLisi
M.D.
President-Elect



René Kahn
M.D., Ph.D.
Past-President



Til Wykes
Ph.D.
Secretary



Shitij Kapur
M.D., Ph.D.
Treasurer

BOARD OF DIRECTORS (2016-2018):

Anissa Abi-Dargham	USA
Geraldo Busatto	Brazil
Tyrone Cannon	USA
Eric Chen	China
Paola Dazzan	United Kingdom
Silvana Galderisi	Italy
Michael Green	USA
Stephan Heckers	USA
Richard Keefe	USA
Patrick McGorry	Australia
Iris Sommer	The Netherlands
Dawn Velligan	USA
Sophia Vinogradov	USA

INCOMING OFFICERS:

Lynn DeLisi	USA, <i>President</i>
Til Wykes	United Kingdom, <i>President-Elect</i>
Paola Dazzan	United Kingdom, <i>Secretary</i>
Robert Buchanan	USA, <i>Treasurer</i>
Patrick McGorry	Australia, <i>Past-President</i>

INCOMING BOARD OF DIRECTORS (2018-2022):

Peter Buckley	USA
Kim Do	Switzerland
Peter Failkai	Germany
Robin Murray	United Kingdom
Merete Nordentoft	Denmark
Sohee Park	USA
Susan Rossell	Australia
Nina Schooler	USA
Mark Weiser	Israel



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

INTERNATIONAL ADVISORY COUNCIL

Deanna Barch	USA	Paulo Menezes	Brazil
Alessandro Bertolino	Italy	Preben Mortensen	Denmark
Robert Buchanan	USA	Patricio O'Donnell	USA
Mary Cannon	Ireland	Christos Pantelis	Australia
David Castle	Australia	Emmanuelle Peters	United Kingdom
Christoph Correll	USA	Anita Riecher-Rössler	Switzerland
Anthony David	United Kingdom	Susan Rossell	Australia
Paola Dazzan	United Kingdom	Sibylle Schwab	Germany
Lynn DeLisi	USA	Iris Sommer	The Netherlands
Smita Deshpande	India	Dawn Velligan	USA
Wolfgang Fleishhacker	Austria	Antonio Vita	Italy
Kyung Sue Hong	Republic of Korea	Mark Weiser	USA
James Kennedy	Canada	Stephen Wood	United Kingdom
Matcheri Keshavan	USA	Alison Yung	United Kingdom
Shon Lewis	United Kingdom		

2018 Meetings Committees

EDUCATION COMMITTEE

Chair: **Mario Alvarez-Jimenez**, Australia

Co-Chair: **Giovanni de Girolamo**, Italy

Barnaby Nelson	Australia	Robin Emsley	South Africa
Douglas Noordsy	USA	Si Tianmei	China
Elisabetta Del Re	USA	Thomas Raedler	Canada
Paola Dazzan	United Kingdom		

AWARDS COMMITTEE

Chair: **Larry Seidman**, USA

Co-Chair: **Celso Arango**, Spain

Rodrigo Bressan	Brazil	Shon Lewis	United Kingdom
Katherine Burdick	USA	Philip McGuire	United Kingdom
Cameron Carter	USA	Vera Morgan	Australia
Paola Dazzan	United Kingdom	Stefan Smesny	Germany
Sonia Dollfus	France	Aristotle Voineskos	Canada
Peter Falkai	Germany	Stephen Wood	Australia
Eoin Killackey	Australia	Robert Zipursky	Canada

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



2018 PROGRAM COMMITTEE

Program Chair: **Paola Dazzan**, United Kingdom

Program Co-Chair: **Eoin Killackey**, Australia

Program Co-Chair: **Bitá Moghaddam**, USA

Jean Addington	Canada	Patrick McGorry	Australia
Celso Arango	Spain	Ingrid Melle	Norway
Christopher Bowie	Canada	Andreas Meyer-Lindenberg	Germany
Rodrigo Bressan	Brazil	Masafumi Mizuno	Japan
Katherine Burdick	USA	Vera Morgan	Australia
Mary Cannon	Ireland	Preben Mortensen	Denmark
Tyrone Cannon	USA	Inez Myin-Germeys	Belgium
Cameron Carter	USA	Barnaby Nelson	Australia
Raymond Chan	China	Igor Nenadic	Germany
Eric Chen	China	Dorien Nieman	The Netherlands
Philippe Conus	Switzerland	Patricio O'Donnell	USA
Christoph Correll	USA	Christos Pantelis	Australia
Deepak D'Souza	USA	Maxine Patel	United Kingdom
Giovanni de Girolamo	Italy	Diana Perkins	USA
Lynn DeLisi	USA	Anita Riecher-Rössler	Switzerland
Sonia Dollfus	France	Stephan Ruhrmann	Germany
Robin Emsley	South Africa	Iris Sommer	The Netherlands
Anthony Grace	USA	Vinod Srihari	USA
Alex Hofer	Austria	Rangaswamy Thara	India
Oliver Howes	United Kingdom	Neeltje Van Haren	The Netherlands
Jan Olav Johannessen	Norway	Jim van Os	The Netherlands
Peter Jones	United Kingdom	Wim Veling	The Netherlands
René Kahn	USA	Dawn Velligan	USA
Shitij Kapur	Australia	Aristotle Voineskos	Canada
Sung-Wan Kim	South Korea	Thomas Weickert	Australia
Nikolaos Koutsouleris	Germany	Stephen Wood	Australia
Marie-Odile Krebs	France	Alexander Wunderink	The Netherlands
Mario Maj	Italy	Alison Yung	United Kingdom
Ashok Malla	Canada	Robert Zipursky	Canada



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Continuing Medical Education



International CME Accreditation

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credits™*. ACCME / *AMA PRA Category 1 Credits™* carry reciprocity with EACCME member countries and most international licensing bodies for physicians, with some exceptions. Physicians should check with their country/board for eligibility.

Physicians

Accreditation Statement - In support of improving patient care, this activity has been planned and implemented by Amedco and the Schizophrenia International Research Society. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Statement - Amedco designates this live activity for a maximum of 24 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To obtain credit, registered participants must complete an online evaluation at the conclusion of the meeting. The evaluation may be completed at www.SchizophreniaConference.org.

Physicians

Amedco certifies that the attendee named above has participated in the live activity titled 6th Biennial Schizophrenia International Research Society Conference in Florence, Italy on April 4 – 8, 2018 and is awarded the number of *AMA PRA Category 1 Credit(s)™* listed above.

COURSE OBJECTIVES:

After participating in the CME Activity, Clinicians should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia
- The Status of genetic findings, and how they can be incorporated into strategies for managing patients with schizophrenia
- The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
- The implications of basic neuroscience findings for managing patients with schizophrenia



After participating in the CME Activity, Researchers should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia
- Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
- Differences in schizophrenia research across diverse cultures and geographic areas
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
- Methods to advance the clinical application of genetic research in schizophrenia

DISCLOSURES

Disclosures for 2018 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

CONFERENCE EVALUATION:

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME) credit for the meeting **are required** to complete the evaluation. This form is available online only. Beginning 8 April, you may complete the evaluation in the Computer Center or on-line at www.SchizophreniaConference.org. All evaluations must be completed by Tuesday, 8 May 2018.

VIDEOTAPING SESSIONS:

Attendees may **not** videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

REGISTRATION

Registration for the 6th Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

DATE

Wednesday, 4 April
Thursday, 5 April
Friday, 6 April
Saturday, 7 April
Sunday, 8 April

TIME

11:00 AM – 7:30 PM
8:00 AM – 6:30 PM
8:00 AM – 7:00 PM
8:00 AM – 8:00 PM
8:00 AM – 12:00 PM



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

REGISTRATION TYPES:

Delegate: Scientific Attendee

Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student's immediate supervisor verifying his/her student status and relevant field will be required for registration.

WELCOME RECEPTION TICKET:

The €60 fee includes welcome reception.

REGISTRATION FEES:

Category	Up to 1 March 2018	2 March or later
SIRS 2017 and 2018 Member	450.00€	500.00€
SIRS 2018 New Member	490.00€	540.00€
SIRS 2017 and 2018 Student Member	170.00€	220.00€
SIRS 2018 New Student Member	210.00€	260.00€
Non-Member Delegate	700.00€	750.00€
Non-Member Student	250.00€	300.00€
Welcome Reception Ticket	60.00€	60.00€

REGISTRATION TIME FRAMES:

Regular: Register June 2017 – 2 March 2018

Late: Register 3 March 2018 – onsite

COMPUTER ACCESS

Complimentary wireless internet is available in the conference center. **To access the wireless internet, input "SIRS2018" as the username and "SIRS2018" as the password.** Conference attendees may also use the Computer Center located in the Limonaia Building.

The Computer Center is provided this year for the convenience of meeting attendees who wish not to bring a laptop. The Computer Center will be open the following hours:

Date	Time
Wednesday, 4 April	1:00 PM – 7:00 PM
Thursday, 5 April	8:00 AM – 6:30 PM
Friday, 6 April	8:00 AM – 6:30 PM
Saturday, 7 April	8:00 AM – 6:30 PM
Sunday, 8 April	8:00 AM – 12:00 PM



SPEAKER READY ROOM:

A speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

**Speaker Ready Room
Sala 103**

Date	Time
Wednesday, 4 April	1:00 PM – 7:00 PM
Thursday, 5 April	8:00 AM – 7:00 PM
Friday, 6 April	8:00 AM – 7:00 PM
Saturday, 7 April	8:00 AM – 7:00 PM
Sunday, 8 April	8:00 AM – 12:00 PM

ABSTRACTS:

Abstracts for all presentations are available online at www.SchizophreniaConference.org.

Abstracts will be published electronically by *Schizophrenia Research* and will be available as an electronic flipbook and as a PDF document.

Awards

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society’s Honoric Award Winners.

SIRS LIFETIME ACHIEVEMENT AWARD



Patrick McGorry, FRCP, M.D., Ph.D., President

Professor Patrick McGorry is the Executive Director of Orygen, Professor of Youth Mental Health at The University of Melbourne, and a Director of the Board of the National Youth Mental Health Foundation (headspace). He is a world-leading researcher in the area of early psychosis and youth mental health, and has a strong interest in promoting the mental health of the homeless, refugees and asylum seekers.

His work has played a critical role in the development of safe, effective treatments and innovative research into the needs of young people with emerging mental disorders, notably psychotic and severe mood disorders. He has also played a major part in the transformational reform of mental health services to better serve the needs of vulnerable young people.

continued on next page



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Patrick McGorry, FRCP, M.D., Ph.D. (continued)

Professor McGorry was a key architect of the headspace model and has been successful in advocating with colleagues for its national expansion. He has successfully advocated for the establishment of a national early psychosis programme based on the Early Psychosis Prevention and Intervention Centre model. He is frequently asked to advise on youth mental health policy both nationally and internationally.

Professor McGorry has published extensively in the specialist literature, and serves as Editor-in-Chief of Early Intervention in Psychiatry. He is a Fellow of the Australian Academy of Science, Academy of the Social Sciences in Australia, the current President of the Society for Mental Health Research, and the President of the Schizophrenia International Research Society.

OUTSTANDING BASIC RESEARCH

Kim Do, D. Sci.

Professor Kim Q. Do is Director of the Center for Psychiatric Neuroscience (Department of Psychiatry, Lausanne University Hospital, Switzerland) and head of the Unit for Research in Schizophrenia (URS). Her major interest lies in bridging basic neuroscience with problems of clinical psychiatry.

She started her career in basic research in chemistry, molecular biology (Federal School of Technology Zurich, ETHZ, Switzerland) and neurobiology (Brain Research Institute, Zurich University), where she highlighted the important role of neuro-glial interaction in excitatory amino acids and nitric oxide transmission.

In 1999, she moved towards “bench to bed” research at the Center for Psychiatric Neuroscience (Department of Psychiatry, Lausanne University Hospital). She set up a translational research program aimed at a better understanding of the causes and mechanisms leading to schizophrenia phenotypes in order to develop markers for early diagnosis, new drug targets as well as preventive and therapeutic measures. She established close collaboration with psychiatrists and developed a multidisciplinary team of excellent young researchers. In addition, she achieved to promote and mentor a new generation of psychiatrists with combined clinical and neuroscientific expertise.

Building on an innovative hypothesis, her work pioneered the involvement of a pathophysiological “hub” in which oxidative stress/redox dysregulation interacts with NMDAR hypofunction, neuroinflammation and dopamine imbalance, leading to the impairment of neural connectivity and synchronization, and to cognitive deficits as observed in patients. Using various experimental models relevant to schizophrenia and autism, her group demonstrated that oxidative stress during brain development impairs myelin formation, and selectively and permanently affects prefrontal parvalbumine GABA interneurons.

Based on these relevant neurobiological data, she spearheaded a clinical study in which a precursor of GSH, N-acetylcysteine (NAC), was administered to chronic patients. This double blind, placebo controlled add-on clinical trial with NAC showed a net improvement in negative symptoms, in auditory evoked





potentials (mismatch negativity), neural synchronization and produced no side effects. Following this exciting proof of concept, she initiated a clinical trial with young first-episode patients, revealing that NAC increased brain GSH levels, improved neurocognition, fornix white matter integrity, and functional connectivity. More importantly, in a subgroup of patients with a high blood oxidative marker, NAC improved positive symptoms, in parallel with changes in the peripheral redox status. Her translational research thus paves the way for promising biomarker guided treatments and prevention.

Her lab is currently investigating biomarkers for early detection, and developing innovative therapeutics to impact the emergence of mental disorders. As Director of the Center for Psychiatric Neuroscience and in addition to her research activities, Professor Kim Q. Do also works on professional education and public outreach towards better care and cure of major psychiatric disorders. Professor Do's research has been supported by the Swiss National Science Foundation, the Human Frontier Science Program, as well as various institutions and foundations of the private sector in Switzerland and abroad. She received the *NARSAD Independent Investigator Award* from the Brain & Behavior Research Foundation (USA) in 2006, and the *NARSAD Distinguished Investigator Award* in 2010.

OUTSTANDING CLINICAL/COMMUNITY RESEARCH

Ashok Malla, FRCPC



Dr. Ashok Malla is a Professor of Psychiatry at McGill University, with an adjunct appointment in Epidemiology and Biostatistics. He holds a Tier 1 Canada Research Chair in Early Psychosis and Early Intervention in Youth Mental Health and is a recipient of an honorary doctorate from l'Université de Montréal (2015). He has founded two leading Prevention and Early intervention Programs for Psychoses (PEPP) in Montréal and London, Ontario and, more recently the Canadian Consortium of Early Intervention Programs for Psychosis. He has led many clinical research projects investigating the neurobiological, psychosocial, and cross-cultural aspects of multidimensional outcomes in early phase of psychotic disorders and early intervention. His research work in early intervention in psychosis has been centred around the objective of improving outcome for young patients with psychosis.

He is currently leading two global mental health projects: understanding differences in outcome in first episode psychosis in India and Canada, and application of a low-cost lay health worker model of mental health service delivery in rural parts of conflict ridden Kashmir, India. He now leads a \$25M, national research project on transformation of youth mental health services (ACCESS OPEN MINDS Canada), under the Strategy for Patient Oriented Research (SPOR) of the Canadian Institutes of Health Research (CIHR), informed by his previous work in early psychosis. He has published more than 325 peer-reviewed articles, held numerous peer-reviewed research grants, supervised many graduate and post-doctoral students, residents and fellows, has been an advisor on program development and research in early intervention in psychotic disorders in several countries. He has worked tirelessly as an advocate for high quality care for the seriously mentally ill. He is also an editor of *Social Psychiatry and Psychiatric Epidemiology*.



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

RISING STAR



Lena Palaniyappan, M.D.

Dr. Palaniyappan is a psychiatrist with a training background in psychology, neuroimaging and systems approach in neuroscience. He is Director of The Prevention and Early Intervention Program for Psychosis in London, Ontario and Associate Professor at the Departments of Psychiatry and Medical Biophysics at the University of Western Ontario. He is also a clinician scientist at Robarts Research Institute and Lawson Health Research Institute in London, Ontario, where he leads Neuroimaging in Mental Illness (NIMI) research group.

He trained as a physician in India, psychiatrist in the UK and a currently being trained as a parent of 2 toddlers in Canada!

The major emphasis of his current work, which originally began in Nottingham in collaboration with Prof. Peter Liddle, is on applying brain imaging to investigate symptom burden, treatment response and prognostic accuracy both in psychotic and affective disorders. The clinical goal of this approach is to understand the pathways that lead to poor long-term outcome in certain individuals with serious mental disorders. To this end, his group concentrates on understanding the intrinsically organized, large-scale brain networks in psychosis. In recent times, this has contributed to developing and testing a specific hypothesis in relation to the dysfunction of 'salience' network in psychosis, expounding the role of gyrification as a marker of prognosis and the synthesizing the concept of progressive post-psychotic reorganization of brain structure in schizophrenia.

His group's work has been supported by the Canadian Institute of Health Research (Foundation Grant, Project Grant), Wellcome Trust, Medical Research Council (UK) and European Commission (7th Framework) and several local and regional charities that support research for patient benefit.



POSTER AWARDS

npj Schizophrenia and *Schizophrenia Bulletin* will award poster prizes during the Closing Session on Sunday, 8 April at 9:30 AM. The SIRS Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

The *Schizophrenia Research Founding Editors Award* will recognize the best paper by both a Young Investigator and by a Senior Investigator. Each will be determined by the journal's Editors.

CONGRATULATIONS TO THE 2018 TRAVEL FELLOWS:

Ozge Akgul	Turkey	Pedro Pan	Brazil
Dana Allswede	USA	Baptiste Pignon	France
Linda Antonucci	Italy	Toby Pillinger	United Kingdom
Marieke Begemann	The Netherlands	Eric Plitman	Canada
Hengyi Cao	USA	Diego Quattrone	United Kingdom
Fernando Caravaggio	Canada	Katya Rubinstein	Israel
Radhika Chadha	USA	Jose Rubio	USA
Adam Chekroud	USA	Cristina Scarpazza	United Kingdom
Leticia Czepielewski	Brazil	Frederika Scheffler	South Africa
Maria Ferrara	USA	André Schmidt	Switzerland
Gagan Fervaha	Canada	Kyra-Verena Sendt	United Kingdom
Joseph Firth	Australia	Esther Setién-Suero	Spain
Yoji Hirano	Japan	Mamidipalli Spoorthy	India
Philipp Homan	Switzerland	Jean Stafford	United Kingdom
Yusuke Iwata	Canada	Branden Stansley	USA
Sameer Jauhar	United Kingdom	Katharina Stegmayer	Switzerland
Hannah Jones	United Kingdom	Wolfgang Strube	Germany
Pernille Kølbaek	Denmark	Karuna Subramaniam	USA
Zhi Li	China	Eric Tan	Australia
Chenxing Liu	Australia	Huai-Hsuan Tseng	Taiwan
Carolina Makowski	Canada	Gianluca Ursini	USA
Paul Metzak	Canada	Bita Vahdani	Iran
Kim Minah	South Korea	Claudia Vingerhoets	The Netherlands
Natasza Orlov	United Kingdom	Samantha Yohn	USA

The **TRAVEL FELLOW AND MENTOR RECEPTION** will be held on Friday, 6 April from 5:45 PM – 6:45 PM on the 4th floor of the Affari Building (*Invitation Only*).



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

KEYNOTE LECTURE: ALASTAIR CAMPBELL



Wednesday, 4 April, 6:15 PM – 7:15 PM
Congressi Auditorium

Alastair Campbell is best known for his role as former British Prime Minister's Tony Blair's spokesman, press secretary and director of communications and strategy. He is involved in multiple mental health charities campaigning to break down the stigma and taboo of mental illness. He will provide a unique perspective on mental health during his

keynote lecture titled, *Changing the Lens on Mental Health*. He lives mainly in London, with his partner of 36 years, journalist and education campaigner Fiona Millar.

PLENARY SPEAKERS



William T. Carpenter, Jr., M.D.

*The Near Future for
Schizophrenia (Psychosis)
Research*



David McDaid

*Investing in Recovery – An
Economic as well as Moral
Imperative*



John F. Cryan, Ph.D.

*The Gut Microbiome:
A Key Regulator of
Neurodevelopment and
Behaviour*



Asya Rolls, Ph.D.

*The Complex Interactions
Between Mind and Body:
It Takes a Brain to Control
Immunity*



Gail L. Daumit, M.D.

*Decreasing Cardiovascular
Risk in Persons with
Schizophrenia: Interventions
and Future Directions*



**Cynthia Shannon Weickert,
BA, MPhil, Ph.D.**

*On the Road to Curing
Schizophrenia*



John Krystal, M.D.

*Microcircuits, Macrocircuits,
and Cortical Dysfunction
in Schizophrenia: A
Computational and
Translational Neuroscience
Perspective*

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



PLENARY SESSIONS

Thursday, 5 April

Congressi Auditorium

8:30 AM – 9:30 AM

Microcircuits, Macrocircuits, and Cortical Dysfunction in Schizophrenia: A Computational and Translational Neuroscience Perspective

John Krystal

2:00 PM – 3:00 PM

Decreasing Cardiovascular Risk in Persons with Schizophrenia: Interventions and Future Directions

Gail Daumit

Friday, 6 April

Congressi Auditorium

8:30 AM – 9:30 AM

On the Road to Curing Schizophrenia

Cynthia Shannon Weickert

2:00 PM – 3:00 PM

The Near Future for Schizophrenia (Psychosis) Research

William Carpenter

Saturday, 7 April

Congressi Auditorium

8:30 AM – 9:30 AM

The Complex Interactions between Mind and Body: It Takes a Brain to Control Immunity

Asya Rolls

2:00 PM – 3:00 PM

Investing in Recovery – An Economic as Well as Moral Imperative

David McDaid

Sunday, 8 April

Congressi Auditorium

8:30 AM – 9:30 AM

The Gut Microbiome: A Key Regulator of Neurodevelopment and Behaviour

John F. Cryan



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

SYMPOSIA SESSIONS

The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

Thursday, 5 April	10:00 AM – 12:00 PM 3:30 PM – 5:30 PM
Friday, 6 April	10:00 AM – 12:00 PM 3:30 PM – 5:30 PM
Saturday, 7 April	10:00 AM – 12:00 PM
Sunday, 8 April	10:00 AM – 12:00 PM

ORAL PRESENTATIONS

Two oral presentation sessions are scheduled on Saturday, 7 April from 3:15 PM – 5:15 PM and again from 5:30 PM – 7:30 PM. Within the concurrent sessions, there are 8 individual presentations. Oral sessions scheduled:

Biomarkers

Chair: Anthony Grace

Cognition

Chair: Susan Rossell

fMRI

Chair: Mette Nielsen

Genetics

Chair: Gianluca Ursini

Comorbidity

Chair: Fiona Gaughran

Neuroimaging

Chair: Elisabetta Del Re

Pharmacology

Chair: Stefan Leucht

Outcome

Chair: Eric Chen

Prediction

Chair: Alexis Cullen

Risk Factors

Chair: Jessica Hartmann

Services and Other Interventions

Chair: Shon Lewis

Socio-economic/Environment

Chair: Merete Nordentoft



POSTERS

Three poster sessions have been scheduled. Presenters should put their poster up by 9:00 AM and remove the poster by 3:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia. Lunch will be served each day with the poster session. Poster viewing will be open until 3:00 PM. E-Posters are available for viewing online at www.SchizophreniaConference.org.

Thursday, 5 April	Poster Session I 12:00 PM – 2:00 PM
Friday, 6 April	Poster Session II 12:00 PM – 2:00 PM
Saturday, 7 April	Poster Session III 12:00 PM – 2:00 PM

REFRESHMENT BREAKS:

All registered individuals are invited. Coffee and light pastries are available Thursday through Sunday mornings at 8:00 AM. The morning break will be located in the Passi Perduti, located outside the Auditorium.

Afternoon coffee/tea breaks will be available Thursday – Saturday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS:

Buffet lunch will be served Thursday through Saturday from 12:00 PM – 2:00 PM in the Cavaniglia during the poster sessions.




6th Schizophrenia International Research Society Conference


Integrated Prevention and Treatment: Shifting the Way We Think

General Information


Floor Plan



Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia. This is a short 3 to 5 minute walk from the Palazzo de Congressi.



Concurrent Symposia and Oral Presentations will be held on the Lower Level, Ground Level, First Level, Second Level of the Palazzo degli Affari.




The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Palazzo Congressi - Villa Vittoria AUDITORIUM




Keynote, Plenary Sessions and some Symposia and Oral Presentations will be held in the Auditorium.




Palazzo Congressi - Villa Vittoria

First Floor



General Information

Second Floor



The Speaker Ready Room (Sala 103) and other small meeting rooms and committee meetings will be in the Villa Vittoria Building on the 1st Floor and 2nd Floor. The Villa Vittoria building is connected to the Auditorium.

The Sala Verde room is on the 2nd floor of the Villa Vittoria building.

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%; background-color: #8B4513; color: white; padding: 5px;">6:00 PM 7:15 PM</div> <div style="width: 85%; background-color: #E6C9A8; padding: 5px;">Opening and Keynote</div> </div>													
Passi Percluti	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%; background-color: #FF8C00; color: white; padding: 5px;">5:30 PM 6:00 PM</div> <div style="width: 85%; background-color: #E6C9A8; padding: 5px;">Coffee Break</div> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="width: 15%; background-color: #008080; color: white; padding: 5px;">7:15 PM 9:00 PM</div> <div style="width: 85%; background-color: #A8D8C9; padding: 5px;">Opening Reception</div> </div>													
Palazzo Affari Entrance	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%; background-color: #0056B3; color: white; padding: 5px;">11:00 AM 7:30 PM</div> <div style="width: 85%; background-color: #A8B8D8; padding: 5px;">Registration</div> </div>													
Sala 103	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%; background-color: #800080; color: white; padding: 5px;">1:00 PM 7:00 PM</div> <div style="width: 85%; background-color: #D8BFD8; padding: 5px;">Speaker Ready Room</div> </div>													
Limonaia	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%; background-color: #D2691E; color: white; padding: 5px;">1:00 PM 7:00 PM</div> <div style="width: 85%; background-color: #F5DEB3; padding: 5px;">Computer Center</div> </div>													

Legend:

-
 Keynote
-
 Special Session
-
 Speaker Ready
-
 Registration
-
 Computer Center
-
 Symposia
-
 Poster Session
-
 Plenary
-
 Oral Presentation
-
 Coffee Break

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



Wednesday, 4 April 2018

SIRS EXECUTIVE BOARD MEETING (INVITATION ONLY)

11:00 AM - 2:00 PM

Location: Congressi, Sala 101

REGISTRATION

11:00 AM - 7:30 PM

Location: Palazzo Entrance

SPEAKER READY ROOM

1:00 PM - 7:00 PM

Location: Congressi, Sala 103

COMPUTER CENTER

1:00 PM - 7:00 PM

Location: Limonaia Building

COFFEE BREAK

5:30 PM - 6:00 PM

Location: Congressi, Passi Perduti

CONFERENCE OPENING AND HONORIFIC AWARD CEREMONY

6:00 PM - 6:15 PM

Location: Congressi Auditorium

KEYNOTE SESSION

6:15 PM - 7:15 PM

KEYNOTE LECTURE: Alastair Campbell - Changing the Lens on Mental Health

Location: Congressi Auditorium

OPENING RECEPTION

7:15 PM - 9:00 PM

Location: Congressi, Passi Perduti

Wednesday 4 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM 12 PM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30 AM - 9:30 AM Microcircuits, Membrane Potential, and Cortical Destabilization in Schizophrenia...	9:30 AM - 10:00 AM Break	10:00 AM - 12:00 PM Pharmaceutical Pipeline	2:00 PM - 3:00 PM Depressing Risk Cardiac Risk in Parents With Schizophrenia...	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Violence in Schizophrenia: Prevalence, Measurement, Prediction and Prevention	5:45 PM - 6:45 PM SIRS Business Meeting						
Sala Verde			10:00 AM - 12:00 PM Innovative Approaches to Early Identification and Treatment: Using Mobile Health Technology to Improve Outcomes in Psychosis											
Palazzo Affari Ground Level			10:00 AM - 12:00 PM Retinal Functions Expressed in Retinal Imaging, Contrast Processing and Electrophysiology,...											
Palazzo Affari Lower Level			10:00 AM - 12:00 PM Excitation-Inhibition Imbalances in Schizophrenia: Mechanisms and Interventions											
Palazzo Affari 1st Level			10:00 AM - 12:00 PM Fact or Artifact? Benefits and Limitations of Advanced Neuroimaging Methods for Psychosis											
Palazzo Affari 2nd Level			10:00 AM - 12:00 PM Rethinking the Taxonomy, Course, and Outcome of Psychoses,...											
Cavaniglia														
Palazzo Affari Entrance														
Sala 103														
Limonaia														
Passi Perduti														

Legend: [Keynote](#) [Special Session](#) [Speaker Ready](#) [Registration](#) [Computer Center](#) [Symposia](#) [Poster Session](#) [Plenary](#) [Oral Presentation](#) [Coffee Break](#)



Thursday, 5 April 2018

REGISTRATION

8:00 AM - 6:30 PM

Location: Palazzo Entrance

PLENARY SESSION: MICROCIRCUITS, MACROCIRCUITS, AND CORTICAL DYSFUNCTION IN SCHIZOPHRENIA: A COMPUTATIONAL AND TRANSLATIONAL NEUROSCIENCE PERSPECTIVE

8:30 AM - 9:30 AM

Location: Congressi Auditorium

John Krystal
Yale University School of Medicine, United States

Abstract: Computational neuroscience may be a critical component of the effort to understand how cortical micro- and macro-circuits support behavior and express the symptoms of neuropsychiatric disorders. This presentation will present an update on an ongoing interdisciplinary effort to understand the role of compromised glutamate synaptic signaling, particularly related to the NMDA glutamate receptor, for the pathophysiology of schizophrenia. This presentation will draw on studies in animal models, healthy humans, and schizophrenia patients. It will draw parallels between the effects of the NMDA receptor antagonist, ketamine, and working memory impairment and abnormalities in cortical functional connectivity in schizophrenia. In so doing, it will highlight examples where computational approaches have affirmed hypotheses arising from experimental work or contributed new predictions that could be tested experimentally. Lastly, it will illustrate a prediction about novel therapeutics for schizophrenia that are embedded in an emerging developmental model for this disorder.

BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti

Thursday 5 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

CONCURRENT SYMPOSIA

10:00 AM - 12:00 PM

PHARMACEUTICAL PIPELINE

Location: Congressi Auditorium

- 10:00 AM** *MIN-101 a sigma2/5HT2 Compound for the Treatment of Negative Symptoms in Schizophrenia*
Michael Davidson
- 10:40 AM** *Using Imaging and Behavioral Methods Probing Reward Functions as Tools for Decision Making in a Proof-Of-Mechanism Study of the PDE10 Inhibitor RG7203 in Patients with Schizophrenia and Negative Symptoms*
Daniel Umbricht
- 11:20 AM** *SEP-363856, a Candidate Antipsychotic and Antidepressant Compound with a Novel Non-D2 Mechanism of Action*
Kenneth Koblan

INNOVATIVE APPROACHES TO EARLY IDENTIFICATION AND TREATMENT: USING MOBILE HEALTH TECHNOLOGY TO IMPROVE OUTCOMES IN PSYCHOSIS

Location: Congressi, Sala Verde

Chair: Laura Tully

- 10:00 AM** *Enhancing Early Psychosis Treatment Using Smartphone Technology: Integration of a Mobile Health Platform in Four Early Psychosis Programs*
Laura Tully
- 10:25 AM** *A Technology-Enhanced Intervention to Reduce the Duration of Untreated Psychosis Through Rapid Identification & Engagement*
Tara Niendam
- 10:50 AM** *Enhancing Social Functioning and Long-Term Recovery in Young People With First Episode Psychosis (FEP) and Young People at Ultra High Risk (UHR) for Psychosis: A Novel Online Social Therapy Approach*
Mario Alvarez-Jimenez
- 11:15 AM** *Internet-Based Interventions for Bipolar Disorder*
Diego Hidalgo-Mazzei

Discussant: Chantel Garrett



RETINAL FUNCTIONS EXPRESSED IN RETINAL IMAGING, CONTRAST PROCESSING AND ELECTRORETINOGRAPHY MAY DECRYPT EARLY RISK MECHANISMS AND PATHOPHYSIOLOGY OF SCHIZOPHRENIA AND MOOD DISORDERS AND ACCELERATE TRANSLATION TO THE CLINIC

Location: Affari, Ground Level

Chair: Michel Maziade

- 10:00 AM** *Electroretinographic Anomalies in Schizophrenia and Their Relationships With Retinal Structure, Visual Functions, Clinical Symptoms, and Medical Comorbidities*
Steven Silverstein
- 10:25 AM** *Electroretinographic Anomalies Seen in Patients Affected by Schizophrenia or Bipolar Disorder are Detectable Early in Children Born to an Affected Parent: Implications for the Staging of Risk Status in Childhood-Adolescence*
Michel Maziade
- 10:50 AM** *Evaluating the Neurobiological Correlates and Impact of Treatment on Cognitive Dysfunction in ADHD and Schizophrenia by Means of the Pattern Electroretinogram*
Emanuel Bubl
- 11:15 AM** *Phenotypic and Genetic Associations Between Schizophrenia and Retinal Vessel Diameter*
Madeline Meier

Discussant: Anne Giersch

EXCITATION-INHIBITION IMBALANCES IN SCHIZOPHRENIA: MECHANISMS AND INTERVENTIONS

Location: Affari, Lower Level

Chair: Lawrence Kegeles

- 10:00 AM** *Enhanced Parvalbumin Network Activity Prolongs Critical Period Plasticity*
Hensch Takao
- 10:25 AM** *Parvalbumin Interneuron Impairment Induced by Oxidative Stress as a Common Pathological Mechanism in Animal Models of Schizophrenia*
Jan Harry Cabungcal
- 10:50 AM** *Disturbances in Neural Oscillations, Glutamate, and GABA: Effects of Ketamine and Comparison to Schizophrenia*
Lawrence Kegeles
- 11:15 AM** *Neural Oscillations and Excitation/Inhibition Balance in Schizophrenia: A Developmental Perspective*
Peter Uhlhaas

Discussant: Kim Do



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

FACT OR ARTIFACT? BENEFITS AND LIMITATIONS OF ADVANCED NEUROIMAGING METHODS FOR PSYCHOSIS

Location: Affari, First Level

Chair: Ofer Pasternak

10:00 AM *Study of Altered Neuroimmunity in Psychosis Using PET-Based Imaging of the Translocator Protein 18 KDa: Promises, Pitfalls, and Future Directions*
Jennifer Coughlin

10:25 AM *Microstructural Imaging With Advanced Diffusion MRI Methods – What is Gained and What is Lost?*
Ofer Pasternak

10:50 AM *EEG as a Tool for Psychosis Research: Challenges, Pitfalls and New Opportunities*
Christoph Mulert

11:15 AM *Brain Functional Connectomics Based on Resting State fMRI: From Nodes to Networks*
Juan Zhou

Discussant: Christos Pantelis

RETHINKING THE TAXONOMY, COURSE, AND OUTCOME OF PSYCHOSES: DIMENSIONAL, LATENT TRAJECTORY, AND TRANSDIAGNOSTIC APPROACHES

Location: Affari, Second Level

Chair: William Carpenter

Co-Chair: Peter Jones

10:00 AM *Dimensions of Psychosis and Their Trajectories During Two Decades After First Hospitalization*
Roman Kotov

10:25 AM *Rethinking the Course of Psychotic Disorders: Identifying Latent Trajectories*
Craig Morgan

10:50 AM *Evidence on a Transdiagnostic Psychosis Spectrum of Schizophrenia, Schizoaffective and Psychotic Bipolar Disorder in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)*
Ulrich Reininghaus

11:15 AM *Biological and Epidemiological Examination of Transdiagnostic and Specific Symptom Dimensions at Psychosis Onset: Findings From the EUGEI Study*

★ *Diego Quattrone*

Discussant: Robin Murray

★ – Travel Awardee

Thursday 5 April



POSTER SESSION I / LUNCH

12:00 PM – 2:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session.

Please see page 68 for a complete listing of posters.

PLENARY SESSION: DECREASING CARDIOVASCULAR RISK IN PERSONS WITH SCHIZOPHRENIA: INTERVENTIONS AND FUTURE DIRECTIONS

2:00 PM – 3:00 PM

Location: Congressi Auditorium

Gail Daumit

Johns Hopkins Medical Institutions, United States

Abstract: Persons with schizophrenia experience two to three times higher mortality than the overall population. This premature death is due in large part to cardiovascular disease and is potentially preventable. All cardiovascular risk factors are elevated in persons with schizophrenia. This presentation will describe the evidence for interventions to reduce cardiovascular risk factors in this vulnerable population, including obesity and tobacco smoking, and will describe models of integrated physical and mental health care. Ongoing research on interventions to decrease cardiovascular risk in schizophrenia will be presented, and future research needs will be discussed including implementation strategies to scale-up interventions to reduce cardiovascular disease risk in community settings.

COFFEE BREAK

3:00 PM – 3:30 PM

Location: Congressi, Passi Perduti

CONCURRENT SYMPOSIA

3:30 PM – 5:30 PM

VIOLENCE IN SCHIZOPHRENIA: PREVALENCE, MEASUREMENT, PREDICTION AND PREVENTION

Location: Congressi Auditorium

Chair: Mark Weiser

3:30 PM *Violent Crime in Schizophrenia and Bipolar Disorder: A Population-Based Study*

Mark Weiser

3:55 PM *Structured Risk Assessment in Psychiatry*

Seena Fazel

4:20 PM *Causes and Prevention of Aggression From Psychotic Inpatients*

Henk Nijman

4:45 PM *Follow-Up Treatment for Individuals With Serious Mental Illness Who Have Committed Major Crimes*

E. Fuller Torrey

Discussant: Robert Zipursky



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

ENDOCANNABINOID MODULATION OF DOPAMINE NEUROTRANSMISSION

Location: Congressi, Sala Verde

Chair: Michael Bloomfield

3:30 PM *Endocannabinoid Modulation of Dopamine Neurotransmission*
Fabricio Moreira

3:55 PM *Cannabidiol as an Antipsychotic Drug*
Francisco Guimaraes

4:20 PM *Effects of Cannabinoids on a Human Oligodendrocyte Culture: Implications for Schizophrenia*
Valéria Almeida

4:45 PM *Cannabinoid Receptor Gene Polymorphisms and Cognitive Performance in Patients With Schizophrenia*
Joao Salgado

Discussant: Marta Di Forti

THE MOLECULAR MECHANISMS OF SCHIZOPHRENIA FROM GLIAL CELLS PERSPECTIVE

Location: Affari, Ground Level

Chair: Sabina Berretta

3:30 PM *Stem Cell-Derived in Vitro Models for Depicting the Role of Glia in Schizophrenia From a Proteomic Perspective*
Juliana Nascimento

3:55 PM *Redox Dysregulation, Oligodendrocytes and White Matter Alterations in Schizophrenia*
Paul Klauser

4:20 PM *Glia-Extracellular Matrix Interactions in the Pathophysiology of Schizophrenia and Bipolar Disorder*
Sabina Berretta

4:45 PM *Diffusion Weighted Spectroscopy Studies of Cell-Type Specific Abnormalities in Schizophrenia*
Dost Ongur

Discussant: Johann Steiner

Thursday 5 April



AEROBIC EXERCISE TRAINING FOR INDIVIDUALS WITH SCHIZOPHRENIA: THE BROAD BENEFITS ACROSS PHYSICAL HEALTH, COGNITION, AND EVERYDAY FUNCTIONING AND PROMISING MECHANISMS OF ACTION

Location: Affari, Lower Level

Chair: Keith Nuechterlein

3:30 PM *Effect of Interval Training on Metabolic Risk Factors in Overweight Individuals With Psychosis: A Randomized Controlled Trial*
Amal Abdel-Baki

3:55 PM *The Impact of Aerobic Exercise on Cognitive Functioning and Biomarkers of Cognitive Change in Individuals With Schizophrenia*
David Kimhy

4:20 PM *Clinical and Neurobiological Effects of a Continuous Aerobic Endurance Training in Multi-Episode Schizophrenia Patients*
Berend Malchow

4:45 PM *Aerobic Exercise Enhances Cognitive Training Effects in First Episode Schizophrenia: Cognitive and Functional Gains and Promising Biological Mechanisms of Action*
Keith Nuechterlein

Discussant: Peter Falkai

DOES BIOLOGY READ THE DSM? TRANSDIAGNOSTIC FINDINGS IN PSYCHOSIS AND IMPLICATIONS FOR TREATMENT

Location: Affari, First Level

Chair: Michael Owen

Co-Chair: Marieke Wichers

3:30 PM *Genomics and Psychiatric Diagnosis*
Michael Owen

3:55 PM *Brain Structural and Neurochemical Heterogeneity and Homogeneity in Psychotic Disorders: Transdiagnostic PET and MRI Imaging Findings in Schizophrenia and Bipolar Affective Disorder*
Oliver Howes

4:20 PM *Psychosis Biotypes Versus Clinical Syndromes Through the Prism of Intrinsic Neural Activity*
Brett Clementz

4:45 PM *Complex System Theory and the Transdiagnostic Use of Early Warning Signals to Foresee the Type of Future Transitions in Symptoms*
Marieke Wichers

Discussant: Lynn DeLisi



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

SYNAPTIC DYSFUNCTION IN SCHIZOPHRENIA: EXPLORATION OF NOVEL HYPOTHESES AND PROMISING NEW LEADS

Location: Affari, Second Level

Chair: Laura Rowland

3:30 PM *Cell-Subtype Specific Bioenergetic Defects in Schizophrenia*
Robert McCullumsmith

3:55 PM *Metabolic Consequences of Developmental NMDA Receptor Hypofunction*
Amy Ramsey

4:20 PM *System Xc- as a Novel Modulator of Corticostriatal Neurotransmission*
Eduard Bentea

4:45 PM *Brain Lactate is Related to Cognition in Schizophrenia*
Laura Rowland

Discussant: Fernanda Laezza

SIRS BUSINESS MEETING (SIRS MEMBERS ONLY)

Location: Congressi Auditorium

5:45 PM – 6:45 PM

Thursday 5 April



NOTES

Thursday 5 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium	8:30 AM - 9:30 AM On the Road to Curing Schizophrenia	9:30 AM - 10:00 AM Break	10:00 AM - 12:00 PM Identifying Individuals at High Risk for Schizophrenia: U Sedman Memorial Symposium	2:00 PM - 3:00 PM The Near Future for Schizophrenia (Psychosis) Research)	3:00 PM - 5:00 PM From Desk to Down: Lifting Trajectories for Schizophrenia Disorders and Their Implications for Functional Recovery and Treatment Decision	3:30 PM Coffee Break	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM	3:30 PM - 5:00 PM
Sala Verde	10:00 AM - 12:00 PM The Application of Stem Cell Models to Validate Rare and Common Variants Contributing to Schizophrenia	10:00 AM - 12:00 PM Beyond Voices: Multisensory Bodily Self Disturbances Across the Schizophrenia Spectrum	10:00 AM - 12:00 PM Cannabidiol as a Treatment in Different Stages of Psychosis - Efficacy and Mechanisms	10:00 AM - 12:00 PM Tracking the Mechanisms Underlying Working Memory Dysfunction in Schizophrenia and Central Microglia for the Spine-Neural Circuit	10:00 AM - 12:00 PM Developmental Biomarkers of Environmental Adversity and Epigenetic Risk for Major Psychiatric Disorders: Clues to Pathogenesis	10:00 AM - 12:00 PM The Implementation of Cognitive Adaptation Training (CAT) Across Countries	12:00 PM - 2:00 PM Poster Session II and Lunch	8:00 AM - 7:00 PM Registration	12:00 PM - 1:00 PM Corporate Sponsor Luncheon	8:00 AM - 7:00 PM Speaker Ready Room	8:00 AM - 6:30 PM Computer Center	8:00 AM - 10:30 AM Coffee Available	12:45 PM - 3:45 PM Coffee Available	5:35 PM - 6:45 PM Travel Fellow and Meitor Reception
Palazzo Afari Ground Level														
Palazzo Afari Lower Level														
Palazzo Afari 1st Level														
Palazzo Afari 2nd Level														
Cavaniglia														
Palazzo Afari Entrance														
Sala 101														
Sala 103														
Limonaia														
Passi Perduti														
Palazzo Afari 4th Floor														

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia

Poster Session

Plenary

Oral Presentation

Coffee Break



Friday, 6 April 2018

REGISTRATION

8:00 AM – 7:00 PM

Location: Palazzo Entrance**PLENARY SESSION: ON THE ROAD TO CURING SCHIZOPHRENIA**

8:30 AM – 9:30 AM

Location: Congressi Auditorium

Cynthia Shannon Weickert

Neuroscience Research Australia: Schizophrenia Research Laboratory, Australia

Abstract: I began my journey to find out what caused schizophrenia around the time me and my twin brother, Scott David, turned 17. My first step was to conceptualize schizophrenia as a biological, cellular and molecular brain problem. This guided my choice of undergraduate and graduate study. I quickly realized that schizophrenia was not a “genetic” disease, nor was it an “environmental” disease, it was both. I prioritized studying RNA as was the active genome, the subcellular substrate where genes and environment interact. Guided from my own experience of watching my normal twin be tortured by schizophrenia in his teens, I sought to find answers by studying the mammalian brain as it developed and changed during adolescence. For my post-doctoral fellowship, I joined the laboratory of Joel Kleinman, who has the largest and best characterized human brain collection of people with schizophrenia in the world. Along my journey, while at NIMH in the USA, I discovered changes in neuronal growth factors and hormone receptors during stages of postnatal life and in the brains of people with schizophrenia compared to controls using the classical hypothesis-driven approach. Since I moved to Sydney Australia, I choose a different, more open-minded approach and let the brains of those who suffered “tell me what happened to them”, using a modern, sensitive discovery-driven RNAseq approach. When I listened, more carefully at the molecular level, what I found told me that I may be headed down the wrong path with my research and that I needed to change direction. It suggested that the emphasis I placed on development molecules maybe in some ways blinding me from more clearly seeing the neuropathology that existed only in only some people at the time of death. I found elevated inflammatory cytokine mRNAs in ~40% in the brains of those diagnosed with chronic schizophrenia. In this talk, I will review my latest discoveries on neuroinflammation in schizophrenia including evidence of gliosis, blood-brain barrier (BBB) changes and increased white blood cells in the brains of some with schizophrenia. Today, many of my fellow seekers, including geneticists (Chr 6, MHC locus) and epidemiologists (maternal infection) and “animal modelers” (poly I:C), are suggesting that the cause of schizophrenia may involve changes to the immune system. These new discoveries suggest that very first steps I took may have been wrong, that perhaps I should have become an immunologist rather than a neurobiologist. However, from my current vantage point, I believe that even if a fault in the immune system plays a role in the causality of schizophrenia, that neurons are the major protagonist behind the manifestation of schizophrenia. The road ahead suggests that we, as a field, need to do some more trial blazing research that conceptualizes schizophrenia as not a “brain” disease and not as an “immune” disease, but as both.



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti

CONCURRENT SYMPOSIA

10:00 AM - 12:00 PM

IDENTIFYING INDIVIDUALS AT HIGH RISK FOR SCHIZOPHRENIA: LJ SEIDMAN MEMORIAL SYMPOSIUM

Location: Congressi Auditorium

Chair: Lynn DeLisi

10:00 AM *Stress and Cognition in Youth at Clinical Risk for Psychosis*

Elaine Walker

10:25 AM *Familial Risk for Schizophrenia*

David Braff

10:50 AM *Neuroimaging Markers of Risk for and Progression to Full Psychosis in the NAPLS Project*

Tyrone Cannon

11:15 AM *Baseline Clinical and Biological Variables Predicting 1 Year Outcome of Subjects at Clinical High Risk of Psychosis: Insight From Shanghai At Risk for Psychosis (SHARP) Program*

TianHong Zhang

Discussant: Matcheri Keshavan

THE APPLICATION OF STEM CELL MODELS TO VALIDATE RARE AND COMMON VARIANTS CONTRIBUTING TO SCHIZOPHRENIA

Location: Congressi, Sala Verde

Chair: Kristen Brennand

10:00 AM *Dissecting the Functional Consequences of Reciprocal Genomic Disorders*

Michael Talkowski

10:25 AM *Analyzing the Molecular Effects of Large Neuropsychiatric CNVs With iPSC Based Neuronal Tissue Culture Models*

Alexander Urban

10:50 AM *Open Chromatin Analyses Inform Functional Noncoding GWAS Variants in iPSC Model of Mental Disorders*

Jubao Duan

11:15 AM *Modeling the Contribution of Common Variants to Schizophrenia Risk*

Kristen Brennand

Discussant: Douglas Ruderfer

Friday 6 April



CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS

Location: Affari, Ground Level

Chair: Sagnik Bhattacharyya

10:00 AM *A Randomized Controlled Trial of Cannabidiol in Schizophrenia*
Philip McGuire

10:25 AM *Efficacy of Cannabidiol in the Treatment of Early Psychosis*
Mohini Ranganathan

10:50 AM *Effect of Cannabidiol on Symptoms, Distress and Neurophysiological Abnormalities in Clinical High-Risk for Psychosis Patients: A Placebo-Controlled Study*
Sagnik Bhattacharyya

11:15 AM *Possible Mechanisms Involved in the Antipsychotic Effects of Cannabidiol (CBD)*
Jose Alexandre Crippa

Discussant: Deepak D'Souza

TRACKING THE MECHANISMS UNDERLYING WORKING MEMORY DYSFUNCTION IN SCHIZOPHRENIA FROM CORTICAL MICROCIRCUITS TO THE SYSTEMS LEVEL

Location: Affari, Lower Level

Chair: Robert Bittner

Co-Chair: Sohee Park

10:00 AM *Molecular Insights to Higher-Order Dorsolateral Prefrontal Cortical Circuits: Implications for the Pathogenesis of Schizophrenia*
Dibyadeep Datta

10:25 AM *Using Computational Estimates of Internal “Noise” to Characterize Visual Perceptual and Working Memory Deficits in Schizophrenia*
Megan Ichinose

10:50 AM *Disturbed and Intact Attentional Processes During Working Memory Encoding in Schizophrenia: Converging Behavioral and Imaging Genetics Evidence*
Robert Bittner

11:15 AM *Characterizing Large-Scale Network Dysconnectivity in Schizophrenia: Modeling Altered E/I Balance*
Alan Anticevic

Discussant: Junghee Lee

Friday 6 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

DEVELOPMENTAL BIOMARKERS OF ENVIRONMENTAL ADVERSITY AND EPIGENETIC RISK FOR MAJOR PSYCHIATRIC DISORDERS: CLUES TO PATHOGENESIS

Location: Affari, First Level

Chair: Kim Do

- 10:00 AM** *Epigenetic Signatures of Childhood and Adolescent Victimization Using a Genetically Sensitive Longitudinal Cohort Study*
Helen Fisher
- 10:25 AM** *Childhood Trauma Engages Oxidative Stress, Hippocampus Alterations, and Poorer Clinical Outcome in Early Psychosis Patients*
Luis Alameda
- 10:50 AM** *Methylomic Changes of Oxidative Stress Regulation, Axon Guidance and Inflammatory Pathways During Conversion to Psychosis*
Oussama Kebir
- 11:15 AM** *Effect of Genotype and Early Adversity Environment on DNA Methylation*
Darina Czamara

Discussant: Philippe Conus

THE IMPLEMENTATION OF COGNITIVE ADAPTATION TRAINING (CAT) ACROSS COUNTRIES

Location: Affari, Second Level

Chair: Dawn Velligan

- 10:00 AM** *From Clinical Trial to the Clinic: Optimizing Cognitive Adaptation Training for Case Management Teams*
Sean Kidd
- 10:25 AM** *Recovery Through Relocation: From Nursing Home to Community Using Cognitive Adaptation Training*
Natalie Maples
- 10:50 AM** *Applying Cognitive Adaptation Training in Finland: Interim Results of the Finnish Cat Implementation Project*
Tuukka Mehtala
- 11:15 AM** *Cat in First-Episode Psychosis: Feasibility, Acceptability and Potential to Enhance Vocational Recovery*
Kelly Allott

Discussant: Marieke (Gerdina) Pijnenborg



POSTER SESSION II / LUNCH

12:00 PM - 2:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session.

Please see page 95 for a complete listing of posters.

**PLENARY SESSION: THE NEAR FUTURE FOR SCHIZOPHRENIA
(PSYCHOSIS) RESEARCH**

2:00 PM - 3:00 PM

Location: Congressi Auditorium

William Carpenter

University of Maryland School of Medicine, United States

Abstract: Implications of a heterogeneous clinical syndrome such as schizophrenia have long been known but little attended. Fundamental problems persist, such as schizophrenia as the phenotype in GWAS studies. But the 21st Century has brought substantial attention to limitations in acquisition of new knowledge. New concepts and methods are being implemented. Selected examples will be reviewed and potential scientific advances that influence clinical care will be outlined. This will include advances in mechanism knowledge, identification of novel targets for therapeutic discovery, re-conceptualization of psychopathology for regulatory purposes, a new integration of behavioral and biological science to inform nosology, enhanced testing of neural circuit hypotheses, and serious attention to primary prevention.

COFFEE BREAK

3:00 PM - 3:30 PM

Congressi, Passi Perduti



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

CONCURRENT SYMPOSIA

3:30 PM - 5:30 PM

FROM DUSK TILL DAWN: LIFELONG TRAJECTORIES OF COGNITIVE FUNCTIONING IN PSYCHOTIC DISORDERS AND THEIR IMPLICATIONS FOR FUNCTIONAL RECOVERY AND TREATMENT DECISION

Location: Congressi Auditorium

Chair: Eva Velthorst

3:30 PM *Neurocognitive Development From Infancy to Early Adulthood in the Psychosis Spectrum*
Josephine Mollon

3:55 PM *Neurocognitive Profiles in the Prodrome to Psychosis in NAPLS-1*
Eva Velthorst

4:20 PM *Eighteen-Year Course of Cognitive Functioning in Psychotic Disorders: Findings From the Suffolk County Mental Health Longitudinal Study*
Fett Anne-Kathrin

4:45 PM *Cognition and Communication as Determinants of Adaptive Deficits in Late Life Schizophrenia*
Philip Harvey

Discussant: Abraham Reichenberg

BEYOND VOICES: MULTISENSORY BODILY SELF DISTURBANCES ACROSS THE SCHIZOPHRENIA SPECTRUM

Location: Congressi, Sala Verde

Chair: Sohee Park

Co-Chair: Lénie Torregrossa

3:30 PM *Varieties of Self Disorder: A Bio-Pheno-Social Model of Schizophrenia*
Barnaby Nelson

3:55 PM *Disorders of the Embodied Self in Schizophrenia: At the Crossroad Between Development and Psychopathology*
Andrea Raballo

4:20 PM *Minimal Self in Schizophrenia: The Time Perspective*
Anne Giersch

4:45 PM *Flexible Body Boundary and Altered Mapping of the Bodily Self in the Schizophrenia Spectrum; Causes, Processes and Potential Intervention*
Sohee Park

Discussant: Francesca Ferri

Friday 6 April



OLIGODENDROCYTE-BASED IMPAIRMENT OF BRAIN CONNECTIVITY AS TARGET FOR NEW TREATMENT STRATEGIES IN SCHIZOPHRENIA

Location: Affari, Ground Level

Chair: Johann Steiner

3:30 PM *Oligodendrocyte Pathology in Prefrontal White Matter in Schizophrenia*
Natalya Uranova

3:55 PM *Understanding White Matter Pathology in Schizophrenia Using Diffusion Tensor Imaging and Magnetic Resonance Spectroscopy*
Adrienne Lahti

4:20 PM *Oligodendrocytes Mediate Energy Metabolism Alterations in Schizophrenia: A Proteomic Study*
Daniel Martins-De-Souza

4:45 PM *Promoting Myelin Repair Rescues Mice From Schizophrenia-Like Behavior Induced by Social Isolation*
Lan Xiao

Discussant: Andrea Schmitt

NOVEL APPROACHES TO PSYCHOSIS RISK: MOVEMENT, STRESS MODULATION, REWARD AND LANGUAGE

Location: Affari, Lower Level

Chair: Cheryl Corcoran

3:30 PM *Motor Subtypes and Prediction of Course in Psychosis Risk Youth*
Vijay Mittal

3:55 PM *Cortical Stress Regulation is Disrupted in Schizophrenia but Not in Clinical High-Risk for Psychosis*
Romina Mizrahi

4:20 PM *Salience Signaling and the Emergence of Psychopathology in Youth at Clinical High Risk for Psychotic Illness*
James Waltz

4:45 PM *Language Disturbance as a Predictor of Psychosis Onset in Youth at Enhanced Clinical Risk*
Cheryl Corcoran

Discussant: Patrick McGorry

Friday 6 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

FRONTAL CORTEX DEVELOPMENT AND RISK FOR PSYCHOPATHOLOGY: MOLECULAR AND GENETIC MEDIATORS AS POSSIBLE BIOMARKERS?

Location: Affari, First Level

Chair: Francesco Papaleo

3:30 PM *Understanding the Role of Schizophrenia/Autism Genes in Cortical Development*
Helen Cooper

3:55 PM *Netrin-1 Receptors Control Mesocortical Dopamine Connectivity in Adolescence*
Cecillia Flores

4:20 PM *Developmental Trajectories of Schizophrenia-Relevant Abnormalities in a Mouse Model of 22q11.2 Deletion Syndrome*
Francesco Papaleo

4:45 PM *Mapping Major Molecular Changes in the Development of the Human Cortex*
Maree Webster

Discussant: Maude Schneider

THE ROLE OF DOPAMINE IN SHAPING CIRCUITRY RELATED TO SCHIZOPHRENIA AND ADDICTION

Location: Affari, Second Level

Chair: Anissa Abi-Dargham

3:30 PM *Translational Evidence of Dopamine-Related Alterations of Basal Ganglia and Thalamo-Cortical Neurocircuitry in Schizophrenia: A Full Clinic-To-Bench-To-Clinic Back-Translation*
Jared Van Snellenberg

3:55 PM *The Dopamine Motive System in Addiction*
Nora Volkow

4:20 PM *Discrete and Coordinated Encoding of Rewarded Actions by Prefrontal Cortex and Dopamine Neurons*
Bita Moghaddam

4:45 PM *Structural, Functional, and Behavioral Insights of Dopamine Dysfunction Revealed by a Deletion in SLC6A3*
Aurelio Galli

Discussant: Andreas Heinz

SIRS TRAVEL FELLOWS & MENTOR RECEPTION (INVITATION ONLY)

5:45 PM - 6:45 PM

Location: Affari, 4th Floor

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



NOTES

Friday 6 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM 12 PM	11 AM 12 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30 AM - 9:30 AM The Complex Interactions of the Immune System: How It Takes a Beat to Control Inflammation	9:30 AM - 10:00 AM Break	10:00 AM - 12:00 PM Stigma and Recovery Among Young People at Risk for Psychosis: Novel Insights From Global Research	10:00 AM - 12:00 PM	2:00 PM - 3:00 PM Investing in Population Health: Economic as Well as Moral Imperative	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Biomarkers	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Risk Factors	5:30 PM - 7:30 PM		
Sala Verde				10:00 AM - 12:00 PM Prevention of Psychosis: An Individual or Population Approach?	10:00 AM - 12:00 PM			3:15 PM - 5:15 PM Neuroimaging	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Socio-economic/Environment			
Palazzo Affari Ground Level				10:00 AM - 12:00 PM OPTIMISE-ing the Treatment of First-Episode Schizophrenia	10:00 AM - 12:00 PM			3:15 PM - 5:15 PM fMRI	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Outcome			
Palazzo Affari Lower Level				10:00 AM - 12:00 PM Digging Deeper in the Probenome of Schizophrenia	10:00 AM - 12:00 PM			3:15 PM - 5:15 PM Genetics	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Prediction			
Palazzo Affari 1st Level				10:00 AM - 12:00 PM An Immune Pathogenesis of Psychosis? Evidence and Challenges From Bench to Bedside	10:00 AM - 12:00 PM			3:15 PM - 5:15 PM Cognition	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Pharmacology			
Palazzo Affari 2nd Level				10:00 AM - 12:00 PM Improving the Detection of Individuals at Risk of Psychosis	10:00 AM - 12:00 PM			3:15 PM - 5:15 PM Comorbidity	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Services and Others Interventions			
Cavaniglia						12:00 AM - 2:00 PM Poster Session III and Lunch							
Palazzo Affari Entrance													
Sala 103													
Limonaia													
Passi Perduti													

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia

Poster Session

Plenary

Oral Presentation

Coffee Break



Saturday, 7 April 2018

REGISTRATION

8:00 AM - 8:00 PM

Location: Palazzo Entrance

**PLENARY SESSION: THE COMPLEX INTERACTIONS BETWEEN MIND AND BODY:
IT TAKES A BRAIN TO CONTROL IMMUNITY**

8:30 AM - 9:30 AM

Location: Congressi Auditorium

Asya Rolls

Israel Institute of Technology, Israel

Abstract: Thoughts and emotions can impact physiology. This connection is evident by the emergence of disease following stress or recovery in response to placebo treatment. Nevertheless, this fundamental aspect of physiology remains largely unexplored. We have recently shown that activation of the brain's reward system, which is active in positive emotional states and positive expectations, boosts immunity. In this talk, I will discuss how brain activity can regulate anti-bacterial and anti-tumor immunity and the potential implications for health and cancer therapy. Given the crucial role of the reward system in emotional processes, our findings offer a new mechanistic insight to the association between the patient's psychological state, physical health and cancer progression.

BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

CONCURRENT SYMPOSIA

10:00 AM - 12:00 PM

STIGMA AND RECOVERY AMONG YOUNG PEOPLE AT RISK FOR PSYCHOSIS: NOVEL INSIGHTS FROM GLOBAL RESEARCH

Location: Congressi Auditorium

Chair: Sara Evans-Lacko

10:00 AM *Drivers of Stigma for the Clinical High Risk State for Psychosis—Is Stigma Due to Symptoms or the At-Risk Identification Itself?*

Lawrence Yang

10:25 AM *Levels of and Implications for Personal Stigma and Mental Health Literacy in Relation to Psychosis Among Young People with and Without Risk of Developing Psychotic Disorder*

Sara Evans-Lacko

10:50 AM *Can the Stigmatizing Risks of the 'At-Risk' State be Reduced by Relabeling it 'High-Risk Health'? Promising Pilot Results From Two Experimental Vignette Studies Among the General Population and Mental Health Professionals*

Dan Koren

11:15 AM *From Personal Experience to Research*

Catherine van Zelst

Discussant: Antonio Lasalvia

PREVENTION OF PSYCHOSIS: AN INDIVIDUAL OR POPULATION APPROACH?

Location: Congressi, Sala Verde

Chair: Mary Cannon

10:00 AM *Only a Small Proportion of Patients With First Episode Psychosis Come via Prodromal Services. a Retrospective Survey of a Large UK Mental Health Programme*

Olesya Ajnakina

10:25 AM *Preventing psychosis: What, (if Anything) can We Learn From the EU-GEI Incidence Study?*

Hannah Jongsma

10:50 AM *Childhood Exposure to Green Space – a Novel Risk-Decreasing Mechanism for Schizophrenia?*

Kristine Engemann

11:15 AM *A Public Health Approach to the Prevention of Psychosis*

Robin Murray

Discussant: Andreas Meyer-Lindenberg

Saturday 7 April



OPTIMISE-ING THE TREATMENT OF FIRST-EPISEODE SCHIZOPHRENIA

Location: Affari, Ground Level

Chair: Celso Arango

- 10:00 AM** *Optimising the Treatment and Management of First-Episode Schizophrenia: The Optimise Clinical Trial*
René Kahn
- 10:25 AM** *Can We Improve Functional Outcome and Adherence in Optimise Participants With a Psychosocial Intervention?*
Richard Drake
- 10:50 AM** *Clinical Utility of MRI Scanning in First Episode Psychosis*
Paola Dazzan
- 11:15 AM** *Genetic, Immunological and Biochemical Markers of Treatment Response in Schizophrenia*
Marion Leboyer

Discussant: William Carpenter

DIGGING DEEPER IN THE PROTEOME OF SCHIZOPHRENIA

Location: Affari, Lower Level

Chair: Daniel Martins-De-Souza

- 10:00 AM** *Mechanisms of Abnormal Posttranslational Protein Processing in Schizophrenia Brain*
James Meador-Woodruff
- 10:25 AM** *Abnormalities of Synaptic Proteomes in Schizophrenia*
Robert McCullumsmith
- 10:50 AM** *Magnifying the Proteome of Schizophrenia Brains*
Mariana Fioramonte
- 11:15 AM** *Altered Complement Pathway Protein Expression is Associated With Psychotic Experiences at Age 11 Which Persist at Age 18*
David Cotter

Discussant: Peter Nilsson



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

AN IMMUNE PATHOGENESIS OF PSYCHOSIS? EVIDENCE AND CHALLENGES FROM BENCH TO BEDSIDE

Location: Affari, First Level

Chair: Rachel Upthegrove

Co-Chair: Tiago Reis Marques

10:00 AM *Immune Pathogenesis of Psychosis: The Challenge of Co-Morbidity*
Rachel Upthegrove

10:25 AM *Genetic Variation Related to Immune Function and Schizophrenia Risk: Evidence for Effects on Cognition*
Gary Donohoe

10:50 AM *Association Between Serum C-Reactive Protein, Positive and Negative Symptoms of Psychosis in a General Population-Based Birth Cohort*
Golam Khandaker

11:15 AM *Prenatal Infection and Long-Term Brain Pathology: From Preclinical Models to Mechanisms*
Tina Notter

Discussant: Bill Deakin

IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS

Location: Affari, Second Level

Chair: Paolo Fusar-Poli

Co-Chair: Philip McGuire

10:00 AM *Do All Individuals with a FEP Pass Through an Earlier CHR-P State? Implications for Clinical Staging, Early Detection and Phase-Specific Interventions*
Jai Shah

10:25 AM *Improving the Detection of Individuals at Risk of Psychosis in Secondary Mental Health Care*
Paolo Fusar-Poli

10:50 AM *Improving the Detection of Individuals at Risk of Developing Psychosis in Primary Mental Health Care*
Jesus Perez

11:15 AM *Improving the Detection of Individuals at Risk of Psychosis in the Community: A Neurodevelopmental Perspective*
Monica Calkins

Discussant: Craig Morgan

Saturday 7 April



POSTER SESSION III / LUNCH

12:00 PM - 2:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session.

Please see page 122 for a complete listing of posters.

PLENARY SESSION: INVESTING IN RECOVERY – AN ECONOMIC AS WELL AS MORAL IMPERATIVE

2:00 PM - 3:00 PM

Location: Congressi Auditorium

David McDaid

London School of Economics and Political Science, United Kingdom

Abstract: ‘Recovery’ is a key concept in mental health policy around the globe. The World Health Organization has called for ‘a recovery-based approach that puts the emphasis on supporting individuals with mental disorders and psychosocial disabilities to achieve their own aspirations and goals’. Investing in evidence-based actions to help foster recovery should therefore be core to any system of support for anyone experiencing schizophrenia or other severe mental health problems. While there is clearly a moral imperative to maximise opportunities for recovery, the economic case for action can also be compelling and complementary. However, the opportunity to make an economic argument to support investment in recovery is not always taken, and even when made it is often too narrow in ambition and scope to have a major influence policy and practice. This presentation will highlight examples of the economic potential of recovery-focused services in health, employment, education and housing services. It will look at strengths and weaknesses in the way in which economic evidence is presented to policy makers, including the extent to which implementation challenges have been considered. It will argue that in making the economic case for recovery it is just as vital to look at the role of the messenger as well as the message that is being communicated.

COFFEE BREAK

3:00 PM - 3:15 PM

Location: Congressi, Passi Perduti



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

ORAL SESSIONS

3:15 PM - 5:15 PM

BIOMARKERS

3:15 PM - 5:15 PM

Location: Congressi Auditorium

Chair: Anthony Grace

- 3:15 PM** *Altered Complement Pathway Protein Expression is Associated With Psychotic Experiences at Age 11 Which Persist at Age 18*
David Cotter
- 3:30 PM** *Peripheral Inflammatory Markers are Predictive of Clinical Characteristics and Outcome in Psychosis*
Graham Blackman
- 3:45 PM** *A Computational Trial-By-Trial EEG Analysis of Hierarchical Precision-Weighted Prediction Errors*
Sara Tomiello
- 4:00 PM** *Cerebrospinal Fluid Findings in Twins With Psychotic Symptoms – Novel Findings and Future Prospects*
Viktoria Johansson
- 4:15 PM** *ICAM-1 is Increased in Brain and Peripheral Levels of Soluble ICAM-1 is Related to Cognitive Deficits in Schizophrenia*
Thomas Weickert
- 4:30 PM** *Increased Complement Factors C3 and C4 in Schizophrenia and the Early Stages of Psychosis: Implications for Clinical Symptomatology and Cortical Thickness*
Vanessa Cropley
- 4:45 PM** *Proteomic Analysis of Blood Based Samples From the Optimise (Optimization of Treatment and Management of Schizophrenia in Europe) Study Point Towards Complement Pathway Protein Changes*
Melanie Föcking
- 5:00 PM** *Stress-Induced Amygdala Hyperactivity Leads to Interneuron Loss and Schizophrenia-Like Pathology in a Developmental Disruption Model of Schizophrenia*
Anthony Grace

Saturday 7 April



NEUROIMAGING

3:15 PM - 5:15 PM

Location: Congressi, Sala Verde

Chair: Elisabetta Del Re

- 3:15 PM** *Hippocampal Volume in Adolescents With Persistent Psychotic Experiences: A Longitudinal Population-Based MRI Study*
Ana Calvo
- 3:30 PM** *Neurobiology of Psychometric Schizotypy: Insights From Multimodal Imaging Research*
Gemma Modinos
- 3:45 PM** *Patterns of Gray Matter Abnormalities in Patients With first-Episode and Treatment-Naïve Schizophrenia*
Mingli Li
- 4:00 PM** *Auditory and Language Areas Distinguish Converters From Non-Converters at Baseline in SHARP Clinical High Risk Subjects for Psychosis Study*
Elisabetta Del Re
- 4:15 PM** *Linking Cortical and Connectional Pathology in Schizophrenia*
Maria Di Biase
- 4:30 PM** *Lack of Antipsychotic Medication Effects on White Matter Microstructure in Schizophrenia*
Nina Kraguljac
- 4:45 PM** *Common Neuroanatomical Abnormalities in First Episode Psychosis Across Several Independent Samples*
Sandra Vieira
- 5:00 PM** *Glutamatergic Dysfunction and Treatment Response in Minimally Treated and Chronic Schizophrenia Patients*
Elias Mouchlianitis

Saturday 7 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

fMRI

3:15 PM - 5:15 PM

Location: Affari, Ground Level

Chair: Mette Nielsen

- 3:15 PM** *Neurotyping Untreated First Episode Schizophrenia on the Basis of Slow-Wave Resting-State Dynamics*
Lena Palaniyappan
- 3:30 PM** *Brain Hyperactivation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk*
★ Hengyi Cao
- 3:45 PM** *Reward Processing as a Vulnerability Indicator for Psychosis: Results From a Twin Study*
Mette Nielsen
- 4:00 PM** *Increased Engagement of the Fronto-Parietal Network and Decreased Engagement of the Default-Mode – Cingulo-Opercular – Sensorimotor Between-Network Connectivity in First-Episode Psychosis Patients*
Eva Rikandi
- 4:15 PM** *Testing the Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in First Episode Bipolar Affective Disorder and Schizophrenia*
★ Sameer Jauhar
- 4:30 PM** *Deficits in Context-Dependent Adaptive Coding in Early Psychosis and Healthy Individuals With Schizotypal Personality Traits*
Matthias Kirschner
- 4:45 PM** *Effect of N-Acetylcysteine on Brain Glutamate Levels and Resting Perfusion in Schizophrenia*
Grant McQueen
- 5:00 PM** *Dorsolateral Prefrontal Cortex in Drug-Naïve First Episode Schizophrenia: Dynamic Phase Coherence of Intraslow Oscillations*
Lena Palaniyappan

★ – Travel Awardee



GENETICS

3:15 PM - 5:15 PM

Location: Affari, Lower Level

Chair: Gianluca Ursini

- 3:15 PM** *Genetic Vulnerability to DUSP22 Promotor Hypermethylation is Involved in the Relation Between in Utero Famine Exposure and Schizophrenia*
Marco Boks
- 3:30 PM** *Heritability and Correlation to Schizophrenia Spectrum Disorder of Glutamate and Other Neurometabolite Levels in Anterior Cingulate and Left Thalamus: A Register Based Magnetic Resonance Twin Study*
Christian Legind
- 3:45 PM** *Increased Cerebral Blood Flow After Single Dose of Antipsychotics in Healthy Subjects Depends on Dopamine D2 Receptor Density Profiles Evaluated With PET and mRNA Expression Data*
Pierluigi Selvaggi
- 4:00 PM** *Does Polygenic Risk Score for Schizophrenia Moderate the Momentary Affective and Psychotic Reactions to Daily-Life Stressors?*
Lotta-Katrin Pries
- 4:15 PM** *Investigating Genetic Profiles Associated With 'Real World' Clinical Outcomes in Psychosis: A Retrospective Cohort Study*
Emma Francis
- 4:30 PM** *Genome-Wide Association Study, Heritability Estimation and Polygenic Risk Analysis of Susceptibility to Infections in 65,534 Individuals With Severe Mental Disorders and Population Controls*
Michael Benros
- 4:45 PM** *Placental Gene Expression, Obstetrical History and Polygenic Risk for Schizophrenia*
★ Gianluca Ursini
- 5:00 PM** *Vulnerable Periods for Cognitive Development in Individuals at High Genomic Risk of Schizophrenia*
Sinead Morrison

Saturday 7 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

COGNITION

3:15 PM - 5:15 PM

Location: Affari, First Level

Chair: Susan Rossell

- 3:15 PM** *First Episode Psychosis Patients Across Europe Differ in Intellectual Quotient (IQ) and Exposure to Environmental Hazards*
Laura Ferraro
- 3:30 PM** *Childhood Adversities and Psychotic Symptoms: The Potential Mediating or Moderating Role of Neurocognition and Social Cognition*
Giovanni Mansueto
- 3:45 PM** *Automated Analysis of Recent-Onset and Prodromal Schizophrenia*
Guillermo Cecchi
- 4:00 PM** *The Missing Piece in the Puzzle: Cognitive Decline in Schizophrenia and Bipolar Patients After the First Episode*
Abraham Reichenberg
- 4:15 PM** *Multisensory Integration Underlying Body Ownership in Schizophrenia and Individuals at Familial Risk to Develop Psychosis: A Study Using the Rubber Hand Illusion Paradigm*
Neeltje Van Haren
- 4:30 PM** *Social Simulation in Virtual Reality Improves Embodiment of Emotions in Schizophrenia*
Lénie Torregrossa
- 4:45 PM** *Can They Hear It? Do Patients With Auditory Verbal Hallucinations Have Auditory Processing Deficits?*
Susan Rossell
- 5:00 PM** *Trajectories of Neurocognitive Functioning Over Time in Youth at Clinical High Risk Who Do and Do Not Transition to Psychosis*
Kristen Woodberry

Saturday 7 April



COMORBIDITY

3:15 PM - 5:15 PM

Location: Affari, Second Level

Chair: Fiona Gaughran

3:15 PM *Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: Preliminary Results From a Meta-Analysis*
Jentien Vermeulen

3:30 PM *Predictors of Cardiometabolic Risk in the Year After Onset of Psychosis: A Prospective Cohort Study*
Fiona Gaughran

3:45 PM *A Comprehensive Nationwide Study of Comorbidity Within Treated Mental Disorders – A Danish Register-Based Study*
Oleguer Plana Ripoll

4:00 PM *Natural Cause Mortality in Persons With Schizophrenia and Bipolar Disorder*
Faith Dickerson

4:15 PM *Sleep in Major Psychiatric Disorders: Results From Nationwide SUPER Finland Study*
Minna Torniaainen-Holm

4:30 PM *Mortality 15-Years After Specialist Early Intervention Treatment for the First Episode of Psychosis*
Susan Cotton

4:45 PM *Risk of Diabetic Complications and Subsequent Mortality Among Individuals With Schizophrenia and Diabetes Mellitus: A Nationwide Population-Based Register Study*
Anita Tønder Nielsen

COFFEE BREAK

5:15 PM - 5:30 PM

Location: Congressi, Passi Perduti

Saturday 7 April



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

ORAL SESSIONS

5:30 PM - 7:30 PM

RISK FACTORS

5:30 PM - 7:30 PM

Location: Congressi Auditorium

Chair: Jessica A. Hartmann

5:30 PM *Disorganized Gyrfication Network Properties During the Transition to Psychosis*
★ André Schmidt

5:45 PM *Psychotic Experiences Are Associated With Health Anxiety and Functional Somatic Symptoms in Pre-Adolescence.*
Martin K. Rimvall

6:00 PM *Early Brain and Cognitive Development in Children at Risk for Schizophrenia*
John Gilmore

6:15 PM *Increased Risks for Non-Affective Psychotic Disorder and Bipolar Disorder in Autism Spectrum Disorder*
Rik Schalbroeck

6:30 PM *Abnormal Modular Organization of the Functional Connectome Predicts Conversion to Psychosis in Clinical High-Risk Youth*
Guusje Collin

6:45 PM *Olanzapine Impairs Central Insulin Action: Effects on Body Fuel Preference in Rats*
Margaret Hahn

7:00 PM *Investigating the Mechanisms Underlying the Beneficial Effects of Estrogens in Schizophrenia*
Deepak Srivastava

7:15 PM *A Pluripotential at Risk Mental State: Initial Results*
Jessica A. Hartmann

Saturday 7 April

★ – Travel Awardee



SOCIO-ECONOMIC/ENVIRONMENT

5:30 PM - 7:30 PM

Location: Congressi, Sala Verde

Chair: Merete Nordentoft

5:30 PM *Examining the Neurobiological Impact of Childhood Trauma: An Important Role for Frontal and Insular Regions*

★ Marieke Begemann

5:45 PM *Sticks and Stones May Break My Bones but Words Increase the Risk of Psychotic Experiences*

Colm Healy

6:00 PM *Protective Factors for Psychotic Experiences Amongst Adolescents Exposed to Multiple Forms of Victimization*

Helen Fisher

6:15 PM *Some of the Individual Differences in Risk to Develop Psychosis Among Cannabis Users Can Be Explained by Where They Live and by Their Age at First Use*

Marta Di Forti

6:30 PM *Genetic and Environmental Predictors of Main Outcomes in the Danish High Risk and Resilience Study - Via 7. A Study of 522 7-Year-Old Children of Parents With Schizophrenia, Bipolar Disorder or Neither of These Disorders*

Merete Nordentoft

6:45 PM *Neighbourhood Ethnic Density and Psychosis – What Can We Learn From Generational Differences?*

Peter Schofield

7:00 PM *Risk of Psychosis in Offspring of Parents With a History of Homelessness During Childhood and Adolescence: A Nationwide, Register-Based, Cohort Study*

Sandra Feodor Nilsson

7:15 PM *Lower Family Income Predicts Psychotic Experiences in a Community Sample of Youths in Brazil: Results From a 3-Year Follow-Up Study*

Lais Fonseca



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

OUTCOME

5:30 PM - 7:30 PM

Location: Affari, Ground Level

Chair: Eric Chen

- 5:30 PM** *Examining Relationships Between Psychotic Experiences and Suicidal Ideation in Adolescents Using a Network Approach*
Daniel Nunez
- 5:45 PM** *Duration of Untreated Psychosis (DUP) is Associated With Worse Response to Treatment in Antipsychotic Naïve First Episode Psychosis*
Daniel Cavalcante
- 6:00 PM** *Clinical and Functional Outcomes in Young Adulthood of Children With Psychotic Symptoms: A Longitudinal Twin Cohort Study*
Antonella Trotta
- 6:15 PM** *The Effect of Early Medication Discontinuation on Long-Term Clinical Outcome in First Episode Psychosis*
Eric Chen
- 6:30 PM** *Schizophrenia and Bipolar Disorder Diagnosis Patterns: Real-World Evidence From US Claims Databases*
Ann Hartry
- 6:45 PM** *The Relationship Between Cognition and Functional Improvement in the Context of a Psychosocial Intervention Targeting Social Disability in First Episode Psychosis*
Sian Griffiths
- 7:00 PM** *Cognitive Subtypes in First-Episode Psychosis and Association to Treatment Response*
Manuela Russo
- 7:15 PM** *Neurocognition in Ultra-High Risk Individuals and Relationship to Transition to Psychosis, Depressive Disorder, and Functioning: Findings From the Neurapro Trial*
Kelly Allott

Saturday 7 April



PREDICTION

5:30 PM - 7:30 PM

Location: Affari, Lower Level

Chair: Alexis Cullen

- 5:30 PM** *Cannabis and Other Substance Use Disorders Predict Conversion From Schizotypal Disorder to Schizophrenia*
Carsten Hjorthøj
- 5:45 PM** *Identifying Psychotic Symptoms and Predicting Relapse Through Social Media*
Michael Birnbaum
- 6:00 PM** *Psychotic Experiences in Common Mental Disorders and as Clinical Markers of Risk for Suicidal Behaviour*
Ian Kelleher
- 6:15 PM** *Predicting Schizophrenia: Identification of Multimodal Markers of Disease Through a Machine Learning Approach*
★ Linda Antonucci
- 6:30 PM** *Aberrant Dopamine System Function Reversed by the Orexin Receptor Antagonist TCS1102 in a Rodent Model of Schizophrenia*
Stephanie Perez
- 6:45 PM** *Specific Symptoms in Adolescence Predict Psychosis in the Northern Finland Birth Cohort 1986*
Juha Veijola
- 7:00 PM** *Individualized Long-Term Outcome Prediction of Psychosis in an Observational Study: A Machine Learning Approach*
Hugo Schnack
- 7:15 PM** *Stress and Cognitive Function Among Individuals at Clinical High-Risk for Psychosis: Findings From the NAPLS Cohort*
Alexis Cullen



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

PHARMACOLOGY

5:30 PM - 7:30 PM

Location: Affari, First Level

Chair: Stefan Leucht

- 5:30 PM** *Midbrain Dopamine Neuron Activity Controls the Effects of Repeated Ketamine on Striatal Dopaminergic Function*
Michelle Kokkinou
- 5:45 PM** *Breakthrough on Antipsychotic Maintenance Medication in a Clinical Cohort*
★ Jose Rubio
- 6:00 PM** *Dose-Response Meta-Analysis to Identify the Optimum and Equivalent Doses of Antipsychotic Drugs for Schizophrenia*
Stefan Leucht
- 6:15 PM** *Systematic Review, Meta-Analysis and Meta-Regression of Predictors of Placebo Response in Acute Schizophrenia*
Claudia Leucht
- 6:30 PM** *Long-Term Safety and Tolerability of Brexpiprazole in Patients With Schizophrenia*
Mika Hakala
- 6:45 PM** *Meta-Analysis of Efficacy of Cognitive Enhancers for Patients With Schizophrenia-Spectrum Disorders*
Igne Sinkeviciute
- 7:00 PM** *Cognitive Functioning Following Discontinuation of Antipsychotic Medication. a Sub-Group Analysis From the Opus II Trial*
Nikolai Albert

Saturday 7 April

★ – Travel Awardee



SERVICES AND OTHER INTERVENTIONS

5:30 PM - 7:30 PM

Location: Affari, Second Level

Chair: Shon Lewis

- 5:30 PM** *A Randomised Controlled Trial of Smartphone Active Symptom Monitoring in Psychosis*
Shon Lewis
- 5:45 PM** *Changes in Psychopathology Predict Changes in Working Alliance in First Episode Psychosis*
Marianne Melau
- 6:00 PM** *A Longitudinal Analysis of the Effects of Neuroticism and Extraversion on Subjective Well-Being in Patients With Schizophrenia*
Floor van Dijk
- 6:15 PM** *Education, Employment and Disability Among Young Persons With Early Psychosis Participating in a Coordinated Specialty Care Program*
Thomas Smith
- 6:30 PM** *Effectiveness of Coordinated Specialty Care for Early Psychosis*
Britta Galling
- 6:45 PM** *Who Gets in to Early Psychosis Intervention Services? A Comparison of Service Users and Non-Users in Health Administrative Data*
Kelly Anderson
- 7:00 PM** *Discharge Planning Practices and Family Involvement in Transitions to Outpatient Care Following Discharge From Hospital Psychiatric Units*
Morgan Haselden
- 7:15 PM** *Prevalence and Predictors of Interview-Assessed Clinical High Risk Symptoms in the General Population*
Frauke Schultze-Lutter

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30 AM - 9:30 AM The Call Microplasma: A New Paradigm for Neurodevelopment and Behaviour	9:30 AM - 9:45 AM Awards Ceremony	10:00 AM - 12:00 PM Reconsidering the Evidence for Clozapine for Treatment Refractory Schizophrenia										
Sala Verde				10:00 AM - 12:00 PM Building on Genetics and Pathophysiology of Schizophrenia to Guide Discovery of New Treatments										
Palazzo Affari Ground Level				10:00 AM - 12:00 PM Viruses and Schizophrenia: Implications for Pathophysiology and Treatment										
Palazzo Affari Lower Level				10:00 AM - 12:00 PM New Insights on the Role of Neuron Inflammation in Schizophrenia Pathophysiology, from Post Mortem and Animal Studies										
Palazzo Affari 1st Level				10:00 AM - 12:00 PM Do NMDAR Antibodies Cause Schizophrenia?										
Palazzo Affari 2nd Level				10:00 AM - 12:00 PM Metabolism and Co-Morbidities in Psychotic Disorders										
Cavanaglia														
Palazzo Affari Entrance			8:00 AM - 12:00 PM Registration											
Sala 103			8:00 AM - 12:00 PM Speaker Ready Room											
Limonaia			8:00 AM - 1:00 PM Computer Center											
Passi Perduti														

Legend:

- Keynote
- Special Session
- Speaker Ready
- Registration
- Computer Center
- Symposia
- Poster Session
- Plenary
- Oral Presentation
- Coffee Break



Sunday, 8 April 2018

REGISTRATION

8:00 AM – 3:00 PM

Location: Palazzo Entrance

PLENARY SESSION: THE GUT MICROBIOME: A KEY REGULATOR OF NEURODEVELOPMENT AND BEHAVIOUR

8:30 AM – 9:30 AM

Location: Congressi Auditorium

John Cryan
University College Cork, Ireland

Abstract: The brain-gut-microbiota axis is emerging as a research area of increasing interest for those investigating the biological and physiological basis of neurodevelopmental, age-related and neurodegenerative disorders. The routes of communication between the gut and brain include the vagus nerve, the immune system, tryptophan metabolism, via the enteric nervous system or by way of microbial metabolites such as short chain fatty acids. These mechanisms also impinge on neuroendocrine function at multiple levels. Studies in animal models have been key in delineating that neurodevelopment and the programming of an appropriate stress response is dependent on the microbiota. Developmentally, a variety of factors can impact the microbiota in early life including mode of birth delivery, antibiotic exposure, mode of nutritional provision, infection, stress as well as host genetics. At the other extreme of life, individuals who age with considerable ill health tend to show narrowing in microbial diversity. Stress can significantly impact the microbiota-gut-brain axis at all stages across the lifespan. Recently, the gut microbiota has been implicated in a variety of conditions including obesity, autism, schizophrenia and Parkinson's disease. Moreover, animal models have been key in linking the regulation of fundamental brain processes ranging from adult hippocampal neurogenesis to myelination to microglia activation by the microbiome. Finally, studies examining the translation of these effects from animals to humans are currently ongoing. Further studies will focus on understanding the mechanisms underlying such brain effects and developing nutritional and microbial-based intervention strategies.

POSTER AWARD SESSION

9:30 AM – 9:45 AM

Location: Congressi Auditorium

BREAK

9:45 AM - 10:00 AM

Location: Congressi, Passi Perduti



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

CONCURRENT SYMPOSIA

10:00 AM - 12:00 PM

RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA

Location: Congressi Auditorium

Chair: James MacCabe

10:00 AM *What Do Meta-Analyses Tell Us About Clozapine's Efficacy and Effectiveness for Treatment Refractory Schizophrenia?*

Dan Siskind

10:25 AM *What Does Epidemiological Data Tell Us about Clozapine's Effectiveness?*

Jari Tiihonen

10:50 AM *Could Clozapine Reduce Violent Offending?*

Vishal Bhavsar

11:15 AM *Deployment of Dedicated Nursing Staff to Stimulate the Initiation of Clozapine. a Cluster-Randomized Trial*

Yvonne Van der Zalm

Discussant: John Kane

BUILDING ON GENETICS AND PATHOPHYSIOLOGY OF SCHIZOPHRENIA TO GUIDE DISCOVERY OF NEW TREATMENTS

Location: Congressi, Sala Verde

Chair: P. Jeffrey Conn

10:00 AM *Genetic Insights Lead to Discovery of Selective Activators of mGlu1 and mGlu3 Metabotropic Glutamate Receptors as Potential Treatments for Schizophrenia*

P. Jeffrey Conn

10:25 AM *Muscarinic M1 Receptors: Involvement in the Pathophysiology and Treatment of Schizophrenia*

Brian Dean

10:50 AM *Complement Dysregulation in Schizophrenia: Implications for Potential Treatment Strategies*

Clare Beasley

11:15 AM *The Role of Molecular Imaging in Guiding Drug Development*

Anissa Abi-Dargham

Discussant: John Krystal



VIRUSES AND SCHIZOPHRENIA: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT

Location: Affari, Ground Level

Chair: Alan Breier

- 10:00 AM** *DNA Methylation of Immune Cells in Persons at Clinical High Risk for Psychosis*
Diana Perkins
- 10:25 AM** *Viral Exposures and Schizophrenia*
Faith Dickerson
- 10:50 AM** *Can Neuroviral Infections With Herpes Simplex Virus, Type 1 (HSV-1) Contribute to RDoC?*
Vishwajit Nimgaonkar
- 11:15 AM** *A Double-Blind Trial of Valacyclovir to Improve Cognition in Early Phase Schizophrenia: Results From the VISTA Study*
Alan Breier

Discussant: Robert Yolken

NEW INSIGHTS ON THE ROLE OF NEUROINFLAMMATION IN SCHIZOPHRENIA PATHOPHYSIOLOGY FROM POST MORTEM AND ANIMAL STUDIES

Location: Affari, Lower Level

Chair: Tertia Purves-Tyson

- 10:00 AM** *Inflammatory Cytokines are Elevated in the Midbrain in Schizophrenia*
Tertia Purves-Tyson
- 10:25 AM** *Maternal Immune Activation Leads to Increased Levels of Inflammatory Cytokines in the Absence of Overt Microglia Anomalies in the Midbrain*
Ulrike Weber-Stadlbauer
- 10:50 AM** *Maternal Immune Activation and Chronic Haloperidol Interact to Increase Microglial Activation in vivo: Do Antipsychotics Inflamm the Brain?*
Anthony Vernon
- 11:15 AM** *Low-Dose Risperidone Treatment in Adolescence Prevents the Development of Neuroinflammation in the Maternal Immune Activation Model*
Ina Weiner

Discussant: Cynthia Shannon Weickert



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

DO NMDAR ANTIBODIES CAUSE SCHIZOPHRENIA?

Location: Affari, First Level

Chair: Belinda Lennox

- 10:00 AM** *Impact of Anti-NMDA Receptor Autoantibodies From Psychotic Patients on the Glutamate Synapse*
Laurent Groc
- 10:25 AM** *Neuronal Autoantibodies in Psychosis: Enough About Prevalence, What's the Relevance?*
Thomas Pollak
- 10:50 AM** *Ongoing Germinal Centre Reactions Contribute to N-Methyl-D-Aspartate Receptor (NMDAR) Antibody Production in NMDAR-Antibody Encephalitis*
Adam Al-Diwani
- 11:15 AM** *Prevalence of Anti-Neuronal Antibodies in Patients Admitted With First Episode of Psychosis and Their Clinical Outcomes*
James Scott

Discussant: Sarosh Irani

METABOLISM AND CO-MORBIDITIES IN PSYCHOTIC DISORDERS

Location: Affari, Second Level

Chair: Matej Oresic

- 10:00 AM** *Body and Mind: Cardio-Metabolic and Immune Function in First Episode Psychosis and Comparison With Central Neurofunctional Measures*
Oliver Howes
- 10:25 AM** *Inflammation and Gut Microbiome in First-Episode Psychosis*
Jaana Suvisaari
- 10:50 AM** *Metabolomics Approaches to Study Metabolic Co-Morbidities in Psychotic Disorders*
Tuulia Hyötyläinen
- 11:15 AM** *The Endocannabinoid System in First-Episode Psychosis*
Jarmo Hietala

Discussant: Matej Oresic



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

POSTERS, THURSDAY 5 APRIL

12:00 P.M. - 2:00 P.M.

Cavaniglia

Travel Awardee Posters are Circled

T1. STRESSFUL LIFE EVENTS AND PERCEIVED STRESS IN THE SAMPLE OF PATIENTS WITH FIRST-EPISODE PSYCHOSIS AND HEALTHY CONTROLS: PRELIMINARY RESULTS

Anna Butjosa, Regina Vila-Badia, Núria Del Cacho, Itziar Riera-López de Aguilera, Mar Álvarez, Daniel Muñoz, Carme Saltó, Núria Grases, Susana Ochoa, PROFEP Group, Judith Usall, Susana Ochoa*

T2. DO ADVERSE LIFE EVENTS AT FIRST ONSET OF AUDITORY VERBAL HALLUCINATIONS INFLUENCE SUBSEQUENT VOICE-CHARACTERISTICS? RESULTS FROM AN EPIDEMIOLOGICAL STUDY

Josef Bless*, Frank Larøi, Julien Laloyaux, Kristiina Kompus, Bodil Kråkvik, Einar Vedul-Kjelsås, Anne Martha Kalhovde, Kenneth Hugdahl

T3. METACOGNITIVE BELIEFS IN SEVERE MENTAL DISORDERS

Tiril Østefjells*, Ingrid Melle, Sofie R. Aminoff, Ole A. Andreassen, Akiha O. Berg, Roger Hagen, Tone Hellvin, Trine V. Lagerberg, Rachel Loewy, June U. Lystad, Kristin L. Romm, Leiv Sandvik, Nasrettin Sönmez, Jan Ivar Røssberg

T4. IDENTIFICATION OF NEUROANATOMICAL SURROGATE MARKERS OF CHILDHOOD TRAUMA

Theresa Haidl*, Marlene Rosen, Mauro Seves, Thorsten Lichtenstein, Anne Ruef, Joseph Kambeitz, Nikolaos Koutsouleris

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS

Michael Tocco*, Andrei Pikalov, Jay Hsu, Josephine Cucchiario, John W. Newcomer, Antony Loebel

T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS

Johannes Schneider-Thoma*, Stefan Leucht

T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENZAZINE TARGET VMAT2/SLC18A2

Clement Zai*, Arun Tiwari, Daniel Mueller, Aristotle Voineskos, Steven G. Potkin, Jeffrey Lieberman, Herbert Meltzer, Gary Remington, James Kennedy

T8. NEUROLOGICAL SOFT SIGNS (NSS) IN SCHIZOPHRENIA: AN UPDATE ON THE STATE-VERSUS TRAIT-PERSPECTIVE

Silke Bachmann*, Johannes Schröder



T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY

Maximus Berger, Patrick D. McGorry, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam Schaefer, Nilufar Mossaheb, Monika Schlogelhofer, Stefan Smesny, Ian Hickie, Gregor Berger, Eric Chen, Lieuwe De Haan, Dorien Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Andrew Thompson, Alison Yung, G. Paul Amminger*

T10. HERITABILITY OF AMYGDALA ACTIVITY AND ITS GENOME-WIDE ASSOCIATION WITH THE SCHIZOPHRENIA RISK LOCUS OF MIR137

Tiziana Quarto*, Giulio Pergola, Pasquale Di Carlo, Vittoria Paladini, Marco Papalino, Raffaella Romano, Antonio Rampino, Daniela Marvulli, Alessandro Bertolino, Giuseppe Blasi

T11. CEREBROSPINAL FLUID (CSF) MARKERS OF INFLAMMATION AND INFECTIONS IN SCHIZOPHRENIA AND AFFECTIVE DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Sonja Orlovska, Ole Köhler-Forsberg, Sophie Brix, Merete Nordentoft, Daniel Kondziella, Jesper Krogh, Michael Benros*

T12. VITAMIN D STATUS AND PSYCHOTIC DISORDER: ASSOCIATIONS WITH CLINICAL VARIABLES AND RISK FACTORS

Christine van der Leeuw*, Lot de Witte, Claude van der Ley, Richard Bruggeman, Jim van Os, Machteld Marcelis

(T13) PROGRESSIVE SPONTANEOUS AND SYNCHRONY GAMMA-BAND OSCILLATION DEFICITS IN FIRST EPISODE SCHIZOPHRENIA

Yoji Hirano*, Naoya Oribe, Toshiaki Onitsuka, Shigenobu Kanba, Martha Shenton, Margaret A. Niznikiewicz, Larry J. Seidman, Robert W. McCarley, Kevin M. Spencer

T14. ASSESSING DIFFERENCES IN INFLAMMATORY MARKERS BETWEEN FIRST EPISODE PSYCHOSIS PATIENTS AND HEALTHY CONTROLS: THE IMPORTANCE OF CONTROLLING FOR CONFOUNDING FACTORS

Annalisa Giordano*, Valeria Mondelli, Mitul A Mehta, Steve Williams, Carmine M Pariante, Paola Dazzan

T15. LONGITUDINAL ASSOCIATIONS BETWEEN CHILDHOOD SALIVARY CORTISOL LEVELS AND PRODROMAL SYMPTOMS IN LATE ADOLESCENCE: FINDINGS FROM A HIGH-RISK COHORT

Alexis Cullen*, Elizabeth Fraser, Helen Fisher, Ruth Roberts, Uzma Zahid, Carmine Pariante, Patricia Zunsain, Philip McGuire, Robin Murray, Valeria Mondelli, Kristin R. Laurens

T16. GLUTAMATERGIC CHANGES IN UHR

Christina Wenneberg*, Brian Broberg, Egill Rostrup, Louise Birkedal Glenthøj, Birte Glenthøj, Merete Nordentoft, Tina Dam Kristensen



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T17. OXIDATIVE STRESS BIOMARKERS AND NEGATIVE DIMENSION IN THE FIRST TEN YEARS OF SCHIZOPHRENIA: A 1-YEAR FOLLOW-UP STUDY

Leticia González-Blanco*, M. Paz Garcia-Portilla, Leticia Garcia-Alvarez, Lorena De La Fuente-Tomas, Pilar Saiz-Martinez, Celso Iglesias, Ana Coto, Julio Bobes

T18. MULTIVARIATE BRAIN ANATOMICAL DIFFERENCES IN POSITIVE AND NEGATIVE SCHIZOTYPY: PRELIMINARY RESULTS FROM THE TYPIA STUDY

Maria F. Urquijo*, Eliana Faiola, Anne Ruef, Anna Kasparbauer, Inga Meyhöfer, Maria Steffens, Ulrich Ettinger, Nikolaos Koutsouleris

T19. MULTIMODAL IMAGING IN FIRST EPISODE PSYCHOSIS: MAGNETOENCEPHALOGRAPHY, 7T FMRI STROOP, AND 7T MRS SPECTROSCOPY

Timothy Gawne*, Greg Overbeek, Jefferey Killen, David White, Meredith Reid, Noah Salibi, Thomas Denny, Ellis Charles, Adrienne Lahti

T20. SEARCHING FOR NOVEL AUTOANTIBODIES WITH CLINICAL RELEVANCE IN PSYCHIATRIC DISORDERS

Mats Persson*, Arasch Zandian, Louise Wingård, Hanna Nilsson, Evelina Sjöstedt, Daniel Johansson, David Just, Cecilia Hellström, Mathias Uhlén, Jochen Schwenk, Anna Häggmark-Månberg, Oscar Norbeck, Björn Owe-Larsson, Peter Nilsson

T21. ALTERATIONS OF CRY2 AND PER3 GENE EXPRESSION ARE ASSOCIATED WITH GRAY MATTER ABNORMALITIES OF THALAMIC-LIMBIC NETWORK IN UNIPOLAR DEPRESSION AND BIPOLAR DEPRESSION

Chengcheng Zhang*, Peiyan Ni, Tao Li

T22. PITUITARY GLAND VOLUME DIFFERENCES IN INDIVIDUALS WITH PSYCHOSIS: RESULTS FROM THE BIPOLAR-SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP) STUDY

Synthia Guimond*, Samantha Tingue, Gabriel A. Devenyi, Yun-Xiang Tang, Luke Mike, M. Mallar Chakravarty, John A. Sweeney, Godfrey D. Pearlson, Brett A. Clementz, Carol A. Tamminga, Matcheri S. Keshavan

T23. DYNAMICS OF NEURONAL METABOLISM AFTER THE ACUTE ONSET OF PSYCHOSIS – A TWO YEARS FOLLOW-UP 1H/31P-MR-SPECTROSCOPY STUDY IN NEUROLEPTIC NAÏVE UHR TRANSITION PATIENTS

Stefan Smesny*, Diana Berberich, Alexander Gussew, Kerstin Langbein, Mario Walther, Juergen Reichenbach

T24. REDOX REGULATORS AND OXIDATIVE STRESS IN SCHIZOPHRENIA

Havard Bentsen*, Dag Solberg, Helge Refsum, Ole Andreassen



T25. ALTERATIONS OF PLASMA PHOSPHOLIPID FATTY ACID PROFILES ARE ASSOCIATED WITH LOCAL BRAIN STRUCTURAL ABNORMALITIES IN NEUROLEPTIC NAÏVE FIRST-EPIISODE PSYCHOSIS PATIENTS

Kerstin Langbein*, Christian Fleischer, Katrin Kuhnt, Christian Gaser, Stefan Smesny

T26. PERINATAL STRESS AND PSYCHOSIS: RESULTS FROM THE BOLOGNA FIRST EPISODE PSYCHOSIS (BO-FEP) STUDY

Ilaria Tarricone, Marcello Lanari, Marta Di Forti*, Robin Murray, Domenico Berardi

T27. DYSFUNCTIONAL ATTITUDES IN ADOLESCENTS WITH EARLY-ONSET PSYCHOSIS: PRELIMINARY RESULTS

Olga Puig-Navarro*, Francina Badia, Yuli Gallegos, Mireia Forner, Inmaculada Baeza, Gisela Sugranyes, Eva Varela, Anabel Martinez-Aran, Eric Granholm

T28. QUALITY OF PARENTAL BONDING AMONG INDIVIDUALS WITH ULTRA-HIGH RISK OF PSYCHOSIS AND SCHIZOPHRENIA PATIENTS

Oon Him Peh, Attilio Rapisarda*, Kang Sim, Jimmy Lee

T29. ELECTRORETINOGRAPHIC RESPONSE IN YOUTHS AT GENETIC RISK OF SCHIZOPHRENIA AND BIPOLAR DISORDER AND IN NORMAL CONTROLS: TRANSVERSAL AND LONGITUDINAL DIFFERENCES AND IMPLICATIONS FOR THE RISK TRAJECTORY

Anne-Marie Gagné, Thomas Paccalet*, Valérie Jomphe, Daphné Lussier, Michel Maziade

T30. TIPPING POINTS – PREDICTING TRANSITIONS TO PSYCHOSIS IN AT-RISK YOUNG PEOPLE

Jessica A. Hartmann*, Patrick D. McGorry, Marieke Wichers, Barnaby Nelson

T31. TEN YEAR CLINICAL FOLLOW-UP OF YOUTH WITH EARLY ONSET PSYCHOSIS

Sugranyes Gisela*, Elena De la Serna, Marina Redondo, Daniel Ilzarbe, Josefina Castro-Fornieles, Inmaculada Baeza

T32. USING PSYCHOSOCIAL INTERVENTION TO ENHANCE KNOWLEDGE OF ATTENUATED PSYCHOSIS SYMPTOMS AND HELP SEEKING BEHAVIORS AMONG AFRICAN AMERICAN YOUNG ADULTS

Huijun Li*, Tanisha Pelham

T33. EARLY INTERVENTION FOR EARLY PSYCHOSIS IN FRANCE, MAPPING OF PROGRAMS

Sophie Meunier-Cussac*, Guy Gozlan, Laurent Lecardeur, Anne Duburcq, Laurène Courouve

T34. CAN VIDEOGAMES ENGAGE ADOLESCENTS AND YOUNG ADULTS AT RISK FOR PSYCHOSIS IN FAMILY THERAPY AND FACILITATE STRESS REACTIVITY? LESSONS FROM A FEASIBILITY TRIAL OF COMPUTER AIDED LEARNING FOR MANAGING STRESS (CALMS)

Kristen Woodberry*, Kelsey Johnson, Cole M. Chokran, Alex Keller, Larry Seidman

T35. DIFFUSION MEASURES OF EXTRACELLULAR FREE WATER IN A NON-HUMAN PRIMATE MODEL OF MATERNAL IMMUNE ACTIVATION: EXPLORING NEUROIMMUNE MECHANISMS OF PSYCHIATRIC DISORDERS

Cameron Carter*, Tyler Lesh, Costin Tanase, Jeffrey Bennett, Ana-Maria Iosif, Judy Van Der Water, Richard Maddock, David Amaral, Melissa Baumann



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T36. THE ANTIPSYCHOTIC-LIKE PROPERTIES OF EVENAMIDE (NW-3509) REFLECT THE MODULATION OF GLUTAMATERGIC DYSREGULATION

Marco Bortolato*, Laura Faravelli, Ravi Anand

T37. THE LONELY MOUSE: A MODEL FOR STUDYING MATERNAL PSYCHOLOGICAL STRESS AND ITS CONSEQUENCES IN THE OFFSPRING

Joseph Scarborough, Flavia Müller, Annamaria Cattaneo, Juliet Richetto*

T38. MOLECULAR INSULTS TO HIGHER-ORDER DORSOLATERAL PREFRONTAL CORTICAL CIRCUITS: IMPLICATIONS FOR THE PATHOGENESIS OF SCHIZOPHRENIA

Dibyadeep Datta*, Amy Arnsten

(T39) NEURAL MECHANISMS OF METABOTROPIC GLUTAMATE RECEPTOR 3 MEDIATED ENHANCEMENT OF SYNAPTIC PLASTICITY AND COGNITION

Branden Stansley*, Max Joffe, Samantha Yohn, Craig Lindsley, Colleen Niswender, P. Jeffrey Conn

T40. GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA

Andrew J. Grottick, Ben Grayson, Giovanni Podda, Nagi Idris, Cornelia Dörner-Ciossek*, Joanna Neill, Scott Hobson

T41. MODIFIED COGNITIVE BEHAVIORAL THERAPY FOR ELDERLY PATIENTS WITH SCHIZOPHRENIA: A RANDOMIZED, CONTROLLED PILOT TRIAL

Bernhard Müller*, Christian Kärger, Magdalena Horacek, Ute Darrelmann, Anja Heger, Daniela Kariofillis, Beate Nentwich, Christoph Meisner, Claudia Ose, Svenja Unsöld, Jens Wiltfang, Stefan Klingberg, Gudrun Sartory

T42. WHEN SHOULD EARLY INTERVENTION START, AND FOR HOW LONG SHOULD IT LAST?

Nikolai Albert*, Marianne Melau, Heidi Jensen, Lene Halling Hastrup, Carsten Hjorthøj, Merete Nordentoft

T43. TRANSCRANIAL DIRECT-CURRENT STIMULATION (TDCS) IN PATIENTS WITH ULTRA-TREATMENT-REFRACTORY AUDITORY HALLUCINATIONS

Jean-Pierre Lindenmayer*, Tania Sultana, Amandeep Kaur, Rang Yang, Anzalee Khan, Mila Kirstie-Kulsa, Isidora Ljuri, Benedicto Parker

T44. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EFFECTS OF VITAMIN B12, B6 AND FOLIC ACID ON COGNITION AND SYMPTOMS IN FIRST-EPIISODE PSYCHOSIS: THE VITAMINS IN PSYCHOSIS STUDY

Kelly Allott*, Patrick McGorry, Hok Pan Yuen, Colin O'Donnell

T45. A COMPARISON OF SCHIZOPHRENIA RELAPSE RATES OF 3 PALIPERIDONE FORMULATIONS, ONCE-DAILY, ONCE-MONTHLY AND ONCE EVERY-3-MONTH: POST-HOC ANALYSIS FROM 3 RANDOMIZED CONTROLLED TRIALS

Maju Mathews, Srihari Gopal*, Arun Singh, Isaac Nuamah, Anne Marie Quinn, Katalin Pungor, Wilson Tan, Bernardo Soares, Edward Kim



T46. TARGETING THE IMMUNE SYSTEM TO TREAT DEPRESSION AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Carl Krynicki*, Rachel Upthegrove, John Suckling, Paola Dazzan, Eileen Joyce, Stephen Lawrie, Nusrat Husain, Imran Chaudhry, Graham Dunn, Peter Jones, Danuta Liseicka, Shon Lewis, Thomas Barnes, Stephen Williams, Stephen Hopkins, Richard Drake, Richard Smallman, Annalisa Giordano, Carmine Pariante, Bill Deakin

T47. IS THERE A DIURNAL VARIATION IN PSYCHIATRIC SYMPTOMS IN SCHIZOPHRENIA?

David Daniel*, Alan Kott

T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION

Ravi Anand*, Emma C. Forrest, Richard D. Hartman, Stephen M. Graham, Laura Faravelli

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION

Monika Schlögelhofer*, Patrick D. McGorry, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam Schäfer, Nilufar Mossaheb, Stefan Smesny, Ian B. Hickie, Gregor Berger, Eric Y. H. Chen, Lieuwe de Haan, Dorien H. Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Andrew Thompson, Alison Ruth Yung, G. Paul Amminger

T50. SYMPTOMATIC AND FUNCTIONAL RESPONSE TO BREXPIPIRAZOLE TREATMENT IN PATIENTS WITH ACUTE SCHIZOPHRENIA BY AGE

Catherine Weiss*, Erin MacKenzie, Francois Therrien, Peter Zhang, Stine Meehan

T51. TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH TRANSCRANIAL CURRENT STIMULATION (TDCS): RESULTS OF RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED TRIAL

Leandro Valiengo*, Pedro Gordon, Mauricio Serpa, Acioly Lacerda, Wagner Gattaz, Martinus Van de Bilt, Helio Helkis, Andre Brunoni

T52. N-ACETYL-CYSTEINE ADD-ON TREATMENT LEADS TO AN IMPROVEMENT OF FORNIX WHITE MATTER INTEGRITY IN EARLY PSYCHOSIS

Paul Klausner, Lijing Xin, Margot Fournier, Alessandra Griffa, Martine Cleusix, Raoul Jenni, Michel Cuenod, Rolf Gruetter, Patric Hagmann, Philippe Conus, Philipp Baumann*, Kim Q. Do

T53. USING ARTIFICIAL INTELLIGENCE PLATFORMS TO ENHANCE STUDY DESIGN IN SCHIZOPHRENIA TRIALS

Laura Shafner*, Chloe Chah

T54. TAILOR – TAPERED DISCONTINUATION VERSUS MAINTENANCE THERAPY OF ANTIPSYCHOTIC MEDICATION IN PATIENTS WITH NEWLY DIAGNOSED SCHIZOPHRENIA SPECTRUM DISORDERS IN REMISSION OF PSYCHOTIC SYMPTOMS

Signe Dolmer*, Mai Nielsen, Merete Birk, Ole Mors, Anne Emilie Stürup, Nikolai Albert, Heidi Dorthe Jensen, Lene Epløv, Carsten Hjortshøj, Bjørn Epdrup, Merete Nordentoft

T55. DRIVING ABILITIES IN CLINICALLY STABLE OUTPATIENTS WITH SCHIZOPHRENIA

Falko Biedermann*, Alex Hofer, Theresia Pichker, Sylvia Pardeller, Georg Kemmler, Bernhard Holzner, Ilse Kurzthaler



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T56. AN EXPLORATORY ANALYSIS CONVERTING SCORES BETWEEN THE PANSS AND BNSS
Alan Kott*, David Daniel

T57. EFFECTS OF 0.5MS AND 1.5MS PULSE-WIDTHS ON CARDIOVASCULAR FUNCTION IN
SCHIZOPHRENIA PATIENTS RECEIVING ELECTROCONVULSIVE THERAPY
Dhruva Ithal*, Mitra Sayantanava, Sundar A. Shyam, Kumar C. N. Naveen, Jagadisha Thirthalli, V. J.
Ramesh, Bangalore Gangadhar

T58. SARCASM COMPREHENSION AS A SOCIAL COGNITION MEASURE IN SCHIZOPHRENIA –
A SYSTEMATIC LITERATURE SEARCH AND META-ANALYSIS ON THE USE OF THE TASIT
Alexander Rapp*, Franziska Purr, Anne Felsenheimer

T59. VIRTUAL REALTY ASSESSMENT OF FUNCTIONAL CAPACITY IN EARLY SCHIZOPHRENIA:
ASSOCIATIONS WITH NEUROCOGNITION, FUNCTIONAL CAPACITY PERFORMANCE, AND
DAILY FUNCTIONING
Joseph Ventura*, Tamara Welikson, Kenneth L. Subotnik, Arielle Ered, Richard Keefe, Gerhard H.
Hellemann, Keith H. Nuechterlein

T60. HEALTH LITERACY IN PEOPLE WITH SCHIZOPHRENIA ATTENDING COMMUNITY
MENTAL HEALTH CLINICS
Sumana Thomson, Cherrie Galletly*, Christopher Prener, Suzanne Garverich, Dennis Liu, Alisa Lincoln

T61. ANTISACCADE AND MEMORY GUIDED SACCADE PERFORMANCE ACROSS THE
SCHIZOPHRENIA CONTINUUM
Elizabeth Thomas, Susan Rossell, Eric Tan, Sean Carruthers, Philip Sumner, Kiymet Bozaoglu, Caroline
Gurvich, Susan Rossell*

T62. COMPARISON OF NEUROCOGNITIVE FUNCTIONS IN FIRST-EPISODE SCHIZOPHRENIA
PATIENTS, NON-PSYCHOTIC SIBLINGS, AND INDIVIDUALS AT CLINICAL HIGH-RISK FOR
PSYCHOSIS

On Ki Chu, Wing Chung Chang*, Hoi Ching Lee, Suet In Chan, Sanyin Chiu, Lai Ming Hui, Kit Wa Chan,
Ho Ming Lee, Yi Nam Suen, Eric Chen

T63. TOWARDS A COMPREHENSIVE SEMANTIC MEMORY NETWORK IN SCHIZOPHRENIA:
PRELIMINARY RESULTS USING MAGNETOENCEPHALOGRAPHY (MEG) IN SCHIZOTYPY
Rachel Batty*, Will Woods, Susan Rossell

T64. OPEN BOARD

(T65) EVALUATING PATTERNS OF SEMANTIC AND EXECUTIVE DYSFUNCTION IN
SCHIZOPHRENIA: A CLUSTER ANALYSIS APPROACH
Eric Tan*, Denny Meyer, Erica Neill, Caroline Gurvich, Susan Rossell

T66. PSYCHOMETRIC VALIDATION OF A NOVEL PATIENT-REPORTED OUTCOME MEASURE
FOR ASSESSING PATIENTS' SUBJECTIVE EXPERIENCE OF COGNITIVE IMPAIRMENT OF
SCHIZOPHRENIA (PRECIS)

Raymond Rosen, Jeremiah Trudeau, Steven Silverstein, David Henderson, Adam Smith, David Walling,
Miguel Garcia, Bethany Davis, Leonard Derogatis, Michael Sand*



T67. NEUROLOGICAL SOFT SIGNS IN THE COURSE OF SCHIZOPHRENIA: A LONGITUDINAL ANALYSIS IN CHRONIC SCHIZOPHRENIA

Christina Herold*, Céline Duval, Marc Lässer, Ulrich Seidl Seidl, Dusan Hirjak, Philipp Thomann, Johannes Schröder

T68. DIFFERENT INFLUENCES OF INTELLECTUAL FUNCTIONING AND COGNITIVE PERFORMANCE TO FUNCTIONAL OUTCOMES IN SCHIZOPHRENIA AND HEALTHY CONTROLS

Leticia Czepielewski*, Clarissa Gama, Cameron Carter, Angus MacDonald, III, James Gold, Steven Silverstein, Deanna Barch

T69. PERFORMANCE OF PATIENTS WITH NMDAR-AB ENCEPHALITIS COMPARED TO PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS USING FUNCTIONAL MAGNETIC RESONANCE IMAGING (FMRI) AND A WORKING MEMORY PARADIGM

Eric Kelleher*, David Mothersill, April Hargreaves, Angela Vincent, Gary Donohoe, Aiden Corvin

T70. RECOVERY IN FIRST –EPISODE PSYCHOSIS: COGNITIVE, CLINICAL AND RESILIENCE (PERSONAL RESOURCES) TRAJECTORIES ACROSS 6 YEARS

Anne-Kari Torgalsboen*, Christine Mohn

T71. CHANGE AND STABILITY IN COGNITIVE TRAJECTORIES FROM CHILDHOOD TO LATE ADOLESCENCE IN YOUNG OFFSPRING AT GENETIC RISK OF SCHIZOPHRENIA AND MOOD DISORDER: IMPLICATIONS FOR THE RISK STATUS

Elsa Gilbert*, Thomas Paccalet, Valérie Jomphe, Daphné Lussier, Michel Maziade

T72. VERBAL MEMORY AND VOXEL BASED MORPHOMETRY IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS: A PROCESS ORIENTED APPROACH

Rosa Ayesa-Arriola*, Esther Setien-Suero, Diana Tordesillas-Gutierrez, Benedicto Crespo-Facorro

T73. NOVEL VISUAL TRAINING FOR COGNITIVE REMEDIATION IN SCHIZOPHRENIA

Toral Surti*, Dayshalis Ofray, Bruce Wexler

T74. ACADEMIC ACHIEVEMENT AND SCHIZOPHRENIA: A META-ANALYSIS

Hannah Dickson*, Alexis Cullen, Sheilagh Hodgins, James MacCabe, Kristin Laurens

T75. GENERAL AND EXECUTIVE COGNITIVE PROFILES: GENERAL COGNITIONS INFLUENCE ON WCST PERFORMANCE

Sean Carruthers*, Caroline Gurvich, Philip Sumner, Eric Tan, Elizabeth Thomas, Susan Rossell

T76. INVESTIGATION OF NAV1.1 POSITIVE MODULATOR EFFECTS ON FAST SPIKING INTERNEURONS IN SOMATOSENSORY CORTEX SLICES

Piszar Ildiko, Just Stefan, Henning Draheim*

T77. DIAGNOSTIC AND NEUROCOGNITIVE CORRELATES OF SCHIZOTYPY WITHIN AND ACROSS THE PRONIA STUDY GROUPS

Carolina Bonivento*, Maria Fernanda Urquijo, Stefan Borgwardt, Eva Meisenzahl, Marlene Rosen, Raimo Salokangas, Rachel Upthegrove, Stephen Wood, Nikolaos Koutsouleris, Paolo Brambilla



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T78. LONG-TERM PROGNOSIS OF SCHIZOPHRENIA - RESULTS FROM THE NORTHERN FINLAND BIRTH COHORT 1966

Erika Jääskeläinen, Matti Penttilä, Jani Moilanen, Marianne Haapea, Anja Hulkko, Irina Rannikko, Nina Rautio, Tanja Nordström, Juha Käkälä, Annika Seppälä, Johanna Immonen, Hanna Korpela, Jussi Seppälä, Graham Murray, Hannu Koponen, Matti Isohanni*, Jouko Miettunen

T79. AFFECTIVE FACE PROCESSING IN SCHIZOPHRENIA: DISORDER-SPECIFIC OR TRANSDIAGNOSTIC DEFICIT?

Jack Cotter*, Kiri Granger, Jennifer Barnett

T80. CALCIUM AND POTASSIUM VOLTAGE-GATED CHANNELS GENES ASSOCIATION ANALYSIS: EVIDENCE ON THEIR ROLE IN COGNITIVE PERFORMANCE OF SCHIZOPHRENIA PATIENTS AND HEALTHY SUBJECTS

Maria Guardiola*, Carmen Almodóvar, Alba Lubeiro Juárez, Silvia Alonso-Lana, Jordi Ortiz-Gil, Amalia Guerrero-Pedraza, Salvador Sarró, Edith Pomarol-Clotet, Mar Fatjó-Vilas

T81. LONG-TERM COURSE OF COGNITIVE PERFORMANCE IN PATIENTS WITH CHRONIC SCHIZOPHRENIA

Thaís Martins*, Thalita Fernandes, Diego Mendes, Gustavo Mustafé, Luis Fernando Pegoraro, Clarissa Dantas

T82. THE RELATIONSHIP BETWEEN SOURCE MONITORING DEFICITS AND NEUROPSYCHOLOGICAL FUNCTIONING IN SCHIZOPHRENIA

Martyna Krężolek*, Łukasz Gawęda

T83. PROCESSING SPEED PERFORMANCE AND FUNCTIONING IN YOUNG ADOLESCENTS EXPERIENCING AUDITORY HALLUCINATIONS

Joanne Kenney*, Ian Kelleher, Colm Healy, Niamh Dooley, Eleanor Carey, Amy Adair, Donal Campbell, Helen Coughlan, Erik O' Hanlon, Mary Cannon

T84. DO SIMILAR COGNITIVE MECHANISMS ENCOURAGE DELUSION-LIKE IDEATION AND BELIEF IN FAKE NEWS?

Michael Bronstein*, Gordon Pennycook, Adam Bear, Tyrone Cannon, David Rand

T85. PRELIMINARY ANALYSES OF THE NEUROCOGNITIVE DATABASE OF PRONIA USING UNIVARIATE STATISTICS: CLINICAL GROUP DIFFERENCES

Marco Garzitto*, Lana Kambeitz-Ilankovic, Carolina Bonivento, Sara Piccin, Stefan Borgwardt, Eva Meisenzahl, Marlene Rosen, Raimo Salokangas, Rachel Uptegrove, Stephen Wood, Nikolaos Koutsouleris, Paolo Brambilla

T86. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS: AN EMPIRICAL LONGITUDINAL STUDY OF RELATIONSHIP TO COGNITIVE, SYMPTOM AND FUNCTIONAL OUTCOMES

Andrew Watson*, Bill Deakin, John Suckling, Paola Dazzan, Stephen Lawrie, Rachel Uptegrove, Nusrat Husain, Imran Chaudhry, Graham Dunn, Peter Jones, Danuta Liseicka, Shon Lewis, Thomas Barnes, Stephen Williams, Stephen Hopkins, Emma Knox, Kelly Byrne, Richard Drake, Richard Smallman, Eileen Joyce



T87. TOWARD DEVELOPING CLINICAL CUTOFF VALUES FOR THE BECK COGNITIVE INSIGHT SCALE

Danielle Penney*, Genevieve Sauve, Ashok Malla, Ridha Joobar, Martin Lepage

T88. CLUSTER ANALYSIS IDENTIFIES TWO NEUROCOGNITIVE PROFILES AMONG OFFSPRING AT GENETIC RISK OF A MAJOR MENTAL DISORDER

Rossana Kathenca Peredo Nunez de Arco*, Michel Maziade, Valérie Jomphe, Elsa Gilbert, Thomas Paccalet, Chantal Merette

T89. DEFINING COGNITIVE “NORMALITY” IN SCHIZOPHRENIA: PREVALENCE OF BROAD AND NARROW CRITERIA AND RELATION TO CLINICAL AND FUNCTIONAL STATUS

Melissa Parlar, Walter Heinrichs, Stephanie McDermid Vaz, Clayton Wilson, Farena Pinnock*

T90. MEMBERSHIP IN A SCHIZOTYPY TAXON PREDICTS HOPELESSNESS AND THOUGHTS OF SELF-HARM 7 YEARS LATER

Richard Linscott*

T91. DEVELOPMENT OF NOVEL BIS-AMIDINES FOR THE TREATMENT OF TOXOPLASMOSIS

Lorraine Jones-Brando*, Claudia Bordón, Robert H. Yolken, Varvara Misheneva, Mikhail Pletnikov, Omkar Revu, James McNulty

T92. QUITLINK: ACCESSIBLE SMOKING CESSATION SUPPORT FOR PEOPLE LIVING WITH SEVERE AND ENDURING MENTAL ILLNESS

Amanda Baker, Ron Borland, Billie Bonevski, David J. Castle*, Jill Williams, Catherine Segan, Peter Kelly, Alyna Turner, Lisa Brophy, Rohan Sweeney

T93. PERSONALITY TRAITS AND PSYCHOTIC SYMPTOMS IN RECENT ONSET OF PSYCHOSIS PATIENTS

Julia Sevilla-Llewellyn-Jones, Olga Santesteban-Echarri*, Pablo Cano-Domínguez, Antonia de-Luis-Matilla, Alberto Espina-Eizaguirre, Berta Moreno-Kustner, Susana Ochoa

T94. HS-CRP TO EVALUATE CHRONIC INFLAMMATION AND CARDIOVASCULAR DISEASES IN SCHIZOPHRENIA

Rahma Nefzi*, Amine Larnaout, Hanen Ben Ammar, Emira Khelifa, Amina Aissa, Zouhaier El Hechmi, Guemira Fethi

T95. PREVALENCE AND CONSEQUENCES OF CARDIAC AUTONOMIC DYSFUNCTION (CADF) IN 112 UNMEDICATED PATIENTS WITH SCHIZOPHRENIA

Berend Malchow*, Andy Schumann, Alexander Refisch, Steffen Schulz, Andreas Voss, Karl Bär

T96. A RETROSPECTIVE DATABASE STUDY OF THE RELATIONSHIP BETWEEN ALCOHOL AND CANNABIS USE AND CLINICAL MEASURES IN EARLY PHASE PSYCHOSIS

Jacob Cooney, Philip Tibbo*, Jacob McGavin, Sherry Stewart

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)

Luccas Coutinho*, Cinthia Higuchi, Daniel Azevedo Cavalcante, Rodrigo Bressan, Quirino Cordeiro, Cristiano Noto, Ary Gadelha



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T98. THE EFFECT OF SUBSTANCE USE ON 10-YEAR OUTCOME IN FIRST EPISODE PSYCHOSIS – EARLY CESSATION RESULTS IN BETTER OUTCOMES

Melissa Weibell*, Ingrid Melle, Inge Joa, Jan Olav Johannessen, Robert Jørgensen, Wenche ten Velden Hegelstad

T99. LONG-TERM CANNABIS USE ASSOCIATED WITH ALTERED FUNCTIONING DURING VERBAL LEARNING

Grace Blest-Hopley*, Aisling O'Neill, Robin Wilson, Vincent Giampietro, Sagnik Bhattacharyya

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA

Hianna Oliveira*, Luccas Coutinho, Cinthia Higuchi, Cristiano Noto, Rodrigo Bressan, Ary Gadelha

T101. ENRICHING PSYCHOTIC DISORDER CLASSIFICATION USING NATURAL LANGUAGE PROCESSING

Rashmi Patel*, Richard Jackson, Robert Stewart, Philip McGuire

T102. AN INVESTIGATION OF SCHIZOPHRENIA-BIPOLAR SUBGROUPS WITH GENETIC AND PROGNOSTIC VALIDATION

Dominic Dwyer*, Janos Kalman, Monika Budde, Urs Heilbronner, Anne Ruef, Heike Anderson-Schmidt, Katrin Gade, Nikola Mueller, Ivan Kondofersky, Sergi Papiol, Peter Falkai, Thomas G. Schulze, Nikolaos Koutsouleris

T103. ODIP (OUTIL DE DIAGNOSTIC INFORMATISÉ DES PSYCHOSES / PSYCHOSIS COMPUTERIZED DIAGNOSTIC TOOL): A NEW, SIMPLE METHOD FOR GENERATING DSM DIAGNOSES FOR PSYCHOTIC DISORDERS

Jean-Romain Richard*, Baptiste Pignon, Franck Schurhoff, Andrei Szoke

T104. ASSESSING THE UTILITY OF COPULA FUNCTIONS FOR RISK PREDICTION OF PSYCHOSIS
Landan Zhang*, Charlotte Gayer-Anderson, The EUGEI study, Craig Morgan, Robin Murray, Michael Pitt, Conrad Iyegbe

T105. FACTOR ANALYSES OF SUCCESSIVE ASSESSMENTS BY MULTIPLE SCALES HAVE A CONSISTENT STRUCTURE IN A COHORT OF FIRST EPISODE PSYCHOSES

Alexandra Berry*, Max Marshall, Max Birchwood, Shon Lewis, Samei Huda, Alison Yung, Richard Drake

T106. IMPROVING PSYCHIATRIC DIAGNOSIS BY ADDING MOTOR FUNCTION NEXT TO MENTAL HEALTH FUNCTION: A NETWORK APPROACH

Galoeh Adrian Noviar*, Didi Rhebergen, P. Roberto Bakker

T107. WHY VALIDATION MATTERS: A DEMONSTRATION PREDICTING ANTIPSYCHOTIC RESPONSE USING 5 RCTS

Adam Chekroud*

T108. ANALYTICAL AND PREDICTIVE VALIDITY OF HALLUCINATIONS IN FIRST PSYCHOTIC EPISODES

Maria Hernandez-Garcia, Carlos Gonzalez, Pablo Soldevilla, Olga Sparano, Miguel Hernandez, Carlos Cañete, Julio Sanjuan*



T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)

Seth Hopkins*, Ajay Origala, Antony Loebel, Kenneth S. Koblan

T110. FIRST EPISODE PSYCHOTIC PATIENTS WITH A HISTORY OF FREQUENT CANNABIS USE EXPRESS MORE POSITIVE SYMPTOMS AT ILLNESS ONSET THAN THOSE WHO NEVER USED CANNABIS

Diego Quattrone*, Charlotte Gayer-Anderson, Laura Ferraro, Giada Tripoli, EUGEI Group, Evangelos Vassos, Pak Sham, Jim Van Os, Craig Morgan, Cathryn Lewis, Ulrich Reininghaus, Robin Murray, Marta Di Forti

T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY

Anzalee Khan*, Lora Liharska, Philip Harvey, Alexandra Atkins, Richard Keefe, Danny Ulshen

T112. TRADITIONAL RISK FACTORS NOT ENOUGH TO EXPLAIN THE SHORT LIFETIME EXPECTANCY IN PATIENTS WITH SCHIZOPHRENIA

Moradi Hawar*, Anna-Karin Olsson, Fredrik Hjärthag, Madeleine Johansson, Maivor Olsson-Tall, Lars Helldin

T113. THE LINK BETWEEN BLUNTED AFFECT AND SUICIDE IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW

Markella Grigoriou*, Rachel Upthegrove, Lisa Bortolotti

T114. SCHIZOTYPAL PERSONALITY QUESTIONNAIRE-BRIEF: FACTOR STRUCTURE ANALYSIS IN A NONCLINICAL ROMANIAN SAMPLE

Aziz Ferchiou*, Maria Ladea, Mihai Bran, Marion Leboyer, Ruxandra Slavu, Franck Schurhoff, Andrei Szoke

T115. REASONING BIAS, WORKING MEMORY PERFORMANCE, AND A TRANSDIAGNOSTIC PHENOTYPE OF AFFECTIVE DISTURBANCES AND PSYCHOTIC EXPERIENCES IN THE GENERAL POPULATION

Christian Rauschenberg*, Ulrich Reininghaus, Margreet ten Have, Ron de Graaf, Saskia van Dorselaer, Nicole Gunther, Lotta-Katrin Pries, Sinan Guloksuz, Rajiv Radhakrishnan, Maarten Bak, Jim van Os

T116. CAFFEINE-INDUCED PSYCHIATRIC MANIFESTATIONS

Kwanghun Lee*, Won-Myong Bahk, Bo-Hyun Yoon, Duk-In Jon, Sang-Yeol Lee, Moon Doo Kim, Beomwoo Nam, Min-Kyu Song

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA

Fernando Rocha Loures Malinowski, Bruno Bertolucci*, Cristiano Noto, Deyvis Rocha, Cinthia Higuchi, Rodrigo Bressan, Ary Gadelha

T118. IMPACT OF DYSFUNCTIONAL METACOGNITIONS AND WORRY ON DEVELOPMENT OF PARANOIA: A 1-YEAR LONGITUDINAL STUDY IN A NON-CLINICAL SAMPLE

Xiaoqi Sun*, Suzanne So, Raymond Chan, Chui-de Chiu, Patrick Leung



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T119. CAN SOME YOUNG PEOPLE RECOVER FROM FIRST-EPISODE PSYCHOSIS WITH INTEGRATED PSYCHOSOCIAL TREATMENT WITHOUT ANTIPSYCHOTIC MEDICATIONS? AN RCT TO ASSESS RISKS, BENEFITS, AND RANGE OF OUTCOMES

Patrick D. McGorry*, Shona Francey, Barnaby Nelson, Jessica Graham, Lara Baldwin, Suzy Harrigan, Hok Pan Yuen, Alex Fornito, Kelly Allott, Mario Alvarez-Jimenez, Brian O'Donoghoe

T120. OPEN BOARD

T121. RATES AND PREDICTORS OF RELAPSE FOLLOWING DISCONTINUATION OF ANTIPSYCHOTIC MEDICATION AFTER A FIRST EPISODE OF PSYCHOSIS

Meghan Bowtell, Scott Eaton, Kristen Thien, Melissa Bardell-Williams, Linglee Downey, Aswin Ratheesh, Eoin Killackey, Patrick D. McGorry, Brian O'Donoghue*

T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY

Amedeo Minichino*, Grazia Rutigliano, Sergio Merlino, Cathy Davies, Dominic Oliver, Andrea De Micheli, Philip McGuire, Paolo Fusar-Poli

T123. PERSISTENT NEGATIVE SYMPTOMS IN FIRST EPISODE PSYCHOSIS: PREVALENCE, PREDICTORS AND PROGNOSIS

Stephen Austin*, Carsten Hjorthøj, Ole Mors, Rikke Gry Secher, Pia Jeppesen, Lone Petersen, Anne Thorup, Merete Nordentoft

T124. CLINICAL DIFFERENCES BETWEEN URBAN AND RURAL SCHIZOPHRENIA

Amine Larnaout*, Rahma Nefzi, Amina Aissa, Rouaa Trabelsi, Emira Khelifa, Hanen Ben Ammar, Zouhaier El Hechmi

T125. INCIDENCE OF TREATMENT RESISTANCE SCHIZOPHRENIA IN A COMMUNITY SAMPLE USING THE TRIP CONSENSUS

Dan Joyce*, Rodrigo Bressan, Sukhi Shergill

T126. PSYCHOTIC EXPERIENCES AND COMMON MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE: BIDIRECTIONAL AND TRANSDIAGNOSTIC ASSOCIATIONS IN A LONGITUDINAL COMMUNITY-BASED STUDY

Pedro Pan*, Giovanni Salum, Felipe Argolo, Ary Gadelha, Rodrigo Bressan

T127. OFFSPRING OF ANTENATALLY DEPRESSED MOTHERS AND PARENTS WITH SEVERE MENTAL DISORDER – A LONG FOLLOW-UP IN THE NORTHERN FINLAND 1966 BIRTH COHORT

Pirjo Mäki*, Tiina Taka-Eilola, Graham Murray, Juha Veijola

T128. THE ASSOCIATION BETWEEN GENETIC RISK FOR SCHIZOPHRENIA AND PATTERNS OF CIGARETTE AND CANNABIS USE IN ADOLESCENCE

Stanley Zammit*, Hannah Jones, Suzanne Gage, Jon Heron, George Davey Smith, Glyn Lewis, Michael O'Donovan, Michael Owen, James Walters, Marcus Munafò



T129. CHARACTERISTICS OF PREMORBID FUNCTIONING IN MALE ADOLESCENTS WHO LATER SUFFERED FROM PSYCHOTIC DISORDERS

Katya Rubinstein*, Ortal Bhuknik-Atzil, Rivka Tuval-Maschiach, Eyal Fruchter, Avi Reichenberg, Mark Weiser

T130. ASSOCIATIONS BETWEEN DIFFERENT TYPES OF CHILDHOOD ADVERSITY AND 5-YEAR OUTCOMES IN FIRST-EPISODE PSYCHOSIS PATIENTS

Olesya Ajnakina*, Antonella Trotta, Marta Di Forti, Simona Stilo, Anna Kolliakou, Poonam Gardner-Sood, Javier-David Lopez-Morinigo, Fiona Gaughran, Anthony David, Paola Dazzan, Carmine Pariante, Valeria Mondelli, Robin Murray, Helen Fisher

T131. INCIDENCE OF FIRST-EPISODE PSYCHOSIS IN THE CATCHMENT AREA OF RIBEIRÃO PRETO, BRAZIL

Cristina Del-Ben*, Shuhama Rosana, Camila Loureiro, Taciana Ragazzi, Daniela Zanatta, Silvia Tenan, Jair Ferreira-Santos, Paulo Louzada-Junior, Antonio Dos Santos, Craig Morgan, Paulo Menezes

T132. ASSESSMENT OF CROSS-NATIONAL EQUIVALENCE OF THE COMMUNITY ASSESSMENT OF PSYCHIC EXPERIENCES (CAPE)

Baptiste Pignon*, Hugo Peyre, Aziz Ferchiou, Jim Van Os, Bart P. F. Rutten, Robin M. Murray, Craig Morgan, Marion Leboyer, Franck Schürhoff, Andrei Szöke

T133. MENTAL HEALTH OF ASYLUM SEEKERS AT THE HUMANITARIAN CAMP IN PARIS

Andrea Tortelli*, Florence Perquier, Norbert Skurnik, René Wulfman, Marina Ibad-Ramos, Andrei Szöke, Alain Mercuel

T134. EXPOSURE TO NITROGEN DIOXIDE DURING CHILDHOOD IS ASSOCIATED WITH INCREASED RISK OF SCHIZOPHRENIA

Sussie Antonsen, Pearl L.H. Mok, Roger T. Webb, Preben Bo Mortensen, John McGrath, Esben Agerbo, Jørgen Brandt, Camilla Geels, Carsten Pedersen*

T135. NEIGHBORHOOD-LEVEL PREDICTORS OF AGE AT ONSET AND DURATION OF UNTREATED PSYCHOSIS IN FIRST-EPISODE PSYCHOSIS

Benson Ku*, Luca Pauselli, Marc Manseau, Michael Compton

T136. DO VITAMIN D SUPPLEMENTATION DURING THE FIRST YEAR OF LIFE PREDICT COGNITION IN PSYCHOSES DURING MIDLIFE?

Jussi Seppälä*, Laura Tröger, Erika Jääskeläinen, Jouko Miettunen, Matti Isdohanni, Marianne Haapea

T137. CLASSIFICATION OF RECENT-ONSET PSYCHOSIS BASED ON RESTING-STATE FUNCTIONAL CONNECTIVITY AND THE RELATIONSHIP TO NEUROCOGNITIVE IMPAIRMENT

Johanna Weiske*, Anne Ruef, Shalaila Haas, Carolina Bonivento, Nikolaos Koutsouleris, Lana Kambeitz-Ilankovic

T138. ACOUSTIC PATTERNS IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Alberto Parola*, Arndis Simonsen, Vibeke Bliksted, Riccardo Fusaroli



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T139. ELECTRORETINOGRAM ABNORMALITIES IN SCHIZOPHRENIA PATIENTS WITH VISUAL HALLUCINATIONS

Vincent Laprevote*, Florent Bernardin, Thomas Schwitzer, Raymund Schwan

T140. RESTING STATE NETWORKS ALTERATION IN SCHIZOPHRENIA

Gianluca Mingoa*, Igor Nenadic

T141. CHARACTERIZATION OF HEMODYNAMIC ALTERATIONS IN SCHIZOPHRENIA AND BIPOLAR DISORDER AND THEIR EFFECT ON RESTING-STATE FUNCTIONAL CONNECTIVITY

Wenjing Yan, Lena Palaniyappan*, Peter Liddle, Gopikrishna Deshpande

T142. PARIETAL CONNECTIVITY IN SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR DISORDER: A COMBINED STRUCTURAL AND DYNAMIC FUNCTIONAL CONNECTIVITY STUDY

Tushar Das, Peter Liddle, Lena Palaniyappan*

T143. NOT A NUISANCE ANY MORE: GLOBAL FMRI SIGNAL AT REST, PROCESSING SPEED AND SYMPTOM SEVERITY IN SCHIZOPHRENIA

Annabel Umeh, Peter Liddle, Susan Fancis, Lena Palaniyappan*

T144. THE ROLE OF TRANSIENT BETA OSCILLATIONS IN ABERRANT SELECTIVE ATTENTION TO SALIENT EVENTS IN SCHIZOPHRENIA

Elizabeth Liddle, Jyothika Kumar, Siân Robson, Emma Hall, Lauren Gascoyne, Mohammad Katshu, Lena Palaniyappan, Peter Morris, Matthew Brookes, Peter Liddle*

T145. ALTERATIONS IN SUPERFICIAL WHITE MATTER IN THE FRONTAL CORTEX IN SCHIZOPHRENIA: A DWI STUDY USING A NOVEL ATLAS

Ellen Ji*, Sarrazin Samuel, Marion Leboyer, Miguel Guevara, Pamela Guevara, Cyril Poupon, Antoine Grigis, Josselin Houenou

T146. AROUSAL AFFECTS DIFFERENTIALLY FIRST-EPIISODE PSYCHOSIS PATIENTS AND CONTROL SUBJECTS' DEFAULT MODE NETWORK FUNCTIONING DURING MOVIE VIEWING

Teemu Mantyla*, Jussi Alho, Eva Rikandi, Tuula Kiesepä, Jaana Suvisaari, Tuukka Raij

T147. DECREASED STRIATAL REWARD PREDICTION ERROR CODING IN UNMEDICATED SCHIZOPHRENIA PATIENTS

Teresa Katthagen*, Jakob Kaminski, Andreas Heinz, Florian Schlagenhaut

T148. THALAMIC-CORTICAL CONNECTIVITY IN PATIENTS WITH AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA

Yulia Zaytseva*, Eva Kozakova, Eduard Bakstein, Jaroslav Hlinka, Maya Schutte, Iris Sommer, Jiri Horacek, Filip Spaniel

T149. METACOGNITIVE DEFICITS IN INTEROCEPTION ARE ASSOCIATED WITH DISSOCIATIVE EXPERIENCES IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

Sarah Garfinkel, Kathy Greenwood*, Charlotte Rae, Geoff Davies, Cassandra Gould Van Praag, Anil Seth, Medford Nick, Hugo Critchley



T150. REAL-TIME FMRI NEUROFEEDBACK TO DOWN-REGULATE SUPERIOR TEMPORAL GYRUS ACTIVITY IN PATIENTS WITH SCHIZOPHRENIA AND AUDITORY HALLUCINATIONS: A PROOF-OF-CONCEPT STUDY

Natasza Orlov*, Vincent Giampietro, Owen O'Daly, Gareth Barker, Katya Rubia, Philip McGuire, Sukhi Shergill, Paul Allen

T151. APATHY AND DIMINISHED EXPRESSION ARE NOT ASSOCIATED WITH VENTRAL OR DORSAL STRIATUM VOLUME IN SCHIZOPHRENIA

Achim Burrer*, Matthias Kirschner, Erich Seifritz, Kaiser Stefan

T152. NRN1 GENE AND FUNCTIONAL MRI: ASSOCIATION ANALYSIS IN SCHIZOPHRENIA PATIENTS AND HEALTHY SUBJECTS

Carmen Almodóvar*, Maria Guardiola, Pilar Salgado-Pineda, Marcos Moreno, Carme Gallego, Claudia Prats, Barbara Arias, Edith Pomarol-Clotet, Peter J. McKenna, Mar Fatjó-Vilas

T153. CAN COGNITIVE TRAINING DECREASE REACTIVE AGGRESSION IN SCHIZOPHRENIA?

Anthony Ahmed*, Matthew Hoptman, Jean-Pierre Lindenmayer

T154. RESTING STATE PERFUSION IN THE REWARD SYSTEM LINKED TO DIMENSIONS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Katharina Stegmayer*, Andrea Federspiel, Roland Wiest, Sebastian Walther

T155. SEPARABLE AND REPLICABLE NEURAL STRATEGIES DURING SOCIAL BRAIN FUNCTION IN PEOPLE WITH AND WITHOUT SEVERE MENTAL ILLNESS

Colin Hawco*, Robert Buchanan, Navona Calrco, Benoit Mulsant, Joseph Viviano, Erin Dickie, Miklos Argyelan, James Gold, Marco Iacoboni, Pamela DeRosse, George Foussias, Anil Malhotra, Aristotle Voineskos

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN

Gilles Tamagnan*, Olivier Barret, David Alagille, Vincent Carroll, Jennifer Madonia, Cristian Constantinescu, Christine SanDiego, Caroline Papin, Thomas Morley, David Russell, Timothy McCarthy, Lei Zhang, David Gray, Anna Villalobos, Chewah Lee, Jianqing Chen, John Seibyl, Kenneth Marek

T157. FRONTOSTRIATAL CONNECTIVITY IN TREATMENT-RESISTANT SCHIZOPHRENIA: RELATIONSHIP TO POSITIVE SYMPTOMS AND COGNITIVE FLEXIBILITY

Vanessa Cropley*, Eleni Ganella, Cassandra Wannan, Andrew Zalesky, Tamsyn Van Rheenen, Chad Bousman, Ian Everall, Alexander Fornito, Christos Pantelis

T158. THE VALUE OF ACTIGRAPHY FOR MEASURING APATHY IN PATIENTS WITH SCHIZOPHRENIA: ASSOCIATIONS WITH CLINICAL MEASURES AND NEUROIMAGING OF ACTION INITIATION

Marie-José van Tol*, Claire Kos, Michelle Servaas, Jan Bernard Marsman, Nicky Klaasen, Oliver Tucha, Henderikus Knegetering, André Aleman



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T159. ASSOCIATION BETWEEN VITAMIN D INSUFFICIENCY AND METABOLIC SYNDROME IN PATIENTS WITH PSYCHOTIC DISORDERS

Sung-Wan Kim*, Taeyoung Yoo, Jung Jin Kim, Jae-Kyeong Kim, Ji-Eun Hong, Ju-Yeon Lee, Jae-Min Kim, G Paul Amminger, Michael Berk, Jin-Sang Yoon

T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL

Dan Siskind*, Anthony Russell, Clare Gamble, Karl Winckel, Sam Hollingworth, Steve Kisely

T161. HEARING VOICES AMONG INDIGENOUS MAASAI WOMEN IN TANZANIA: IMPLICATIONS FOR GLOBAL MENTAL HEALTH

Neely Myers, Luca Pauselli*, Michael Compton

T162. LEFT PREFRONTAL GYRIFICATION IN HEALTHY SUBJECTS ASSOCIATED WITH SUBCLINICAL PSYCHOTICISM PHENOTYPE

Igor Nenadic*, Katharina Frisch, Bianca Besteher, Christian Gaser

T163. USING LONGITUDINAL NEUROIMAGING TO EXAMINE PROGRESSIVE BRAIN CHANGES FOLLOWING A FIRST EPISODE OF PSYCHOSIS: THE EFFECTS OF ACTIVE PSYCHOTIC SYMPTOMS

Martin Lepage*, Carolina Makowski, Michael Bodnar, Ridha Joobor, Ashok Malla

T164. STRUCTURAL COVARIANCE IN DRUG-NAÏVE FIRST EPISODE PSYCHOSIS: AN ULTRA-HIGH FIELD MRI STUDY

Tushar Das, Kara Dempster, Michael Mackinley, Peter Jeon, Joe Gati, Jean Theberge, Ali Khan, Lena Palaniyappan*

T165. ULTRA-HIGH FIELD MORPHOMETRY IN DRUG-NAÏVE FIRST EPISODE PSYCHOSIS

Tushar Das, Kara Dempster, Michael Mackinley, Peter Jeon, Joe Gati, Jean Theberge, Ali Khan, Lena Palaniyappan*

T166. SPATIAL INCOHERENCE OF LARGE-SCALE CORTICAL NETWORKS RELATES TO FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA: A 7T MRI-BASED THICKNESS STUDY

Lena Palaniyappan*, Ali Al-Radaideh, Penny Gowland, Peter Liddle

T167. ABERRANT MYELINATION OF THE CINGULUM BUNDLE IN PATIENTS WITH SCHIZOPHRENIA: A 7T MTI/DTI STUDY

Lena Palaniyappan*, Ali Radaideh, Olivier Mouglin, Penny Gowland, Peter Liddle

T168. STRUCTURAL COVARIANCE AND CORTICAL REORGANIZATION IN SCHIZOPHRENIA: A MRI-BASED MORPHOMETRIC STUDY

Lena Palaniyappan*, Peter Liddle

T169. COGNITIVE INSIGHT AND CORTICAL THICKNESS IN SCHIZOPHRENIA

Arpitha Jacob, Mariamma Philip, Rose Bharath, Shivarama Varambally, Ganesan Venkatasubramanian, Gopikrishna Deshpande, Naren Rao*, Ayushi Shukla



T170. THE SUPERIOR LONGITUDINAL FASCICULUS: CAN CSD BASED TRACT DELINEATION AND NODAL ANALYSIS CLARIFY THE PRESENCE OF TARGETED DIVERGENT DEVELOPMENTAL STRUCTURAL CONNECTIVITY IN ADOLESCENTS REPORTING PSYCHOTIC EXPERIENCES

Erik O'Hanlon*, Niamh Dooley, Colm Healy, Mary Cannon

T171. REDUCED FRONTAL CORTICAL THICKNESS AND SURFACE IN A 10 YEARS FOLLOW-UP OF EARLY ONSET PSYCHOSIS

Daniel Ilzarbe*, Elena de la Serna, Inmaculada Baeza, Jose Pariente, Adriana Fortea, Marina Redondo, Nuria Bargallo, Josefina Castro-Fornieles, Gisela Sugranyes

T172. MULTIMODAL QUANTIFICATION OF MEMORY CIRCUIT MICROSTRUCTURE IN FIRST EPISODE PSYCHOSIS

Carolina Makowski*, Christine Tardif, Gabriel Devenyi, Robert Amaral, Gabriella Buck, Ridha Joobar, Ashok Malla, Jai Shah, Mallar Chakravarty, Martin Lepage

T173. GABA AND GLUTAMATE IN PATIENTS WITH 22Q11.2 DELETION SYNDROME AND HEALTHY VOLUNTEERS AND THE RELATION WITH COGNITION: A RANDOMIZED DOUBLE-BLIND 7TESLA PHARMACOLOGICAL MRS STUDY

Claudia Vingerhoets*, Desmond Tse, Mathilde van Oudenaren, Esther van Duin, Dennis Hernaus, Jan Ramaekers, Jaap Janssen, Grainne McAlonan, Oswald Bloemen, Therese van Amelsvoort

T174. STRUCTURAL ABNORMALITIES IN THE CINGULATE CORTEX IN ADOLESCENTS AT ULTRA-HIGH RISK WHO LATER DEVELOP PSYCHOSIS

Adriana Fortea*, Phillip van Eindhjoven, Jose Pariente, Anna Calvo, Albert Batalla, Elena de la Serna, Daniel Ilzarbe, Jordina Tor, Montserrat Dolz, Inmaculada Baeza, Gisela Sugranyes

T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS

Diana Tordesillas-Gutiérrez*, Ayesa-Arriola Rosa, Victor Ortiz-García de la Foz, Esther Setien-Suero, Javier Vázquez-Bourgon, Benedicto Crespo-Facorro

T176. REDUCED WHITE MATTER 'CONNECTIVITY' IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA

Idaiane Assunção-Leme, André Zugman, Luciana Monteiro de Moura, João Ricardo Sato, Deyvis Rocha, Bruno Bertolucci Ortiz, Cristiano Noto, Vanessa Ota, Sintia Belangero, Rodrigo Bressan, Andrea Parolin Jackowski, Ary Gadelha*

T177. STRUCTURAL ORGANIZATION OF THE PRAXIS NETWORK PREDICTS GESTURE PRODUCTION: EVIDENCE FROM HEALTHY SUBJECTS AND PATIENTS WITH SCHIZOPHRENIA

Petra Viher*, Ahmed Abdulkadir, Katharina Stegmayer, Peter Savadijev, Marek Kubicki, Nikos Makris, Sarina Karmacharya, Andrea Federspiel, Stephan Bohlhalter, Tim Vanbellingen, René Müri, Roland Wiest, Werner Strik, Sebastian Walther

T178. PRIOR SUB-THRESHOLD PSYCHOTIC SYMPTOMS ASSOCIATED WITH THICKER RIGHT INFERIOR FRONTAL GYRUS AMONG PATIENTS IN A FIRST EPISODE OF PSYCHOSIS

Rachel Rosengard*, Carolina Makowski, Jai Shah, Ashok Malla, Ridha Joobar, Martin Lepage



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T179. DO INDIVIDUALS IN A CLINICAL HIGH-RISK STATE FOR PSYCHOSIS DIFFER FROM HEALTHY CONTROLS IN THEIR CORTICAL FOLDING PATTERNS?

Rachele Sanfelici*, Dominic B. Dwyer, Anne Ruef, Linda A. Antonucci, Nikolaos Koutsouleris, The PRONIA Study Group

T180. LOWER GLUTAMATE LEVEL IN TEMPORO-PARIETAL AREA MAY PREDICT A BETTER RESPONSE TO TDCS IN SCHIZOPHRENIA: A PILOT STUDY

Junhee Lee*, Youngwoo Yoon, Andrea Wijtenburg, Laura Rowland, In Chan Song, Kang Ik Cho, Minah Kim, Tae Young Lee, Jun Soo Kwon

T181. ABNORMAL FRONTAL AND PARIETAL SYNAPTIC GAIN RESPONSES IN FIRST EPISODE SCHIZOPHRENIA DURING A P300 TARGET DETECTION TASK

Alvaro Diez*, Alba Lubeiro Juárez, Benjamín Cañas, Aldara Alvarez-Astorga, Angel Nevado, Vicente Molina

T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA

Tzung-Jeng Hwang*, Jing-Ying Huang, Chih-Min Liu, Yu-Jen Chen, Yung-Chin Hsu, Hai-Gwo Hwu, Yi-Tin Lin, Ming-Hsien Hsieh, Chen-Chung Liu, Yi-Ling Chien, Wen-Yih Isaac Tseng

T183. AUDITORY-STEADY-STATE RESPONSES AND CORTICAL VOLUME IN PATIENTS WITH SCHIZOPHRENIA

Do-Won Kim*, Sungkean Kim, Seon-Kyeong Jang, Jihoon Kang, Chang-Hwan Im, Seung-Hwan Lee

T184. BRAIN-WIDE FUNCTIONAL DYSCONNECTIVITY IN SCHIZOPHRENIA: PARSING DIATHESIS, RESILIENCE AND THE EFFECTS OF CLINICAL EXPRESSION

Shuixia Guo, Wei Zhao, Haojuan Tao, Liu Zhening, Lena Palaniyappan*

T185. DIFFERENTIAL ACTIVITY OF TRANSCRIBED ENHANCERS IN THE PREFRONTAL CORTEX OF 592 CASES WITH SCHIZOPHRENIA AND CONTROLS

Panos Roussos*

T186. ASSOCIATION BETWEEN POLYMORPHISMS OF THE NEUREGULIN 1 (NRG1) GENE AND SCHIZOPHRENIA

Junzhe Xu*, Jianxin Yuan, Te-An Chen, Anna Li, Meghan Helm, Steve Dubovsky

T187. ALTERED DNA METHYLATION OF THE OXYTOCIN RECEPTOR GENE IS ASSOCIATED WITH SUSCEPTIBILITY TO PSYCHOSIS AND ANHEDONIA-ASOCIALITY IN FEMALES: EPIGENETIC EVIDENCE IN RECENT-ONSET SCHIZOPHRENIA AND ULTRA-HIGH RISK FOR PSYCHOSIS

Minji Bang, Se Joo Kim, Kyung Ran Kim, Su Young Lee, Jin Young Park, Eun Lee, Jee In Kang, Suk Kyoong An*

T188. MASSIVE OPEN ONLINE DISCOVERY 'MOOD' FOR SCHIZOPHRENIA RESEARCH

Madhavi Ganapathiraju*, Narayanaswamy Balakrishnan



T189. PEPTIDE SHARING BETWEEN SCHIZOPHRENIA-RELATED PROTEINS AND THE INFLUENZA A VIRUS MAY OFFER A WINDOW INTO THE IMMUNE AETIOLOGY OF PSYCHOTIC DISORDERS

Adrianna Kepinska*, Thomas Pollak, Conrad Iyegbe, Robin Murray

T190. ASSOCIATION OF THE HUMAN MU-OPIOID RECEPTOR GENE POLYMORPHISM ASN40ASP WITH SCHIZOPHRENIA

Anna Li*, Jiaxin Yuan, Te-An Chen, Meghan Helm, Steve Dubovsky, Junzhe Xu

T191. RANDOMIZED DOUBLE-BLIND FEASIBILITY STUDY OF A GLUTEN-FREE DIET IN PEOPLE WITH SCHIZOPHRENIA AND ELEVATED ANTIGLIADIN ANTIBODIES (AGA IGG)

Deanna Kelly*, Haley Demyanovich, Katrina Rodriguez, Daniela Cihakova, Monica Talor, James Gold, Sharon August, Robert Buchanan, Stephanie Feldman, Fang Liu, William Carpenter, William Eaton

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION

Sarah Kanji, Ilona Gorbovskaia, Trehani Fonseka, Kazunari Yoshida, Victoria Marshe, Malgorzata MacKenzie, Premysl Bercik, Elena Verdu, Margaret Hahn, Daniel J. Mueller*

T193. CHRONIC HALOPERIDOL TREATMENT INDUCES SIGNIFICANT CHANGES IN MICROGLIA AND IN THE EXPRESSION OF THE 18 KDA TRANSLOCATOR PROTEIN TSPO IN NAIVE ADULT RAT BRAINS

Marie Cotel*, Ewelina Lenartowicz, Sridhar Natesan, Maria Dadabhoy, Anthony Vernon

T194. BRAIN STRUCTURAL AND BEHAVIORAL ABNORMALITIES FOLLOWING PRENATAL EXPOSURE TO MATERNAL INFLAMMATION ARE PREVENTED BY EARLY BUT NOT LATE INTERVENTION

Yael Piontkewitz*, Michal Arad, Ina Weiner

T195. GAMMA SYNCHRONY IS DYSFUNCTIONAL DURING COGNITIVE PROCESSING IN FIRST ONSET SCHIZOPHRENIA

Anthony Harris*, Annie Brennan, Leanne Williams

T196. CALRETININ INTERNEURON DENSITY IN THE CAUDATE NUCLEUS IS LOWER IN SCHIZOPHRENIA

Istvan Adorjan*, Bin Sun, Virginia Feher, Teadora Tyler, Bori Damo-Csorba, Benedek Pour, Daniel Veres, Olaf Ansorge, Steven Andrew Chance, Francis Szele

T197. A DRD2 CO-EXPRESSION GENE SET ENRICHED FOR SCHIZOPHRENIA RISK GENES IS CHARACTERIZED BY A COMMON TRANSCRIPTIONAL REGULATION INVOLVING NURRI TRANSCRIPTION FACTOR

Silvia Torretta*, Antonio Rampino, Giulio Pergola, Maria Pennuto, Manuela Basso, Pasquale Di Carlo, Rita Masellis, Giuseppe Blasi, Alessandro Bertolino



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T198. A SCHIZOPHRENIA-LIKE BIRTH SEASONALITY AMONG MATHEMATICIANS AND AN OPPOSITE SEASONALITY AMONG BIOLOGISTS: MORE EVIDENCE IMPLICATING BIMODAL RHYTHMS OF GENERAL BIRTHS

Giovanni Marzullo*

T199. DEVIANT CORTICAL SULCATION RELATED TO SCHIZOPHRENIA, BUT NOT COGNITIVE DEFICITS, LIKELY PREDATE BRAIN DEVELOPMENT IN THE SECOND TRIMESTER

Lena Palaniyappan*

T200. DISTINCT ASSOCIATIONS OF MOTOR DOMAINS WITH THE GENETIC RISK FOR PSYCHOSIS – DIFFERENT PATHWAYS TO MOTOR ABNORMALITIES IN SCHIZOPHRENIA?

Lea Schäppi*, Katharina Stegmayer, Petra Viher, Sebastian Walther

T201. THE STUDY OF WHITE MATTER MATURATION IN THREE POPULATIONS OF GENETIC HIGH RISK FOR SCHIZOPHRENIA INDIVIDUALS SPANNING THE DEVELOPMENTAL TIMELINE

Amanda Lyall*, Nathaniel Simes, Fan Zhang, James Robertson, Lauren J. O'Donnell, Yogesh Rathi, Ofer Pasternak, Peter Savadjiev, Martin Styner, Zachary Fitzgerald, Raquelle Meshulam-Gately, Heidi Thermenos, Susan Whitfield-Gabrieli, Matcheri Keshavan, Lynn DeLisi, John Gilmore, Larry J. Seidman, Marek Kubicki

T202. HUMOR-SKILLS TRAINING IN PATIENTS WITH SCHIZOPHRENIA: EFFECTS ON SYMPTOMS AND SOCIAL FUNCTIONING

Irina Falkenberg*, Florian Bitsch, Philipp Berger, Arne Nagels, Benjamin Straube

T203. ILLICIT DRUGS USE AND ULTRA-HIGH RISK (UHR) FOR PSYCHOSIS STATUS IN A LATIN-AMERICAN SAMPLE

Mauricio Serpa*, Alexandre Andrade Loch, Camille Chianca, Elder Freitas, Julio Cesar Andrade, Tania Maria Alves, Lucas Hortêncio, Martinus Theodorus van de Bilt, Wagner Gattaz, Wulf Rossler

T204. NOVEL VIRTUAL REALITY SOCIAL SKILLS TRAINING FOR INDIVIDUALS WITH SCHIZOPHRENIA

Lénie Torregrossa*, Laura Hieber Adery, Megan Ichinose, Heathman Nichols, Alena Gizdić, Joshua Wade, Dayi Bian, Eric Granholm, Nilanjan Sarkar, Sohee Park

T205. CHANGES IN SOCIAL ATTENTION AND EMOTION RECOGNITION FOLLOWING A PILOT SOCIAL SIMULATION COMPUTER GAME INTERVENTION FOR INDIVIDUALS WITH SCHIZOPHRENIA

Megan Ichinose*, Joshua Wade, Laura Hieber Adery, Lénie Torregrossa, Heathman Nichols, Dayi Bian, Alena Gizdic, Nilanjan Sarkar, Sohee Park

T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?

Benedetta Seccomandi*, Deborah Agbedjro, Morris Bell, Richard Keefe, Matcheri Keshavan, Silvana Galderisi, Alice Medalia, Joanna Fiszdon, Mario Maj, Armida Mucci, Roberto Cavallato, Til Wykes, Matteo Cella

T207. A REVIEW OF PREDICTORS OF RESPONSIVENESS TO CBT FOR PSYCHOSIS

Ana Elisa Farias de Sousa*, Martin Lepage, Mathieu Brodeur



T208. LONGITUDINAL FEASIBILITY AND ACCEPTABILITY OF THE EXPRESS SMARTPHONE APP: RECRUITMENT, RETENTION AND PRELIMINARY FINDINGS

Emily Eisner*, Sandra Bucci, Richard Emsley, Christine Barrowclough, Richard Drake

T209. TESTING CORTICAL RTMS TARGETS TO IMPROVE PSYCHOMOTOR SLOWING IN SCHIZOPHRENIA AND MAJOR DEPRESSION IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Sebastian Walther*, Lea Schäppi, Danai Alexaki, Katharina Stegmayer, Georgios Schoretsanitis

T210. PSYCHOSOCIAL CORRELATES OF INTERPERSONAL PLEASURE IN SCHIZOPHRENIA-SPECTRUM PATIENTS

Diane Gooding*, Yael Ratner, Nina Mendyk, Herman Farkash, Michael Ermiyev, Michael S. Ritsner

T211. BASIC SELF-DISTURBANCE AS A PREDICTOR OF DETERIORATION IN ATTENUATED PSYCHOSIS: A 1-YEAR FOLLOW-UP STUDY AMONG COMMUNITY-DWELLING ADOLESCENTS

Dan Koren*, Liza Lacoua, Lily Rothshield, Maya Rothbaum, Neta Cohen, Josef Parnas

T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY

Lena Palaniyappan*, Tushar Das, Fabienne Harrisberger, Undine E. Lang, Anita Riecher-Rössler, André Schmidt, Stefan Borgwardt

T213. THE EFFECT OF ACUTE STRESS ON PARANOID THINKING AND CORTISOL DURING SOCIAL INTERACTION IN HIGH AND LOW SCHIZOTYPES

James Gilleen*

T214. STIGMA ABOUT SCHIZOPHRENIA: THE EFFECTS OF DIAGNOSTIC LABELS, SYMPTOMS, AND ILLNESS PHASE

Christopher Groot*, Kelton Hardingham

T215. CLINICAL PREDICTORS OF HOSPITALIZATIONS IN FIRST EPISODE PSYCHOTIC PATIENTS. A NATURALISTIC FOLLOW UP STUDY

Olga Sparano*, Pau Soldevila-Matias, Carlos Gonzalez, Lucia Bonet, Esther Lorente, Jose Miguel Carot, Julio Sanjuan

T216. THE CULTURAL EXPERIENCES OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA IN SOUTH AFRICA

Wilna Basson*

T217. FACTORS RELATED TO SUICIDAL BEHAVIOR IN KOREAN PATIENTS WITH BIPOLAR DISORDER: THE EFFECT OF MIXED FEATURES ON SUICIDALITY

Hye-Jin Seo*, Hee Ryung Wang

T218. IDENTIFICATION OF FIRST-EPISODE PSYCHOSIS SUBGROUPS BASED ON POSITIVE SYMPTOM DOMAINS AND THEIR SOCIODEMOGRAPHIC AND CLINICAL CORRELATES

Chiara Galletti*, Luca Pauselli, Marc Manseau, Alfonso Tortorella, Michael T. Compton



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T219. THE ROLE OF MELATONIN AND MELATONIN AGONISTS IN COUNTERACTING ANTIPSYCHOTIC-INDUCED METABOLIC SIDE EFFECTS: A SYSTEMATIC REVIEW
Won-Myong Bahk*, Young Joon Kwon, Bo-Hyun Yoon, Sang-Yeol Lee, Kwanghun Lee, Duk-In Jon, Moon Doo Kim, Eunsung Lim

T220. THE GLUTAMINASE INHIBITOR EBSELEN PREVENTS AMPHETAMINE SENSITIZATION IN MICE
Lior Heffetz-Giterman, Sharon S. Lander, Reut Cohen, Amit Gross, Inna Gaisler-Salomon*

T221. LURASIDONE DISPLAYS ANTIDEPRESSANT AND PRO-COGNITIVE EFFECTS IN THE CHRONIC MILD STRESS MODEL: A ROLE FOR REDOX MECHANISMS AND PARVALBUMIN EXPRESSION
Andrea Carlo Rossetti, Maria Serena Paladini, Paola Brivio, Giulia Sbrini, Mariusz Papp, Francesca Calabrese, Raffaella Molteni, Marco Andrea Riva*

T222. EARLY TREATMENT RESISTANCE IN A LATIN-AMERICAN COHORT OF PATIENTS WITH SCHIZOPHRENIA
Cristian Mena, Alfonso Gonzalez-Valderrama, Barbara Iruretagoyena, Juan Undurraga, Nicolas Crossley*

T223. REAL WORLD EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS IN PATIENTS WITH SCHIZOPHRENIA: A 10-YEARS RETROSPECTIVE STUDY
Tae Young Lee*, Minah Kim, Junhee Lee, Jun Soo Kwon

T224. THE FUNCTIONAL CONNECTIVITY DERIVED WITH BIVARIATE ANALYSIS, COHERENCE AND PHASE LOCKING VALUE IN PATIENTS WITH SCHIZOPHRENIA UNDER CLOZAPINE
Yong Sik Kim*, In Won Chung, Hee Yeong Jung, Tak Youn, Se Hyun Kim, Nam Young Lee, Seong Hoon Jeong, Kyung Tae Park, Sang Hoon Yi, Yong Min Ahn

T225. OPERATIONAL DEFINITIONS FOR ANTIPSYCHOTIC RESPONSE IN DELUSIONAL DISORDER: A SYSTEMATIC AND CRITICAL REVIEW
Alexandre González-Rodríguez*, Francesc Estrada, José Antonio Monreal, Diego Palao, Javier Labad

T226. CLINICAL PREDICTORS OF FUNCTIONAL CAPACITY IN TREATMENT RESISTANT SCHIZOPHRENIA PATIENTS: COMPARISON WITH RESPONDER PATIENTS, ROLE OF NEGATIVE SYMPTOMS, PROBLEM SOLVING DYSFUNCTIONS, AND NEUROLOGICAL SOFT SIGNS
Felice Iasevoli*, Luigi D'Ambrosio, Danilo Notar Francesco, Eugenio Razzino, Camilla Avagliano, Elisabetta Filomena Buonaguro, Thomas Patterson, Andrea de Bartolomeis

T227. THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 REGULATES STRIATAL DOPAMINE RELEASE VIA AN ENDOCANNABINOID-DEPENDENT MECHANISM: IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA
Samantha Yohn*, Daniel Covey, Daniel Foster, Mark Moehle, Jordan Galbraith, Joseph Cheer, Craig Lindsley, P. Jeffrey Conn

T228. VARIABILITY AND UNDERUTILISATION OF CLOZAPINE IN SPAIN
Francisco Javier Sanz-Fuentenebro*, Jose Juan Uriarte Uriarte, Pere Bonet Dalmau, Vicente Molina Rodriguez, Alba Lubeiro Juárez, Miguel Bernardo Arroyo



T229. ANTIPSYCHOTIC DRUG USE AND THYROID FUNCTION IN PATIENTS WITH SEVERE MENTAL DISORDERS

Trude Iversen*, Nils E. Steen, Kåre I. Birkeland, Ragni H. Mørch, Elina J. Reponen, Jannicke F. Anderssen, Linn Rødevand, Ingrid Melle, Ole A. Andreassen, Espen Molden, Erik Jönsson

T230. DOSE TRENDS OF ARIPIPRAZOLE FROM 2004 TO 2014 IN PSYCHIATRIC INPATIENTS IN KOREA

Young-Joon Kwon*, Won-Myong Bahk, Bo-Hyun Yoon, Duk-In Jon, MoonDoo Kim, Beomwoo Nam, Eunsung Lim, Sung-Yong Park

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA

Juan-Antonio Garcia-Carmona*

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA

Britta Galling*, Christoph Correll

T233. DEFINING TREATMENT RESPONSE AND RESISTANCE IN FIRST EPISODE SCHIZOPHRENIA

Kara Dempster*, Lena Palaniyappan, Ross Norman

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS

Jose Rubio*, Kinza Ahmed, Christoph Correll, Katsuhiko Hagi, Taishiro Kishimoto, John Kane

T235. SELF ASSESSMENT OF SOCIAL COGNITIVE ABILITY IN SCHIZOPHRENIA: ASSOCIATION WITH SOCIAL COGNITIVE TEST PERFORMANCE, INFORMANT ASSESSMENTS OF SOCIAL COGNITIVE ABILITY, AND EVERYDAY OUTCOMES

Philip Harvey*, Amy Pinkham, David Penn

T236. TECHNOLOGY LITERACY AND ENGAGEMENT IN PEOPLE WITH SCHIZOPHRENIA

Kwok Tung Gordon Wong, Daniel King, Ryan Balzan, Dennis Liu, Cherrie Galletly*

T237. USER EXPERIENCE TOWARDS AN INTEGRAL INTERVENTION MODEL BASED ON M-HEALTH SOLUTION FOR PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (M-RESIST): QUALITATIVE INFORMATION FROM PATIENTS, CAREGIVERS AND CLINICIANS IN A PILOT STUDY

Silvia Marcó-García, Elena Huerta-Ramos, Susana Ochoa*, Eva Grasa, Anna Alonso, Erika Jääskeläinen, Elisenda Reixach, Jesús Berdún, Charlotte Jewel, m-RESIST Group, Iluminada Corripio, Judith Usall

T238. THE ASSOCIATION OF PSYCHOSOCIAL FUNCTIONING WITH BRAIN VOLUME IN THE EARLY STAGES OF (PSYCHOTIC) ILLNESS

Renate Reniers*, Rachel Uptegrove, Karen Heinze, Katharine Chisholm, Ashleigh Lin, Beth Charters, Hannah Ball, Graham Hall, Stephen Wood



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T239. SINGLE-SUBJECT PREDICTION OF FUNCTIONAL OUTCOMES IN CLINICAL HIGH RISK SUBJECTS USING CLINICAL DATA

Marlene Rosen*, Nathalie Kaiser, Theresa Haidl, Mauro Seves, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Eva Meisenzahl, Christos Pantelis, Stephan Ruhrmann, Raimo Salokangas, Rachel Upthegrove, Stephen Wood, Nikolaos Koutsouleris, The PRONIA Group

T240. CAREGIVER BURDEN OF OUTPATIENTS WITH SCHIZOPHRENIA IN UNIVERSITY CLINIC IN SAO PAULO, BRAZIL

Elaine Di Sarno*, Isabel Cristina Napolitano, Mario Rodrigues Louzã Neto

T241. INTERPERSONAL COGNITIVE RIGIDITY AFFECTS SOCIAL FUNCTIONING IN PSYCHOSIS MORE THAN THEORY OF MIND: A STUDY WITH THE REPERTORY GRID TECHNIQUE

Helena García-Mieres*, Susana Ochoa, Victoria Furlan, Raquel Lopez Carrilero, Anna Villaplana, Regina Vila-Badia, Eva Grasa, Ana Barajas, Esther Pousa, Guillem Feixas

T242. DEVELOPMENT OF SELF-STIGMA INVENTORY FOR PATIENTS WITH SCHIZOPHRENIA (SSI-P): RELIABILITY AND VALIDITY STUDY IN TURKEY

Mustafa Yildiz, Fatma Kiras, Aysel İncedere, Fatma Betül Abut*

T243. RESOURCE GROUP-ACT: RELATIVES' PERSPECTIVES

Nils Sjöström*, Mats Ewertzon, Bente Weimand, Anita Johansson, Zophia Mellgren, Ola Johansson, Jane Ek-Persson, Margda Waern

T244. SELF-DEFINING MEMORIES PREDICT ENGAGEMENT IN STRUCTURED ACTIVITY IN FIRST EPISODE PSYCHOSIS

Abigail Wright*, Geoff Davies, David Fowler, Kathryn Greenwood

T245. THE ROLE OF PROTECTIVE FACTORS IN THE FIRST-EPISODE PSYCHOSIS: PRELIMINARY RESULTS

Regina Vila-Badia*, Anna Butjosa, Núria Del Cacho, Itziar Riera-López de Aguilera, Mar Álvarez, Marta Pardo, Marta Coromina, Núria Grases, Susana Ochoa, PROFEP Group, Judith Usall

T246. DECREASING AGGRESSIVE BEHAVIOR IN PATIENTS WITH COGNITIVE IMPAIRMENTS BY TRAINING PSYCHIATRIC STAFF IN INTERACTIVE SKILLS

Daniel Abrams*, Anneli Goulding, Margda Waern, Nils Sjöström

T247. INSIGHT INTO NEGATIVE SYMPTOMS AS AN IMPORTANT TARGET FOR PSYCHOSOCIAL REHABILITATION IN RELATION TO CLINICAL CHARACTERISTICS

Maria Minyaycheva*, Igor Gladyshev, Oleg Papsuev

T248. PSYCHOPATHOLOGY IN F2X.X-UNAFFECTED CO-TWINS AS A VULNERABILITY INDICATOR OF PSYCHOSIS

Rikke Hilker*, Mette Nielsen, Christian Legind, Maria H Jensen, Simon Anhøj, Brian Broberg, Birgitte Fagerlund, Merete Nordentoft, Birte Glenthøj



T249. THE ROYAL AUSTRALIAN AND NEW ZEALAND CLINICAL PRACTICE GUIDELINES FOR SCHIZOPHRENIA AND RELATED DISORDERS (2016) – A STEP TOWARDS BETTER CARE? Cherrie Galletly*, David Castle, Frances Dark, Verity Humberstone, Assen Jablensky, Eoin Killackey, Jayashri Kulkarni, Patrick McGorry, Olav Nielsen, Nga Tran

T250. CLINICAL CORRELATES OF SUBJECTIVE QUALITY OF LIFE IN INDIVIDUALS WITH AT-RISK MENTAL STATE FOR PSYCHOSIS IN HONG KONG

Irving Teng, Wing Chung Chang*, Hoi Ching Lee, Cheuk Fei Wong, Sui Fung Wo, Suet In Chan, Sanyin Chiu, Lai Ming Hui, Kit Wa Chan, Ho Ming Lee, Yi Nam Suen, Eric Chen

T251. THE STUDY OF QUALITY OF LIFE AND A GLOBAL FUNCTIONING FOR THE SCHIZOPHRENIA PATIENTS IN COMMUNITY BY THEIR RESIDENTIAL ENVIRONMENT

Sang-Yeol Lee*, Young-Joon Kwon, Bo-Hyun Yoon, Kwanghun Lee, Moon Doo Kim, Beomwoo Nam, Sung-Yong Park, Eunsung Lim

T252. TREATMENT DELAY AND OUTCOME COMPARISON OF EXTENDED EARLY INTERVENTION SERVICE AND STANDARD PSYCHIATRIC CARE FOR ADULTS PRESENTING WITH FIRST-EPIISODE PSYCHOSIS IN HONG KONG

Wing Chung Chang*, Chun Ho, Chi Fai Or, Tsz Ting Liu, Fu Chun Lau, On Ki Chu, Lai Ming Hui, Kit Wa Chan, Ho Ming Lee, Yi Nam Suen, Eric Chen

T253. THE CORRELATION ANALYSIS BETWEEN RENAMING SCHIZOPHRENIA AND VISITING FREQUENCY OF MENTAL HEALTH SERVICES BY BIG DATA ANALYSIS (INTERNET SEARCHES AND NEWSPAPER ARTICLES) IN SOUTH KOREA

Sang Yup Lee, Kyung Sue Hong, Yeon Ho Joo, Shinsuke Koike, Yu Sang Lee*, Jun Soo Kwon

T254. IMPACT OF A DROP IN, OPEN ENDED, PSYCHO EDUCATIONAL GROUP ON CLIENT ENGAGEMENT IN AN EARLY PSYCHOSIS INTERVENTION PROGRAM

Crystal Morris*, Elham Sadeh, Greg McMillan, Sharman Robertson

T255. WHO PARTICIPATED IN FAMILY WORK IN THE US RAISE-ETP FIRST EPISODE SAMPLE?

Shirley Glynn*, Susan Gingerich, Piper Meyer-Kalos, Kim Mueser, Alec Chan-Golston, Catherine Sugar, Nina Schooler, John Kane

T256. AZERI ACUTE PHASE/RECENT ONSET PSYCHOSIS SURVEY (ARAS): INTRODUCING A FIRST EPISODE PSYCHOSIS COHORT IN THE MIDDLE EAST

Sara Farhang*, Mehrdad Ghaemmaghami, Gholamreza Noorazar, Ayyoub Malek, Wim Veling, Behrooz Z. Alizadeh, Richard Bruggeman

T257. RECOVER: A RANDOMISED CONTROLLED TRIAL OF A TAILORED PSYCHOLOGICAL INTERVENTION FOR FIRST EPISODE BIPOLAR DISORDER

Susan Cotton*, Craig Macneil, Henry Jackson, Greg Murray, Aswin Ratheesh, Kate Filia, Andrew Chanen, Christopher G. Davey, Barnaby Nelson, Melissa Hasty, Michael Berk

T258. THE RISK OF NON-AFFECTIVE AND AFFECTIVE PSYCHOTIC DISORDERS IN IMMIGRANTS

Els van der Ven*, Fabian Termorshuizen, Jean-Paul Selten



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

T259. PHARMACOGENETIC INTERVENTIONS MAY IMPROVE THE SAFETY OF ANTIPSYCHOTIC TREATMENTS

Rosa Catalan Campos*, Alexandre Gonzalez, Rafael Penades, Fina Perez Blanco, Justo Pinzon, Blanca Guierrez, Laura Ibañez, Barbara Arias, María Jesús Arranz

T260. SEVERITY CLASSIFICATION BASED ON THE UNIVERSITY OF CALIFORNIA SAN DIEGO PERFORMANCE-BASED SKILLS ASSESSMENT

You-Na Kim*, Do-Un Jung, Dong-Wook Jeon, Sung-Jin Kim, Yoon-Ho Lee

T261. SUBDOMAINS OF NEGATIVE SYMPTOMS IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS

Matilda Azis*, Gregory P. Strauss, Elaine Walker, Vijay Mittal

T262. EFFECTS OF BUILT AND PHYSICAL ENVIRONMENT ON THE BRAIN STRUCTURE OF INDIVIDUALS AT ULTRA HIGH RISK OF DEVELOPING PSYCHOSIS

Stefania Tognin*, Matthew Kempton, James Kirkbride, Evangelos Vassos, Lucia Valmaggia, Philip McGuire

T263. ANTIPSYCHOTIC-INDUCED WEIGHT GAIN AND WEIGHT AT BIRTH IN PSYCHOSIS: A TEST FOR THE THRIFTY PSYCHIATRIC PHENOTYPE

Marina Garriga, Andrea Mallorqui, Lourdes Serrano, Cristina Oliveira, Eduard Vieta, Miquel Bernardo, Clemente Garcia-Rizo*



POSTERS, FRIDAY 6 APRIL

12:00 P.M. - 2:00 P.M.

Cavaniglia

Travel Awardee Posters are Circled

F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS
Malgorzata Maciukiewicz, Arun Tiwari, Vanessa Goncalves, Clement Zai, Eva Brandl, Natalie Freeman, Lieberman Jeffrey, Herbert Meltzer, Christopher Laughlin, Erika Nurmi, James Kennedy, Daniel J. Mueller*

F2. CHILDHOOD TRAUMA AND LACK OF CULTURAL IDENTITY AS RISK FACTORS OF ATTENUATED PSYCHOSIS SYMPTOMS AMONG AFRICAN AMERICAN YOUNG ADULTS
Huijun Li*, Monique Rowe

F3. A CASE OF LEUKOCYTOSIS ASSOCIATED WITH CLOZAPINE TREATMENT FOR THE MANAGEMENT OF CHRONIC SCHIZOPHRENIA
Min-Kyu Song*, Won-Myong Bahk, Young Joon Kwon, Bo-Hyun Yoon, Sang-Yeol Lee, Duk-In Jon, Sung-Yong Park, Eunsung Lim

F4. LINKING LIFE EVENTS WITH NEGATIVE AFFECT AND PSYCHOTIC EXPERIENCES IN DAILY LIVES OF YOUTH: STRESS SENSITIVITY AS A PUTATIVE MECHANISM?
Christian Rauschenberg*, Jim van Os, Dimitri Cremers, Matthieu Goedhart, Jan Schieveld, Ulrich Reininghaus

F5. CLOZAPINE RELATED THROMBOCYTOSIS AND THROMBOCYTOPENIA
Yuree Kang*, Seung-Hyun Shon, Woon Yoon, Jungsun Lee

F6. PSYCHOLOGICAL RESILIENCE TO SUICIDAL THOUGHTS AND BEHAVIOURS: A QUALITATIVE EXAMINATION OF THE EXPERIENCES OF PEOPLE WITH MENTAL HEALTH PROBLEMS ON THE SCHIZOPHRENIA SPECTRUM
Kamelia Harris*, Patricia Gooding, Gillian Haddock, Sarah Peters

F7. SEX DIFFERENCES IN THE ASSOCIATION BETWEEN SELF-REPORTS OF CHILDHOOD ADVERSITIES AND SCHIZOTYPAL PERSONALITY TRAITS
Diamantis Toutountzidis*, Tim Gale, Karen Irvine, Shivani Sharma, Keith Laws

F8. SEARCHING FOR A STRATIFICATION MARKER FOR ANTIOXIDANT USE IN SCHIZOPHRENIA AND BIPOLAR DISORDER: A META-ANALYSIS OF MRS STUDIES OF ANTERIOR CINGULATE GLUTATHIONE
Avyartha Dey, Alborz Javadzadeh, Priyadharshini Sabesan, Joaquim Radua, Jean Theberge, Lena Palaniyappan*

F9. ALTERATIONS OF NEURONAL METABOLISM IN PATIENT SUBGROUPS AT ULTRA-HIGH RISK FOR PSYCHOSIS ACCORDING TO PACE CRITERIA – A 1H/31P-MR-SPECTROSCOPY STUDY
Stefan Smesny*, Stephan Schack, Alexander Gussew, Kerstin Langbein, Juergen Reichenbach



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F10. DIFFERENTIAL EXPRESSION OF MICRORNAS IN CEREBROSPINAL FLUID AND PLASMA SAMPLES IN SCHIZOPHRENIA

Juan Gallego*, Eric Alsop, Todd Lencz, Kendall Van Keuren-Jensen, Anil Malhotra

F11. TRANSLATIONAL STUDY OF GRIN1, GRIN2A AND 2B GENE EXPRESSION IN PATIENTS WITH SCHIZOPHRENIA AND ANIMAL MODELS

Loureiro Camila Marcelino, Corsi-Zuelli Fabiana, Fachim Helene Aparecida, Shuhama Rosana, Joca Sâmia Regiane Lourenço, Menezes Paulo Rossi, Del-Ben Cristina Marta, Paulo Louzada-Junir*

F12. INFLAMMATORY BIOMARKERS AND COGNITION IN FIRST EPISODE PSYCHOSIS: GENDER DIFFERENCES

Bibiana Cabrera Llorca*, Miquel Bioque, Gisela Mezquida, Ana Gonzalez-Pinto, Mara Parellada, Julio Bobes, Antonio Lobo, Borja García-Bueno, Karina MacDowell, Carla Torrent, Pilar Saiz-Martinez, Juan Carlos Leza, Miquel Bernardo

F13. TOWARDS MOLECULAR INSIGHTS INTO PSYCHIATRIC DISORDERS USING AFFINITY PROTEOMICS

David Just*, Anna Månberg, Eva Lindholm Carlström, Janet Cunningham, Peter Nilsson

F14. REDUCED DURATION MISMATCH NEGATIVITY ASSOCIATED WITH DECREASED GLUTAMATE+GLUTAMINE LEVEL IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS

Yingying Tang*, TianHong Zhang, Junjie Wang, LiHua Xu, Zhenying Qian, HuiRu Cui, Larry J. Seidman, Robert W. McCarley, Matcheri S. Keshavan, William S. Stone, Margaret Niznikiewicz, Jijun Wang

F15. DIFFERENTIAL EXPRESSION PATTERNS OF EPIDERMAL GROWTH FACTOR (EGF) AND IMMUNE SYSTEM MARKERS IN DORSOLATERAL PREFRONTAL (BA46) AND ORBITOFRONTAL (BA11) CORTICES IN SCHIZOPHRENIA AND MOOD DISORDER

Tharini Ketharanathan*, Avril Pereira, Ian Everall, Suresh Sundram

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAÏVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS

Kirsten Bojesen*, Brian Broberg, Kasper Jessen, Anne Sigvard, Karen Tangmose, Mette Ødegaard Nielsen, Egill Rostrup, Birte Glenthøj

F17. DIFFERENCES IN INTRACRANIAL VOLUME, IQ AND PSYCHOPATHOLOGY IN YOUNG OFFSPRING OF PATIENTS AFFECTED WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

Neeltje van Haren, Setiaman Nikita*, Martijn Koevoets, Heleen Baalbergen, Matthijs Vink, Esther Mesman, René Kahn, Manon Hillegers

F18. IS SCHIZOPHRENIA A MULTI-SYSTEM DISORDER? CONSIDERING NEUROLOGICAL, IMMUNE, CARDIOMETABOLIC, AND ENDOCRINE ALTERATIONS IN FIRST EPISODE PSYCHOSIS

Toby Pillingner*, Enrico D'Ambrosio, Rob McCutcheon, Oliver Howes

F19. TELOMERE SHORTENING IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTH FOLLOW-UP STUDY

David Fraguas*, Sandra Recio, Covadonga M. Diaz-Caneja, Maria A. Blasco, Ana Carolina Moisés, Celso Arango



F20. SEX-SPECIFIC STRUCTURAL AND FUNCTIONAL CIRCUIT DIFFERENCES IN YOUTH WITH PSYCHOSIS SPECTRUM SYMPTOMS

Grace Jacobs*, Stephanie Ameis, Joseph Viviano, Erin Dickie, Anne Wheeler, Sonja Stojanovski, Aristotle Voineskos

F21. ELECTROPHYSIOLOGICAL PARAMETERS OF SELECTIVE ATTENTION IN ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS: A COMPARISON WITH ADHD

Iris Selten*, Jacob Rydkjaer, Anne Katrine Pagsberg, Birgitte Fagerlund, Birte Glenthøj, Jens Richardt Møllegaard Jepsen, Bob Oranje

F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS

Sherif M. Gohar*, Ingrid Dieset, Nils Eiel Steen, Ragni H. Mørch, Trude S. Iversen, Vidar M. Steen, Ole A. Andreassen, Ingrid Melle

F23. LOW-GRADE INFLAMMATORY PROFILE IN FIRST-EPISODE PSYCHOSIS: RESULTS FROM THE STREAM STUDY IN BRAZIL

Fabiana Corsi-Zuelli*, Camila Loureiro, Fachim Helene Aparecida, Rosana Shuhama, Menezes Paulo Rossi, Paulo Louzada-Junior, Del-Ben Cristina Marta

F24. OMEGA-6 PUFA METABOLISM DISTURBED IN PHOSPHO- AND SPHINGOLIPIDS IN NEUROLEPTIC-NAÏVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS – A FATTY ACID PROFILING STUDY IN FIVE LIPID FRACTIONS

Kerstin Langbein*, Christian Fleischer, Katrin Kuhnt, Stefan Smesny

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS

G. Paul Amminger*, Barnaby Nelson Nelson, Hok Pan Yuen, Connie Markulev, Miriam R. Schäfer, Monika Schlögelhofer, Nilufar Mossaheb, Stephan Smesny, Ian Hickie, Gregor Berger, Eric Chen, Lieuwe de Haan, Dorien H. Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Maximus Berger, Andrew Thompson, Alison Yung, Patrick D. McGorry

F26. THE NATURE OF CLINICAL HIGH RISK SYMPTOMS: NEW INSIGHTS GAINED FROM AGE EFFECTS

Frauke Schultze-Lutter*, Chantal Michel, Stefanie Schmidt

F27. LATENT PROFILES OF DEVELOPMENTAL SCHIZOTYPY IN THE GENERAL POPULATION: ASSOCIATIONS WITH CHILDHOOD TRAUMA AND FAMILIAL MENTAL ILLNESS

Melissa Green*, Richard J. Linscott, Kristin R. Laurens, Stacy Tzoumakis, Kimberlie Dean, Johanna C. Badcock, Vaughan J. Carr

F28. PROGRESSIVE POST-ONSET REORGANISATION OF MRI-DERIVED CORTICAL THICKNESS IN ADOLESCENTS WITH SCHIZOPHRENIA

Lena Palaniyappan*, Anthony James



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F29. HIGH-RISK SYMPTOMS FOR PSYCHOSIS IN ADOLESCENTS AND ITS RELATIONSHIP WITH FAMILY BURDEN

Olga Puig-Navarro*, Elena De la Serna, Jordina Tor, Anna Sintes, Gisela Sugranyes, Marina Redondo, Marta Pardo, Montse Dolz, Inmaculada Baeza

F30. SMARTPHONE APPLICATION “ROBIN”: FEASIBILITY, ENGAGEMENT AND SATISFACTION OF A SMARTPHONE APPLICATION APPROACH TO SUPPORT TREATMENT OF (ATTENUATED) PSYCHOTIC SYMPTOMS IN ADOLESCENTS

Nina Traber-Walker*, Sibylle Metzler, Miriam Gerstenberg, Susanne Walitzka, Maurizia Francini

F31. POLYGENIC RISK SCORES AND EARLY RISK ENDOPHENOTYPES IN CHILDREN AT GENETIC RISK OF SCHIZOPHRENIA AND BIPOLAR DISORDER: IMPLICATIONS FOR THE DEFINITION OF THE CHILDHOOD RISK STATUS

Thomas Paccalet*, Alexandre Bureau, Elsa Gilbert, Nicolas Berthelot, Pierre Marquet, Sébastien Boies, Valérie Jomphe, Daphné Lussier, Michel Maziade

F32. DIFFERENCES BETWEEN YOUTH AT CLINICAL HIGH-RISK FOR PSYCHOSIS WHO DO NOT TRANSITION TO PSYCHOSIS: THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY (NAPLS-2)

Olga Santesteban-Echarri*, Jacqueline Stowkowy, Scott W. Woods, Lu Liu, Kristin S. Cadenhead, Tyrone D. Cannon, Barbara A. Cornblatt, Thomas H. McGlashan, Diana O. Perkins, Larry J. Seidman, Ming T. Tsuang, Elaine F. Walker, Carrie E. Bearden, Daniel H. Mathalon, Jean M. Addington

F33. MATERNAL AND PATERNAL CANNABIS USE DURING PREGNANCY AND RISK OF PSYCHOTIC SYMPTOMS IN THE OFFSPRING

Koen Bolhuis*, Steven A. Kushner, Manon H.J. Hillegers, Henning Tiemeier, Hanan El Marroun

F34. AUDITORY SENSORY GATING IN YOUNG ADOLESCENTS WITH EARLY-ONSET PSYCHOSIS: A COMPARISON WITH ADHD

Cecilie Lemvig*, Jens Richardt Møllegaard Jepsen, Birgitte Fagerlund, Anne Katrine Pagsberg, Birte Glenthøj, Jacob Rydkjaer, Bob Oranje

F35. PRESCRIPTION PATTERN OF ANTIPSYCHOTICS FOR CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA IN KOREA BASED ON NATIONWIDE DATA

Kee Jeong Park*, Jung Sun Lee, Hyo-Won Kim

F36. SELF-ESTEEM AND SYMPTOMS IN INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS

Caridad Benavides*, Gary Brucato, David Kimhy

F37. CACNA1C HYPOFUNCTION IN KETAMINE-ACTIVATED BRAIN NETWORKS IMPAIRS MEMORY CONSOLIDATION AND FUNCTIONAL BRAIN NETWORK CONNECTIVITY

Rebecca Hughes, Cosima Willi, Jayde Whittingham-Dowd, Susan Broughton, Greg Bristow, Neil Dawson*

F38. WINTER-LIKE PHOTOPERIOD GESTATION DELETERIOUSLY AFFECT EXPERIENTIAL-BUT NOT EXPRESSIVE-RELATED BEHAVIORS, WHILE ADULT PHENCYCLIDINE TREATMENT INCREASES EXPERIENTIAL BEHAVIORS: RELEVANCE TO SCHIZOPHRENIA

Molly Kwiatkowski, Zackary Cope, Chuck van de Chapelle, Davide Dulcis, Susan Powell, Jared Young*



F39. MATERNAL IMMUNE ACTIVATION MODELS: MIND YOUR CAGING SYSTEMS!

Flavia Müller*, Urs Meyer, Ulrike Weber-Stadlbauer

F40. NEUREXIN-1 α (NRX1 α) HYPOFUNCTION INDUCES SCHIZOPHRENIA-RELEVANT DEFICITS IN CEREBRAL METABOLISM, COGNITIVE PROCESSING SPEED AND COGNITIVE FLEXIBILITY

Rebecca Hughes*, Jayde Whittingham-Dowd, Greg Bristow, Stephen Clapcote, Susan Broughton, Neil Dawson

F41. SCHIZOPHRENIA-RELEVANT ALTERATIONS IN CEREBRAL METABOLISM, GLUTAMATE AND MONOAMINERGIC NEUROTRANSMITTER SYSTEM FUNCTION IN A MOUSE MODEL OF 16P11.2 DUPLICATION

Greg Bristow*, David Thomson, Judith Pratt, Brian Morris, Neil Dawson

F42. CHONDROTIN-6 SULFATE CLUSTERS: ASSOCIATION OF SYNAPTIC DOMAINS AND REGULATION OF SYNAPTIC PLASTICITY DURING FEAR LEARNING

Gabriele Chelini*, Cristina Berciu, Kanoelani Pilobello, Durning Peter, Jenkins Rachel, Moazzam Kahn, Teniel Ramikie, Siva Subramanian, Kerry Ressler, Charalampos Pantazopoulos, Sabina Berretta

F43. POTENTIATION OF INHIBITORY NEUROTRANSMISSION IN THE TREATMENT OF RECENT-ONSET SCHIZOPHRENIA BY MODIFICATION OF DEVELOPMENTAL PRUNING OF PREFRONTAL CIRCUITRY

Erin Burke, Joanne Wojcik, Larry J. Seidman, Alan Green, Tsung-Ung Wilson Woo*

F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT

Philippe Conus*, Margot Fournier, Lijing Xin, Martine Cleusix, Philipp S. Baumann, Carina Ferrari, Ann Cousins, Luis Alameda, Mehdi Gholam-Razae, Philippe Golay, Raoul Jenni, Tsung-Ung Wilson Woo, Matcheri Keshavan, Chin B. Eap, Joanne Wojcik, Michel Cuenod, Thierry Buclin, Rolf Gruetter, Larry Seidman, Kim Q. Do

F45. THE EFFICACY AND SAFETY OF BLONASERIN AFTER SWITCHING FROM OTHER ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC INPATIENTS: AN OPEN-LABEL, MULTI-CENTER TRIAL

Bo-Hyun Yoon*, Won-Myong Bahk, Young Joon Kwon, Sang-Yeol Lee, Kwanghun Lee, Moon Doo Kim, Sung-Yong Park, Min-Kyu Song

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

Robert Davis, Alex Dmitrienko, Steven Glass, Susan Kozauer, Jelena Saillard, Michal Weingart, Andrew Satlin, Sharon Mates, Christoph Correll, Kimberly Vanover*



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

- F47. COGNITIVE REMEDIATION AND PHYSICAL EXERCISE IN MULTI-EPISODE SCHIZOPHRENIA: STUDY PROTOCOL FOR A RANDOMISED CONTROLLED TRIAL
Nuria Pujol*, Víctor Pérez-Solà, Romina Cortizo, Lourdes Ayllon, Teresa Salvador, Daniel Moreno, Ferran Català, Jacobo Chamorro, Silvia Oller, Javier Polo-Velasco, Adelina Abellanas, Cristobal Diez-Aja, Anna Mane
- F48. RANDOMISED CONTROLLED TRIAL OF SOCIAL COGNITION INTERACTION TRAINING
Frances Dark*, James Scott, Andrea Baker, Stephen Parker, Anne Gordon, Ellie Newman, Victoria Gore-Jones, Sukanta Saha, Carmen Lim, David Penn
- F49. EFFECTIVENESS OF THE META-COGNITIVE TRAINING IN PEOPLE WITH FIRST-EPISODE PSYCHOSIS. DOES GENDER MATTERS?
Susana Ochoa*, Miriam Salas, Raquel Lopez-Carrilero, Esther Pousa, Ana Barajas, Eva Grasa, Maria Luissa Barrigón, Esther Lorente, Jordi Cid, Fermin González, Isabel Ruiz, Irene Birulés
- F50. METACOGNITIVE REFLECTION AND INSIGHT THERAPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
Steven de Jong*, Rozanne van Donkersgoed, Marieke Timmerman, Marije aan het Rot, Lex Wunderink, Johan Arends, Mark van der Gaag, Andre Aleman, Paul Lysaker, Marieke Pijnenborg
- F51. INTEGRATED COGNITIVE REMEDIATION THERAPY PREVENTS RELAPSES IN SCHIZOPHRENIA OUTPATIENTS DURING 8-YEARS FOLLOW-UP
Daniel R. Mueller*, Conny Steichen, Annina R. Reymond, Volker Roder
- F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
Robert Goldman, Michael Tocco*, Andrei Pikalov, Josephine Cucchiario, Ling Deng, Antony Loebel
- F53. DOSE REDUCTION OF HIGH-DOSE FIRST-GENERATION ANTIPSYCHOTICS OR SWITCH TO ZIPRASIDONE IN LONG-STAY PATIENTS WITH SCHIZOPHRENIA: A 1-YEAR DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL
Jan Bogers*, Raphael Schulte, Broekman Theo, Lieuwe de Haan
- F54. PHARMACOLOGICAL ENHANCEMENT OF COGNITION AND SOCIAL COGNITION IN THE PSYCHOSIS SPECTRUM
M. Mercedes Perez-Rodriguez*, Daniel Rosell, Scott Moeller, Prantik Kundu, Margaret McClure, Erin Hazlett, Antonia New
- F55. EFFICACY OF COMPUTER ASSISTED COGNITIVE REMEDIATION IN MID-AGED AND OLDER INPATIENTS WITH CHRONIC SCHIZOPHRENIA IN KOREA
Kee-Hong Choi, Jinsook Kang, Sun-Min Kim, Seung-Hwan Lee, Seon-Cheol Park, Won-Hye Lee, Sun Choi, Kiho Park*, Tae-Yeon Hwang
- F56. IMPACT OF SIDE EFFECTS DUE TO SECOND-GENERATION ANTIPSYCHOTICS ON THE FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: AN OBSERVATIONAL, PATIENT CENTERED, WEB SURVEY
Rajiv Tandon*, Catherine Weiss, William Lenderking, Owen Cooper, Huda Shalhoub, Leah Kleinman, Jun Chen, Ann Hartry, Mallik Green, Stine R. Meehan, Laëtitia Bouérat Douvold



F57. CORRELATION FACTORS OF ABNORMAL MENSES IN SCHIZOPHRENIA TREATMENT WITH RISPERIDONE

Fang Dong*, Qijing Bo, Chuanyue Wang

F58. COMMUNITY-BASED MULTI-SITE RANDOMIZED CONTROLLED TRIAL OF BEHAVIORAL ACTIVATION FOR NEGATIVE SYMPTOMS OF INDIVIDUALS WITH CHRONIC SCHIZOPHRENIA

Eunbyeol Lee*, Yun-Ji Cha, Ji-Hye Oh, Na-Ri Hwang, Kee-Hong Choi, Ho-Jun Seo

F59. VISUALIZING MENTAL REPRESENTATION OF TRUSTWORTHY FACES IN SCHIZOPHRENIA

Neeltje Van Haren*, Loek Brinkman, Henk Aarts, Ron Dotsch

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE

Andrei Pikalov*, Brian Miller, Cynthia Siu, Michael Tocco, Joyce Tsai, Philip Harvey, Antony Loebel

F61. THE RELATIONSHIP OF AGE AND SYMPTOMS WITH COGNITIVE PLANNING IN SCHIZOPHRENIA

Dimitrios Kontis*, Alexandra Giannakopoulou, Eirini Theochari, Angeliki Andreopoulou, Spyridoula Vassilouli, Dimitra Giannakopoulou, Eleni Sietto, Eleftheria Tsaltas

F62. RISKY DECISION-MAKING PERFORMANCE IN PATIENTS WITH EARLY SCHIZOPHRENIA-SPECTRUM DISORDER

Sin Ki Luk, Tatia M.C. Lee, Eric YH Chen, Wing Chung Chang*

F63. COGNITIVE CORRELATES OF THE NEGATIVE SYMPTOMS EXPRESSIVE AND EXPERIENTIAL DEFICIT FACTORS IN PSYCHOSIS

Serge Sevy, Anzalee Khan, Jean-Pierre Lindenmayer*, Susan McGurk, Benedicto Paker, Isidora Ljuri, Mohan Parak, Abraham Goldring

F64. DISRUPTION IN WORKING MEMORY GATING OBSERVED IN SCHIZOPHRENIA

Rachael Blackman*, Noah Philip, David Badre

F65. NETWORK ANALYSIS OF EMPATHY, SCHIZOTYPY AND AFFECTIVE STATES IN A COLLEGE SAMPLE

Yi Wang*, Wen-hua Liu, Hai-song Shi, Raymond C. K. Chan

F66. DO CLINICAL VARIABLES DURING THE EARLY ILLNESS PERIOD PREDICT THE COGNITIVE COURSE IN EARLY-ONSET SCHIZOPHRENIA?

Charlotte Teigset*, Christine Mohn, Bjorn Rund

F67. NEUROCOGNITION IN 7-YEAR-OLD CHILDREN OF PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

Nicoline Hemager*, Kerstin Plessen, Anne Amalie Thorup, Camilla J. Christiani, Ditte Ellersgaard, Katrine Søborg Spang, Birgitte Klee Burton, Aja Greve, Ditte L. Gantriis, Anne Søndergaard, Maja Gregersen, Ole Mors, Merete Nordentoft, Jens Richardt Møllegaard Jepsen



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY

Victoria Rodriguez*, Olesya Ajnakina, Simona Stilo, Valeria Mondelli, Tiago Reis Marques, Antonella Trotta, Giada Tripoli, Diego Quattrone, Marco Colizzi, Poonam Sood, Ben Wiffen, Paola Dazzan, Evangelos Vassos, Marta Di Forti, Anthony David, Robin Murray

F69. MUSCARINIC M1 RECEPTOR SEQUENCE VARIATION AND GENERAL COGNITION

Sean Carruthers*, Kiyomet Bozaoglu, Caroline Gurvich, Philip Sumner, Eric Tan, Elizabeth Thomas, Susan Rossell

F70. COMPUTERIZED SOCIAL COGNITIVE TRAINING (SCT) IMPROVES COGNITION AND RESTORES FUNCTIONAL CONNECTIVITY IN RECENT ONSET PSYCHOSIS: AN INTERIM REPORT

Shalaila Haas*, Nikolaos Koutsouleris, Anne Ruef, Bruno Biagianti, Joseph Kambeitz, Dominic Dwyer, Ifrah Khanyaree, Rachele Sanfelici, Lana Kambeitz-Ilankovic

F71. THE STRUCTURE OF NEUROCOGNITION ACROSS CHILDHOOD AND ADULTHOOD IN YOUNG PEOPLE WITH PSYCHOSIS

Josephine Mollon*, Anthony David, Stanley Zammit, Glyn Lewis, Avi Reichenberg

F72. NEUROCOGNITION AND ADAPTIVE FUNCTIONING IN THE 22Q11.2 DELETION SYNDROME MODEL OF SCHIZOPHRENIA

Fiksinski Ania*, Elemi Breetvelt, Jacob Vorstman, Eva Chow, Erin Lee, Lisa Palmer, Erik Boot, Nancy Butcher, Rene Kahn, Anne Bassett

F73. COGNITIVE CLUSTERING IN SCHIZOPHRENIA PATIENTS, THEIR FIRST-DEGREE RELATIVES AND HEALTHY SUBJECTS IS ASSOCIATED WITH ANTERIOR CINGULATE CORTEX VOLUME

Kazutaka Ohi*, Takamitsu Shimada, Kiyotaka Nemoto, Yuzuru Kataoka, Toshiki Yasuyama, Kohei Kimura, Hiroaki Okubo, Takashi Uehara, Yasuhiro Kawasaki

F74. CLINICAL SYMPTOMS AND NOT OBJECTIVE COGNITIVE PERFORMANCE DRIVE SUBJECTIVE COGNITIVE COMPLAINTS IN PATIENTS WITH SCHIZOPHRENIA

Jack Cotter*, Kiri Granger, John Evenden, Jennifer Barnett, Michael Sand

F75. MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS

Mallik Greene, Tingjian Yan, Eunice Chang, Ann Hartry*, Beth Pulasky

F76. CHILDHOOD TRAUMA RELATED TO ABNORMAL SOCIAL COGNITION IN SCHIZOPHRENIA

Aldara Alvarez Astorga*, Alba Lubeiro Juárez, Eva Sotelo, Mercedes Vaquero, Vicente Molina Rodriguez



F77. OXYTOCIN ENHANCES VISUAL ATTENTION TO FACIAL STIMULI IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FROM AN EYE-TRACKING STUDY

Lilla Porffy*, Rebekah Wigton, Antoine Coutrot, Dan Joyce, Isabelle Mareschal, Sukhi Shergill

F78. OVERCOMING A BOTTOM-UP ATTENTIONAL BIAS BY PROVIDING TOP-DOWN INFORMATION DURING WORKING MEMORY ENCODING IN SCHIZOPHRENIA

Catherine Barnes*, Lara Rösler, Michael Schaum, Deliah Macht, Benjamin Peters, Jutta Mayer, Michael Wibral, Andreas Reif, Robert Bittner

F79. ATTRIBUTION OF INTENTIONS IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS WITH PERSECUTORY DELUSIONS

Michal Hajdúk*, Lucia Pavelková, Peter Ohrablo, Veronika Petrušová, Anton Heretik, Lubica Forgáčová

F80. COGNITIVE TRAJECTORIES OVER 6 YEARS IN FIRST-EPISEODE SCHIZOPHRENIA AND HEALTHY CONTROLS – A PROSPECTIVE LONGITUDINAL MULTI-ASSESSMENT STUDY

Susie Fu*, Nikolai Czajkowski, Anne-Kari Torgalsboen

(F81) AGE OF ONSET OF CANNABIS USE AND COGNITIVE FUNCTION IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS PATIENTS: 3-YEAR FOLLOW-UP OUTCOME

Esther Setién-Suero*, Diana Tordesillas-Gutierrez, Benedicto Crespo-Facorro, Rosa Ayesa-Arriola

F82. COGNITIVE BIASES IN PATIENTS WITH SCHIZOPHRENIA AND HIGH SCHOOL STUDENTS: ASSOCIATION WITH PSYCHOPATHOLOGICAL SYMPTOMS

Francesc Estrada*, Maribel Ahuir, Josep Maria Crosas, Claudia Vilaplana, Alba González-Fernández, Meritxell Tost, Irina Olasz, Nora Mesa, Estefanía Gago, Montserrat Pàmias, José Antonio Monreal, Diego Palao, Javier Labad

F83. INVESTIGATING THE RELATIONSHIP BETWEEN NEGATIVE SYMPTOM PROFILE AND COGNITIVE FUNCTION IN SCHIZOPHRENIA

Caitlin Yolland*, Wei Lin Toh, Eric Tan, Caroline Gurvich, Erica Neill, Susan Rossell

F84. ASSOCIATIONS BETWEEN INTELLIGENCE, VERBAL WORKING MEMORY AND PROCESSING SPEED IN PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER AND THEIR 7-YEAR OLD OFFSPRING

Aja Greve*, Jens Richardt Møllegaard Jepsen, Erik Lykke Mortensen, Rudolf Uher, Lynn Mackenzie, Leslie Foldager, Ditte Gantriis, Birgitte Klee Burton, Ditte Ellersgaard, Camilla Jerlang Christiani, Katrine Spang, Nicoline Hemager, Maria Toft Henriksen, Kate Kold Zahle, Henriette Stadsgaard, Anne Thorup, Merete Nordentoft, Kerstin Plessen, Ole Mors, Vibeke Bliksted

F85. THE RELATIONSHIP BETWEEN JUMPING TO CONCLUSIONS AND NEUROPSYCHOLOGICAL FUNCTIONING IN SCHIZOPHRENIA

Martyna Krężolek*, Renata Pionke, Beata Banaszak, Andrzej Kokoszka, Łukasz Gawęda

F86. SOCIAL COGNITION IN HOMICIDE OFFENDERS WITH SCHIZOPHRENIA

Katharina Engelstad*, Bjørn Rishovd Rund, Anne-Kari Torgalsboen, Anja Vaskinn



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F87. SERUM PROLACTIN LEVELS AND COGNITIVE OUTCOME IN FIRST EPISODE PSYCHOSIS: A PROSPECTIVE 1-YEAR FOLLOW-UP STUDY

Meritxell Tost Bonet*, Itziar Montalvo, Francesc Estrada, Maria Isabel Ahuir Perez, Ángel Cabezas, Montse Paños, Montserrat Sole, José Antonio Monreal, vanessa Sanchez-gistau, Elisabet Vilella, Diego Palao, Javier Labad

F88. MANIPULATION OF THE GUT MICROBIOTA WITH A PREBIOTIC IN SCHIZOPHRENIA: A DOUBLE-BLINDED RANDOMIZED PLACEBO-CONTROLLED CROSS-OVER STUDY

Amy Kao*, Phil Burnet, Belinda Lennox

F89. COGNITIVE IMPAIRMENT WORSENING ACROSS AFFECTIVE TO PSYCHOSIS SPECTRUM: A COHORT STUDY OF UNIPOLAR/BIPOLAR DEPRESSION AND BIPOLAR SCHIZOAFFECTIVE DISORDERS

Martin Roy*, Marie-Pierre Strippoli, Caroline Vandeleur, Elsa Gilbert, Enrique Castela, Jean-Michel Aubry, Pierre Marquet, Martin Preisig

F90. SOCIAL INFERENCE AND BELIEFS DIFFER IN INDIVIDUALS WITH SUBCLINICAL PERSECUTORY DELUSIONAL TENDENCIES

Katharina Wellstein*, Andreea Diaconescu, Martin Bischof, Annia Rüesch Ranganadan, Johannes Ullrich, Klaas Enno Stephan

F91. ASSOCIATION BETWEEN SYMPTOM DIMENSIONS AND EXECUTIVE FUNCTION IN SCHIZOPHRENIA

Ana Luiza Franco*, Bruno Bertolucci Ortiz, Felipe Ferreira, Ana Olívia Fonseca, Arthur de Almeida Berberian, Deyvis Rocha, Cristiano Noto, Rodrigo Bressan, Ary Gadelha

F92. COMPARISONS BETWEEN CANNABIS USERS AND NON-USERS PATIENTS WITH FIRST-EPISODE PSYCHOSIS IN NEUROCOGNITIVE FUNCTIONING: A META-ANALYSIS

Teresa Sanchez-Gutierrez*, Belén Fernandez-Castilla, Sara Barbeito, Juan Antonio Becerra, Ana Calvo

F93. SUBCLINICAL PSYCHOSIS COMPONENTS MAKE DIRECT AND INDIRECT CONTRIBUTIONS TO ACTIVE SUICIDE IDEATION IN ADOLESCENTS

Richard Linscott*, Theresa Parker

F94. A PREVALENCE PILOT STUDY FOR OBSTRUCTIVE SLEEP APNEA SYNDROME IN CLOZAPINE USERS

M.F. Knevel, L.B. Luteijn*, Jan Bogers, Jean-Paul Selten

F95. ASSESSING MANIC SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA USING THE YOUNG MANIA RATING SCALE

Tae Yong Kim*, Seon-Cheol Park, Joonho Choi, Han-Yong Jung, Joo Eon Park



F96. AGE AND GENDER DETERMINED DIFFERENCES IN THE ONSET OF CHRONIC PHYSICAL MULTIMORBIDITIES AMONG PATIENTS WITH SCHIZOPHRENIA OR DEPRESSION AND THE GENERAL POPULATION

Ivona Šimunović Filipčić*, Ena Ivezic, Željko Milovac, Ines Kašpar, Sandra Kocijan Lovko, Lada Goršić, Tomislav Gajšak, Strahimir Sučić, Antonija Slaviček Sučić, Majda Grah, Nikolina Tunjić Vukadinović, Žarko Bajić, Marijana Braš, Igor Filipčić

F97. CHRONIC PHYSICAL MULTIMORBIDITIES, GENDER DISPARITIES AND TREATMENT OUTCOME IN SCHIZOPHRENIA

Igor Filipčić*, Ivona Šimunović Filipčić, Ena Ivezic, Sanja Devčić, Davor Bodor, Branka Restek Petrović, Ivana Bakija, Paola Presečki, Silvana Jelavić, Nino Mimica, Katarina Matić, Dina Librenjak, Nenad Jakšić, Žarko Bajić

F98. HYPOVITAMINOSIS D IN SCHIZOPHRENIA: ASSOCIATED CARDIOVASCULAR RISK

Rahma Nefzi*, Amine Larnaout, Hanen Ben Ammar, Emira Khelifa, Amina Aissa, Zouhaier El Hechmi

F99. FIRST EPISODE PSYCHOSIS PATIENTS WHO USED CANNABIS DEVELOP THEIR ILLNESS AT A SIGNIFICANT YOUNGER AGE THAN THOSE WHO NEVER USED CONSISTENTLY ACROSS EUROPE AND BRAZIL

Caterina La Cascia, Laura Ferraro*, Fabio Seminerio, Giada Tripoli, Lucia Sideli, Diego Quattrone, Marta Di Forti, Daniele La Barbera, Robin Murray

F100. FACTOR STRUCTURE OF THE CANNABIS EXPERIENCES QUESTIONNAIRE IN A FIRST-EPISODE PSYCHOSIS SAMPLE

Michael Birnbaum, Luca Pauselli*, Sean Cleary, Claire Ramsey Wan, Michael Compton

F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS. RESULTS FROM A 3-YEARS LONGITUDINAL STUDY.

Javier Vázquez-Bourgon, Lucía Sanchez Blanco, Ruth Landera Rodriguez, Esther Setién Suero, Rodrigo Romero Jiménez, Diana Tordesillas-Gutiérrez*, Rosa Ayesa Arriola, Benedicto Crespo-Facorro

F102. CHANGE IN PATTERNS OF CANNABIS AND OTHER SUBSTANCE USE OVER TIME IN EARLY PSYCHOSIS- EXAMINING THE EFFECT OF DEVELOPMENT OF PSYCHOSIS

Musa Sami*, Michael Lynskey, Sagnik Bhattacharyya

F103. A META-ANALYSIS OF PERSONALITY TRAITS IN DUAL DIAGNOSIS PSYCHOSIS AND SUBSTANCE USE DISORDER

Hyeonju Oh*, Seon-Kyeong Jang, Kee-Hong Choi

F104. A STANDARDISED EMPIRICAL INVESTIGATION OF THE CLINICAL PROFILE OF PSYCHOSIS FOLLOWING TRAUMATIC BRAIN INJURY (PFTBI)

Rachel Batty*, Neil Thomas, Andrew Francis, Malcolm Hopwood, Jennie Ponsford, Susan Rossell

F105. MEASURING EMPATHY IN SCHIZOPHRENIA: THE EMPATHIC ACCURACY TASK AND ITS CORRELATION WITH OTHER EMPATHY MEASURES

Rozanne van Donkersgoed, Bouwina Sportel*, Steven De Jong, Marije aan het Rot, Alexander Wunderink, Paul Lysaker, Ilanit Hasson-Ohayon, Andre Aleman, Marieke (Gerdina) Pijnenborg



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F106. STATE AND TRAIT RELATED NATURE OF INSIGHT IMPAIRMENT IN SCHIZOPHRENIA
Lebogang Phahladira*, Bonginkosi Chiliza, Laila Asmal, Sanja Kilian, Freda Scheffler, Robin Emsley

F107. CSF ABNORMALITIES IN SCHIZOPHRENIA AND DEPRESSION: PRELIMINARY RESULTS
FROM A LARGE SCALE COHORT

Tatiana Oviedo Salcedo*, Anna Gagsteiger, Lot de Witte, Tania Kümpfel, Rene Kahn, Peter Falkai, Peter Eichhorn, Jurjen Luykx, Alkomiet Hasan

F108. PSYCHOTIC EXPERIENCES IN A NORWEGIAN SAMPLE - TENTATIVE RESULTS OF A
QUESTIONNAIRE VALIDATION

Isabella Kusztrits*, Frank Larøi, Julien Laloyaux, Lynn Marquardt, Igne Sinkeviciute, Eirik Kjelby, Erik Johnsen, Josef Bless, Kristiina Kompus, Kenneth Hugdahl, Marco Hirnstein

F109. BOUNDARIES BETWEEN DEFICIT AND NONDEFICIT SCHIZOPHRENIA: LONG TERM
STABILITY AND OUTCOMES

Gustavo Mustafé*, Diego Mendes, Thaís Martins, Thalita Fernandes, Clarissa Dantas

F110. THE BRIEF NEGATIVE SYMPTOM SCALE (BNSS): VALIDATION IN A MULTICENTER
BRAZILIAN STUDY

Heydrich Medeiros, Helio Elkis*, Selene Vasconcelos, Diana Martins, Raissa Alexandria, Ana Albuquerque, Rosana Freitas, Maria Scardoelli, Elaine Di Sarno, Isabel Napolitano, Graça Oliveira, Adriana Vizzotto, Antônio Peregrino, Murilo Lima

F111. ELECTROPHYSIOLOGICAL CORRELATES OF AVOLITION-APATHY DOMAIN IN
SCHIZOPHRENIA

Giulia Giordano*, Thomas Koenig, Armida Mucci, Annarita Vignapiano, Antonella Amodio, Giorgio Di Lorenzo, Cinzia Niolu, Mario Altamura, Antonello Bellomo, Silvana Galderisi

F112. LESS SYMPTOMS IN SCHIZOPHRENIA – A RISK FACTOR FOR IMPAIRED INSIGHT OF
FUNCTIONING?

Olsson Anna-Karin*, Maivor Olsson-Tall, Hawar Moradi, Fredrik Hjärthag, Lars Helldin

F113. IMPACT OF NEIGHBORHOOD CHARACTERISTICS ON PARANOIA, LONELINESS, AND
PERCEIVED REJECTION IN A TRANSDIAGNOSTIC SAMPLE WITH PSYCHOSIS

Christina Savage*, Cristina Garcia, LeeAnn Shan, Alexandra Andrea, Melanie Bennett, Jack Blanchard

F114. DISORGANIZATION AND COGNITIVE DYSFUNCTIONS IN SCHIZOPHRENIA: A STUDY OF
RESTING STATE EEG

Anarita Vignapiano*, Thomas Koenig, Armida Mucci, Giulia Maria Giordano, Antonella Amodio, Giorgio Di Lorenzo, Cinzia Niolu, Mario Altamura, Antonello Bellomo, Silvana Galderisi

F115. INSIGHT AND MANIC SYMPTOMS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA IN
THE KOREAN COMMUNITY

Duk-In Jon*, Bo-Hyun Yoon, Sang-Yeol Lee, Kwanghun Lee, Won-Myong Bahk, Beomwoo Nam, Sung-Yong Park, Min-Kyu Song



F116. CAN INSIGHT LEAD TO REMISSION - FOR PATIENTS WITH SCHIZOPHRENIA?

Maivor Olsson-Tall*, Fredrik Hjärthag, Anna-Karin Olsson, Madeleine Johansson, Hawar Moradi, Lars Helldin

F117. SCHIZOTYPY PERSONALITY TRAITS RELATED TO PSYCHOLOGICAL FUNCTIONING AND INTERNALIZED STIGMA

Olivia Altamirano*, Amy Weisman de Mamani

F118. ARCHITECTURE OF PSYCHOSIS SYMPTOMS AND NEURAL PREDICTORS OF CONVERSION AMONG CLINICAL HIGH RISK INDIVIDUALS WITH AUTISM SPECTRUM DISORDER

Jennifer Foss-Feig*, Eva Velthorst, Sylvia Guillory, Holly Hamilton, Brian Roach, Peter Bachman, Aysenil Belger, Ricardo Carrion, Erica Duncan, Jason Johannesen, Gregory Light, Margaret Niznikiewicz, Jean Addington, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Thomas McGlashan, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Carrie Bearden, Daniel Mathalon

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA

Cynthia Higuchi, Hugo Cogo-Moreira, Bruno Bertolucci*, Christoph U. Correll, Cristiano Noto, Quirino Cordeiro, Rosana Freitas, Hélio Elkis, Sintia I. Belangero, Rodrigo A. Bressan, Ary Gadelha

F120. USING DIGITAL MEDIA ADVERTISING IN EARLY PSYCHOSIS INTERVENTION

Michael Birnbaum*, Chantel Garrett, Amit Baumel, Asra Rizvi, Whitney Muscat, John Kane

F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE?: ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA

Hiroyoshi Takeuchi*, Cynthia Siu, Gary Remington, Gagan Fervaha, George Foussias, Robert Zipursky, Ofer Agid

F122. CLINICAL CHARACTERISTICS OF LATE-ONSET SCHIZOPHRENIA IN COMPARISON WITH EARLY-ONSET SCHIZOPHRENIA: ONE YEAR FOLLOW-UP STUDY

Jung Suk Lee*, Mi-Ae Ko, Seon-Koo Lee

F123. BELIEFS ABOUT THEIR VOICES AND DEGREE OF RESILIENCE IN PERSONS WITH AUDITORY VERBAL HALLUCINATIONS WITH AND WITHOUT NEED FOR CARE

Julien Lalouaux*, Alberto Collazzoni, Isabella Kusztrits, Marco Hirnstein, Kristiina Kompus, Josef J. Bless, Frank Larøi

F124. SEX DIFFERENCES IN OUTCOME IN FIRST EPISODE PSYCHOSIS PATIENTS: A 10-YEAR FOLLOW-UP STUDY

Rosa Ayesa-Arriola*, Esther Setién-Suero, Diana Tordesillas-Gutierrez, Benedicto Crespo-Facorro

F125. POOR OUTCOME SCHIZOPHRENIA (KRAEPELINIAN SUB-TYPE): SOCIAL COGNITIVE AND NEURODEVELOPMENTAL MARKERS

Emmanuel Chevallier, Audrey Tanguy, Marie-Odile Krebs, Serge Mitelman, Monte Buchsbaum, Marie-Cécile Bralet*



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F126. PATHWAYS FROM SPEECH ILLUSIONS TO PSYCHOTIC SYMPTOMS IN SUBJECTS AT ULTRA-HIGH RISK FOR PSYCHOSIS: COMBINING AN EXPERIMENTAL PARADIGM OF ABERRANT EXPERIENCES WITH NETWORK ANALYSIS

Adela-Maria Isvoranu, Lindylou Boyette*, Frederike Schirmbeck, Eva Velthorst, Claudia Simons, Denny Borsboom, Lieuwe De Haan, EU-GEI WP5 At Risk Study

F127. GLOBAL RECOVERY IN A FIRST EPISODE PSYCHOSIS PROGRAM IN SOUTH AMERICA

Barbara Iruretagoyena*, Nicolas Crossley, Juan Undurruga, Carmen Castañeda, Carlos Gallardo, Felipe Mancilla, Alfonso Gonzalez

F128. THE AGE OF ONSET OF SCHIZOPHRENIA SPECTRUM DISORDERS

Jouko Miettunen*, Johanna Immonen, John McGrath, Matti Isohanni, Erika Jääskeläinen

F129. COMBINED PATTERNS OF TOBACCO AND CANNABIS USE IN ADOLESCENCE AND THEIR ASSOCIATION WITH PSYCHOTIC EXPERIENCES: A LONGITUDINAL ANALYSIS

Stanley Zammit*, Hannah Jones, Suzanne Gage, Jon Heron, Matthew Hickman, Glyn Lewis, Marcus Munafo

F130. INCREASED RISK OF PSYCHOTIC DISORDERS IN AFRICAN MIGRANTS TO AUSTRALIA

Linglee Downey, Scott Eaton, Kristen Thien, Melissa Bardell-Williams, Meghan Bowtell, Aswin Ratheesh, Patrick D. McGorry, Brian O'Donoghue*

F131. CHILDHOOD ADVERSITIES IN PEOPLE AT ULTRA-HIGH RISK (UHR) FOR PSYCHOSIS: SYSTEMATIC REVIEW & META-ANALYSIS

Oon Him Peh, Attilio Rapisarda*, Jimmy Lee

F132. IDENTIFICATION OF PATIENTS WITH RECENT ONSET PSYCHOSIS IN KWAZULU NATAL, SOUTH AFRICA: A PILOT STUDY WITH TRADITIONAL HEALTH PRACTITIONERS AND DIAGNOSTIC INSTRUMENTS

Wim Veling*, Jonathan Burns, Hans W. Hoek, Ezra Susser

F133. ARE WE UNDERESTIMATING THE INCIDENCE OF PSYCHOTIC DISORDER? ESTIMATES FROM POPULATION-BASED HEALTH ADMINISTRATIVE DATA FROM ONTARIO, CANADA

Kelly Anderson*, Ross Norman, Arlene MacDougall, Jordan Edwards, Lena Palaniyappan, Cindy Lau, Paul Kurdyak

F134. MATERNAL PRENATAL C-REACTIVE PROTEIN AND ADOLESCENT

NEURODEVELOPMENTAL OUTCOMES IN THE NORTHERN FINLAND BIRTH COHORT 1986
Hugh Ramsay*, Golam Khandaker, Heljä-Marja Surcel, Juha Veijola

F135. BODY MASS INDEX TRAJECTORIES IN CHILDHOOD AND RISK FOR NON-AFFECTIVE PSYCHOSIS – A GENERAL POPULATION COHORT STUDY

Elina Sormunen*, Maiju Saarinen, Raimo K.R. Salokangas, Jorma Viikari, Olli Raitakari, Jarmo Hietala

F136. PARSING DUP TO REFINE EARLY DETECTION: QUANTILE REGRESSION OF RESULTS FROM THE SCANDINAVIAN TIPS STUDY

Maria Ferrara*, Sinan Guloksuz, Shadie Burke, Fangyong Li, Svein Friis, Wenche ten Velden Hegelstad, Inge Joa, Jan Olav Johannessen, Ingrid Melle, Erik Simonsen, Vinod Srihari



F137. INFECTIONS OF THE CENTRAL NERVOUS SYSTEM AS A RISK FACTOR FOR MENTAL DISORDERS AND COGNITIVE IMPAIRMENT: A NATIONWIDE REGISTER-BASED STUDY
Emilie Pedersen*, Ole Köhler-Forsberg, Merete Nordentoft, Liselotte Petersen, Michael Eriksen Benros

F138. INVESTIGATING A CAUSAL ASSOCIATION BETWEEN NEUROTICISM AND SCHIZOPHRENIA USING TWO-SAMPLE MENDELIAN RANDOMIZATION
Hannah Jones*, George Davey Smith, Michael C. O'Donovan, Michael J. Owen, James Walters, Stanley Zammit

F139. INCLINATION OF STIGMA TOWARD SCHIZOPHRENIA, ATTENUATED PSYCHOSIS, PSYCHOTIC-LIKE EXPERIENCES AND DEPRESSION AMONG DIFFERENT SUBPOPULATIONS IN TAIWAN
Chen-Chung Liu*, Yen-Chin Wang

F140. HOMICIDES OF PHYSICIANS AND MENTAL HEALTH WORKERS
Michael Knable*

F141. DUTY TO WARN FOR POTENTIAL RISK OF PSYCHOLOGICAL HARM: A CASE REPORT
Naista Zhand*, David Attwood

F142. THE USE OF NEUROIMAGING MARKERS IN STRATIFIED DIAGNOSIS AND THERAPY OF SCHIZOPHRENIC AND AFFECTIVE DISORDERS
Oliver Gruber*

F143. PREDICTORS OF RELAPSE: PATIENT, DISEASE, COGNITIVE, AND FUNCTIONAL CHARACTERISTICS WITH COMT GENE VAL158MET POLYMORPHISM IN A 2-YEAR FOLLOW-UP
Anzalee Khan*, Jean-Pierre Lindenmayer, Isidora Ljuri, Veronica Ozog, Amod Thanju

F144. MUSCARINIC M1 RECEPTOR SIGNALLING UNDERLYING COGNITION IN PSYCHOTIC DISORDERS
Therese van Amelsvoort, Geor Bakker, Claudia Vingerhoets, Barbara J. Sahakian, Oswald Bloemen, Matthan Caan, Jan Booij, Therese van Amelsvoort*

F145. WHAT ARE THE MAIN BRAIN CHANGES IN FMRI AFTER TREATMENT IN FIRST EPISODE PSYCHOSIS? A SYSTEMATIC REVIEW
Carlos Gonzalez, Olga Sparano, Pau Soldevila-Matias, Gracian Garcia-Marti, Luis Marti-Bonmati, Benedicto Crespo-Facorro, Julio Sanjuan*

F146. S-KETAMINE-INDUCED NMDA RECEPTOR BLOCKADE DURING NATURAL SPEECH PRODUCTION AND ITS IMPLICATIONS FOR FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA: A PHARMACO-FMRI STUDY
Tilo Kircher*, Arne Nagels

F147. RESTING STATE NETWORKS ALTERATION IN PANTOTHENATE-KINASE ASSOCIATED NEURODEGENERATION (PKAN)
Gianluca Mingioia*, Peter Stoeter, Rea Rodriguez-Raecke



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F148. A PILOT STUDY OF [11C] (R)-MEQAA PET BRAIN IMAGING ANALYSIS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS AVAILABILITY IN SCHIZOPHRENIA
Tomoyasu Wakuda*, Masamichi Yokokura, Kyoko Nakaizumi, Yasuhiko Kato, Yosuke Kamen, Masami Futatsubashi, Etsuji Yoshikawa, Yasuhiro Magata, Yasuomi Ouchi, Hidenori Yamasue, Nori Takei

F149. NEUROBIOLOGY OF SELF-AGENCY DURING REALITY MONITORING AND SPEECH FEEDBACK MONITORING: IMPLICATIONS FOR TREATMENT DEVELOPMENT IN SCHIZOPHRENIA

Karuna Subramaniam*, Leighton Hinkley, Hardik Kothare, Danielle Mizuiri, Sophia Vinogradov, John Houde, Srikantan Nagarajan

F150. OVERESTIMATING ENVIRONMENTAL VOLATILITY INCREASES SWITCHING BEHAVIOR AND IS LINKED TO ACTIVATION OF DORSOLATERAL PREFRONTAL CORTEX IN SCHIZOPHRENIA

Lorenz Deserno, Rebecca Boehme, Christoph Mathys, Teresa Katthagen, Jakob Kaminski, Klaas Enno Stephan, Andreas Heinz, Florian Schlagenhaut*

F151. A SYSTEMATIC REVIEW OF TASK-BASED FUNCTIONAL NEUROIMAGING STUDIES IN THOUGHT DISORDER

Philip Sumner*, Imogen Bell, Susan Rossell

F152. N-ACETYL-CYSTEINE SUPPLEMENTATION IMPROVES FUNCTIONAL CONNECTIVITY IN THE CINGULATE CORTEX IN EARLY PSYCHOSIS

Emeline Mullier, Timo Roine, Alessandra Griffa, Philipp S. Baumann, Paul Klauser*, Philippe Conus, Kim Q. Do, Patric Hagmann

F153. NEUROMAGNETIC MISMATCH NEGATIVITY IN CLINICAL HIGH RISK AND FIRST-EPIISODE PSYCHOSIS INDIVIDUALS

Emmi Mikanmaa*, Marc Recasens, Hanna Thuné, Tineke Grent-'t-Jong, Andrew Gumley, Matthias Schwannauer, Stephen Lawrie, Ruchika Gajwani, Joachim Gross, Peter Uhlhaas

F154. ABERRANT SALIENCE NETWORK FUNCTIONAL CONNECTIVITY IN AUDITORY VERBAL HALLUCINATIONS: A FIRST EPISODE PSYCHOSIS SAMPLE

Paris Alexandros Lalouis*, Pavan Mallikarjun, Thomas Frederick Dunne, Kareen Heinze, Renate Reniers, Matthew R. Broome, Baldeep Farmah, Femi Oyebo, Stephen Wood, Rachel Upthegrove

F155. THE NEUROPHYSIOLOGICAL AND BEHAVIOURAL EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON WORKING MEMORY AND EXECUTIVE FUNCTIONING IN SCHIZOPHRENIA

Natasza Orlov*, Owen O'Daly, Derek Tracy, John Rothwell, Sukhi Shergill

F156. LONGITUDINAL WORKING MEMORY FUNCTIONAL DYSCONNECTIVITY REFLECTS HETEROGENEITY IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS

Siwei Liu*, Jimmy Lee, Jesisca Tandi, Chenhao Wang, Joseph K.W. Lim, Newfei Ho, Joann Poh, R. Alison Adcock, Richard Keefe, Stephen Wood, Ranga Krishnan, Michael Chee, Juan Zhou



F157. HIERARCHICAL PREDICTION ERRORS DURING AUDITORY MISMATCH UNDER PHARMACOLOGICAL MANIPULATIONS: A COMPUTATIONAL SINGLE-TRIAL EEG ANALYSIS
Lilian Weber*, Andreea Diaconescu, Sara Tomiello, Dario Schöbi, Sandra Iglesias, Christoph Mathys, Helene Haker, Gabor Stefanics, André Schmidt, Michael Kometer, Franz X. Vollenweider, Klaas Enno Stephan

F158. FUNCTIONAL CONNECTIVITY DIVERSITY OF THE INSULA CORTEX IN SCHIZOPHRENIA: SUBREGIONS OR CONTINUA?

Ye Tian*, Chad Bousman, Chenxing Liu, Christos Pantelis, Andrew Zalesky

F159. NEUROMAGNETIC 40 HZ AUDITORY STEADY STATE RESPONSES AND AUDITORY CORTICAL GABA AND GLX IN CLINICAL HIGH RISK AND FIRST EPISODE OF PSYCHOSIS INDIVIDUALS

Hanna Thuné*, Tineke Grent-'t-Jong, Emmi Mikanmaa, Marc Recasens, Frances Crabbe, Jozien Goense, Andrew Gumley, Matthias Schwannauer, Stephen Lawrie, Ruchika Gajwani, Joachim Gross, Peter Uhlhaas

F160. CLASSIFYING SCHIZOPHRENIA BY PATTERNS OF BOLD FLUCTUATIONS USING MULTIVARIATE PATTERN RECOGNITION ANALYSIS

Jing Shang*, Christian Sorg, Josef G. Bäuml, Joseph Kambeitz, Felix Brandl, Nikolaos Koutsouleris

F161. BRAIN VOLUME CHANGE IN PATIENTS WITH SCHIZOPHRENIA AND ITS RELATION WITH ANTIPSYCHOTIC DRUG USE

Fatma Kiras*, Mustafa Yildiz, Yonca Anik

F162. MORE EFFORT, BUT LESS EFFICIENCY - WORKING MEMORY IN SCHIZOPHRENIA. AN INVESTIGATION INTO CAUSE FOR DIVERGENT RESULTS

Pavan Mallikarjun*, Sabrina Meecham, Rachel Upthegrove, Paris Alexandros Lalousis, Anna Diukova, Dorothee Auer, Peter Liddle

F163. STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN DURING WORKING MEMORY IN MEDICATION-NAÏVE PATIENTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS

Kolbjørn Brønnick, Jens Gisselgård, Inge Joa, Aase Ingvild, Robert Jørgensen, Jan Olav Johannessen, Jan Olav Johannessen*

F164. VENTRAL AND DORSAL STRIATAL DYSFUNCTION DURING REWARD ANTICIPATION IS ASSOCIATED WITH NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY INDIVIDUALS

Marta Stepien, Andrei Manoliu, Roman Kubli, Karoline Schneider, Philippe N. Tobler, Erich Seifritz, Marcus Herdener, Stefan Kaiser, Matthias Kirschner*

F165. OBSTRUCTIVE SLEEP APNOEA IS COMMON IN SCHIZOPHRENIA AND RESPONDS WELL TO TREATMENT – A NOVEL AND PRACTICAL MEANS TO IMPROVE COGNITION AND METABOLIC HEALTH?

Cherrie Galletly*, Hannah Myles, Andrew Vincent, Nicholas Myles, Robert Adams, Madhu Chandratilleke, Dennis Liu, Jeremy Mercer, Andrew Vakulin, Gary Wittert



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F166. LOW-GRADE INFLAMMATION IN FIRST-EPIISODE PSYCHOSIS IS DETERMINED BY WAIST CIRCUMFERENCE INCREASE

Jaakko Keinänen*, Outi Mantere, Tuula Kieseppä, Maija Lindgren, Teemu Mäntylä, Eva Rikandi, Jouko Sundvall, Minna Torniainen-Holm, Jaana Suvisaari

F167. ACCESS, UNDERSTAND, APPRAISE AND APPLY TO / OF HEALTH INFORMATION AND HEALTH LITERACY IN INDIVIDUALS AT-RISK FOR PSYCHOSIS; A SYSTEMATIC REVIEW

Mauro Seves*, Theresa Haidl, Susanne Eggers, Ayda Rostamzadeh, Anna Genske, Saskia Jünger, Christiane Woopen, Frank Jessen, Stephan Ruhrmann

F168. PSYCHOTIC EXPERIENCE AND ADOLESCENT BRAIN TRAJECTORY: EVIDENCE FOR STRUCTURAL ALTERATIONS IN DOPAMINERGIC REGIONS

Andre Zugman*, Ary Gadelha, Felipe Argolo, Pedro Pan, Luis Augusto Rohde, Euripedes C. Miguel, Rodrigo Bressan, Andrea Parolin Jackowski

F169. BRAIN CONNECTIVITY DURING PSYCHOLOGICAL STRESS IN PATIENTS WITH SCHIZOPHRENIA

Mariana Castro*, Gabriela De Pino, Hernán Bocaccio, Stella Sanchez, Lucas Drucaroff, Elsa Costanzo, Agustina Wainsztein, Salvador M. Guinjoan, Mirta F. Villarreal

F170. SCHIZOPHRENIA POLYGENIC RISK SCORE ASSOCIATED WITH LEFT TEMPORAL GYRIFICATION

Igor Nenadic*, Stephanie Gräger, Swapnil Awasthi, Kerstin Langbein, Maren Dietzek, Bianca Besteher, Stephan Ripka, Markus M. Noethen, Heinrich Sauer, Christian Gaser, Franziska Degenhardt

F171. ALTERED DIFFUSIVITY IN THE BRAIN OF PATIENTS WITH SCHIZOPHRENIA: A DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING STUDIES WITH PUBLIC NEUROIMAGING DATA

Young Tak Jo, Yeon Ho Joo*, Harin Kim, Seung-hyun Shon, Woon Yoon, Sung Woo Joo, Jungsun Lee

F172. INDIVIDUAL PREDICTION OF RISK IN ADOLESCENT OFFSPRING OF PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER: A MACHINE LEARNING NEUROIMAGING STUDY WITH A CROSS-STAGE VALIDATION

Hugo Schnack*, Julia Binnewies, Nikita Setiawan, Woutje Berdowski, Neeltje van Haren, Rene Kahn, Manon Hillegers

F173. PITCH AND DURATION MISMATCH NEGATIVITY, AUDITORY CORTEX GRAY MATTER, AND PRODROMAL ROLE FUNCTIONING IN THE FIRST EPISODE SCHIZOPHRENIA SPECTRUM

Dean Salisbury*, Anna Shafer, Brian Coffman, Timothy Murphy

F174. OBESITY AND BRAIN INTEGRITY IN SCHIZOPHRENIA AND BIPOLAR DISORDER: DIVERGENT PATTERNS OF WHITE MATTER MICROSTRUCTURE DAMAGE IN A TRANSDIAGNOSTIC APPROACH

Ramiro Reckziegel, Raffael Massuda, Leticia Czepielewski, Monise Costanzi, Rodrigo Spinz, Isadora Remus, Clarissa Gama*



F175. NEUROLOGICAL SOFT SIGNS (NSS) AND BRAIN MORPHOLOGY IN PATIENTS WITH CHRONIC SCHIZOPHRENIA AND HEALTHY CONTROLS

Christina Herold*, Marc Lässer, Ulrich Seidl, Dusan Hirjak, Philipp Thomann, Marco Essig, Johannes Schröder

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAÏVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST

Kasper Jessen*, Ejgil Rostrup, Rene C. W. Mandl, Mette Ø. Nielsen, Nikolaj Bak, Birgitte Fagerlund, Birte Y. Glenthøj, Bjørn H. Ebdrup

F177. THALAMIC SUBREGION RESTING STATE CONNECTIVITY IN SCHIZOPHRENIA MEASURED AT 7T

Jun Hua, Ann Choe, Nicholas Blair, Anita Barber, Allison Brandt, James Pekar, Peter van Zijl, Christopher Ross, Issel Lim, Feng Xu, Russell Margolis*

F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA

Eric Plitman*, Yusuke Iwata, Shinichiro Nakajima, Jun Ku Chung, Raihaan Patel, Fernando Caravaggio, Julia Kim, Vincenzo De Luca, Sofia Chavez, Gary Remington, M. Mallar Chakravarty, Philip Gerretsen, Ariel Graff-Guerrero

F179. NEURAL CORRELATES IN MUSICAL DEFICITS IN SCHIZOPHRENIA

Ken Sawada*, Sanae Hatada, Ryoshuke Fujito, William Honer

F180. CANNABINOID 1 RECEPTOR AVAILABILITY & MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY

Faith Borgan*, Mattia Veronese, Owen O'Daly, Tiago Reis Marques, Maria Rogdaki, Oliver Howes

F181. CHANGE IN PREFRONTAL-LIMBIC MORPHOLOGY AND COGNITION IN DRUG-NAÏVE FIRST-EPISODE PSYCHOSIS PATIENTS FOLLOWING ATYPICAL ANTIPSYCHOTIC TREATMENT: A BRIEF LONGITUDINAL STUDY

Melissa Woodward*, Geoffrey Smith, William Honer, Vina Goghari, Lili Kopala, Kristina Gicas, Allen Thornton, Wayne Su, William MacEwan, Donna Lang

F182. SYMPTOM-RELATED STRUCTURAL BRAIN PATTERN IN PATIENTS WITH SCHIZOPHRENIA-A PARTIAL LEAST SQUARE ANALYSIS

Susanna Muckenhuber-Sternbauer*, Anne Ruef, and The PRONIA Team, Peter Falkai, Dominic Dwyer, Nikolaos Koutsouleris

F183. FUSIFORM GYRUS ABNORMALITIES RELATED TO VERBAL INTELLIGENCE AND NEGATIVE SYMPTOMS IN FIRST-EPISODE PSYCHOSIS

Sang-Hyuk Lee, Jeong Hoon Kim, Sra Jung*, Arira Lee

F184. TESTING THE GABA-GLUTAMATE HYPOTHESIS FOR SCHIZOPHRENIA IN RELATION TO AUDITORY HALLUCINATIONS - PRELIMINARY RESULTS

Helene Hjelmervik*, Alexander R. Craven, Erik Johnsen, Kristiina Kompus, Rune A. Kroken, Else-Marie Løberg, Kenneth Hugdahl



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F185. BRAIN STRUCTURAL PATTERNS DIFFERENTIATE EARLY- AND LATE-ONSET CANNABIS USE IN PSYCHOTIC PATIENTS: PRELIMINARY RESULTS FROM THE PRONIA STUDY
Nora Penzel*, The PRONIA Group, Peter Falkai, Nikolaos Koutsouleris, Joseph Kambeitz

F186. TAPETUM ABNORMALITIES IN FIRST-EPISODE PSYCHOSIS AND RELATIONSHIP TO SYMPTOM SEVERITY AND DURATION OF UNTREATED PSYCHOSIS
Sun Woo Lee, Arira Lee, Kang-Soo Lee, Jeong Hoon Kim, Sang-Hyuk Lee*

F187. TBSS ANALYSIS OF WHITE MATTER ALTERATIONS IN SCHIZOPHRENIA PATIENTS VS. HEALTHY CONTROLS – RELATION TO AUDITORY VERBAL HALLUCINATIONS
Justyna Beresiewicz*, Rene Westerhausen, Erik Johnsen, Kenneth Hugdahl, Kristiina Comps

F188. THALAMIC MICROSTRUCTURE IN UNAFFECTED RELATIVES OF SCHIZOPHRENIA
Wu Jeong Hwang*, Kang Ik Cho, Yoo Bin Kwak, Tae Young Lee, Jun Soo Kwon

F189. PERSONALIZED MEDICINE. ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
Hugo Geerts*, Athan Spiros

F190. EFFECT OF SELECTED GENE VARIANTS ON THE RELATIONSHIP BETWEEN EARLY CANNABIS USE AND AGE OF ONSET OF PSYCHOSIS
Rohit Lodhi, Yabing Wang, Gina McIntyre, David Rossolatos, Sudhakar Sivapalan, Beatriz Henriques, Brodie Heywood, Candice Crocker, Scot Purdon, Kathy Aitchison, Philip Tibbo*

F191. THE GENETICS OF DRUG-RELATED MOVEMENT DISORDERS AN UMBRELLA REVIEW OF META-ANALYSES
Nadine van der Burg, P. Roberto Bakker*, Jim Van Os, Peter Van Harten, Asmar Al Hadithy

F192. SYSTEMATIC META-ANALYSIS IDENTIFIES FIVE NOVEL ASSOCIATION LOCI FOR SCHIZOPHRENIA

Chenxing Liu*, Tetsu Kanazawa, Ye Tian, Suriati Saini, Christos Pantelis, Ian Everall, Chad Bousman

F193. DYSREGULATION OF RETINOID SIGNALLING IN SCHIZOPHRENIA OBSERVED IN WHOLE GENOME SEQUENCE ANALYSIS
William Reay*, Joshua Atkins, Chantel Fitzsimmons, Melissa Green, Vaughn Carr, Murray Cairns

F194. ASSOCIATION STUDY BETWEEN TREATMENT RESPONSE OF AMISULPRIDE AND DOPAMINE D3 RECEPTOR GENE POLYMORPHISMS
Kwanghun Lee*, Won-Myong Bahk, Bo-Hyun Yoon, Duk-In Jon, Sang-Yeol Lee, Moon Doo Kim, Beomwoo Nam, Min-Kyu Song

F195. ENRICHMENT OF PATHOGENIC VARIANTS ASSOCIATED WITH TREATABLE GENETIC DISEASES IN LARGE SCHIZOPHRENIA, BIPOLAR AND DEPRESSION COHORTS
Venuja Sriretnakumar, Ricardo Harripaul, John Vincent, James Kennedy, Joyce So*



F196. DIFFERENTIAL EFFECTS OF MGLU5 RECEPTOR BLOCKADE ON BEHAVIOR, SCHIZOPHRENIA-RELEVANT GENE EXPRESSION AND NEURONAL ACTIVATION PATTERNS FROM DEVELOPMENT TO AGING MICE

Dragos Inta, Alessia Luoni, Marco A. Riva, Peter Gass*

F197. PROMOTING MYELIN REPAIR RESCUES MICE FROM SCHIZOPHRENIA-LIKE BEHAVIOR INDUCED BY SOCIAL ISOLATION

Lan Xiao*

F198. EFFECTS OF CANNABINOIDS ON A HUMAN OLIGODENDROCYTE CULTURE: IMPLICATIONS FOR SCHIZOPHRENIA

Valéria Almeida*, Gabriela Seabra, Jose Alexandre Crippa, Jaime Eduardo Hallak, Antonio W. Zuardi, Daniel Martins-De-Souza

F199. O-GLCNAC DYSREGULATION IN SCHIZOPHRENIA CORTEX

Toni Mueller*, Anita Pinner, James Meador-Woodruff

F200. ELUCIDATING THE ROLE OF CILIA IN NEUROPSYCHIATRIC DISEASES THROUGH INTERACTOME ANALYSIS

Madhavi Ganapathiraju*, Srilakshmi Chaparala, Cecilia Lo

F201. KINASE NETWORK DYSREGULATION IN SCHIZOPHRENIA: IMPLICATIONS FOR NEW TREATMENT STRATEGIES

Eduard Bentea*, Erica Depasquale, Jarek Meller, Zhexing Wen, Robert E. McCullumsmith

F202. ABNORMAL REMODELING PROCESSING IN NEURAL GPI-APS SECRETORY PATHWAY IN SCHIZOPHRENIA

Pitna Kim*, James Meador-Woodruff

F203. A META-ANALYSIS OF MINOR PHYSICAL ANOMALIES IN FIRST-DEGREE UNAFFECTED RELATIVES OF PATIENTS WITH SCHIZOPHRENIA

Ozge Akgul*, Emre Bora, Berna Binnur Akdede, Köksal Alptekin

F204. THE DANISH HIGH RISK AND RESILIENCE STUDY - VIA 7 - A PROSPECTIVE COHORTE STUDY OF 522 7 YEARS OLD CHILDREN BORN TO PARENTS DIAGNOSED WITH SCHIZOPHRENIA OR BIPOLAR DISORDER - RESULTS ON PSYCHOPATHOLOGY, COGNITION AND LIVING CONDITIONS

Anne Amalie Thorup*, Nicoline Hemager, Ditte V. Ellersgaard, Camilla Jerlang Christiani, Birgitte Klee Burton, Katrine S. Spang, Maja Gregersen, Anne Søndergaard, Ditte L. Gantriis, Aja Greve, Jens Richardt Jepsen, Ole Mors, Kerstin von Plessen, Merete Nordentoft

F205. OLFATORY IDENTIFICATION IN 7-YEAR OLD CHILDREN AT FAMILIAL RISK TO DEVELOP SCHIZOPHRENIA

Anna Hester Ver Loren van Themaat*, Jens Richardt Møllegaard Jepsen, Camilla Christiani, Merete Nordentoft



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F206. A TRANSLATIONAL STUDY OF BEHAVIOR, BRAIN STRUCTURE AND GENE PATHWAY IN ERBB4 KNOCKOUT MICE AND FIRST-EPISODE TREATMENT-NAÏVE PATIENTS WITH SCHIZOPHRENIA

Chengcheng Zhang*, Peiyan Ni, Tao Li

F207. SCHIZOTYPY AND SENSORY GATING: A 6-MONTH-OLD EEG STUDY

Eleanor Smith*, Trevor Crawford, Megan Thomas, Vincent Reid

F208. COGNITION, POSITIVE SYMPTOMS, AND INTERNET USE FOR MENTAL HEALTH IN PEOPLE WITH PSYCHOSIS

Kristi-Ann Villagonzalo, Chelsea Arnold, Fiona Foley, Denny Meyer, John Farhall, Susan Rossell*, Neil Thomas

F209. TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) IN A NON-CLINICAL POPULATION AS A MODEL FOR TREATMENT OF AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA

Marquardt Lynn*, Isabella Kusztrits, Alex Craven, Kenneth Hugdahl, Marco Hirnstein

F210. EXAMINING PATTERNS AND PREDICTORS OF INDIVIDUAL RESPONSE TO COGNITIVE REMEDIATION THERAPY

Maree Reser*, Susan Rossell

F211. FINDING AND FIXING ATTENTIONAL DYSFUNCTION IN SCHIZOPHRENIA

Robert Reinhart*

F212. IMPROVEMENT IN COGNITIVE BIASES AFTER GROUP PSYCHOEDUCATION AND METACOGNITIVE TRAINING IN RECENT ONSET PSYCHOSIS

Maria Isabel Ahuir Perez*, Ángel Cabezas, Maria José Miñano, Maria José Algora, Francesc Estrada, Montserrat Sole, Juan David Barbero, Itziar Montalvo, Alfonso Gutierrez-Zotes, Vanessa Sanchez-Gistau, José Antonio Monreal, Elisabet Vilella, Diego Palao, Javier Labad

F213. THE EFFECTS OF GROUP INTEGRATIVE ARTS THERAPY BASED ON SOCIAL SKILL TRAINING ON THE SOCIAL ADAPTIVE FUNCTION, EMPOWERMENT AND SUBJECTIVE WELL-BEING IN INPATIENTS WITH CHRONIC SCHIZOPHRENIA

Eunsung Lim*, Sang-Yeol Lee, Won-Myong Bahk, Bo-Hyun Yoon, Duk-In Jon, Moon Doo Kim, Sung-Yong Park, Min-Kyu Song

F214. PSYCHOLOGICAL INTERVENTIONS FOR POSITIVE SYMPTOMS IN SCHIZOPHRENIA: A NETWORK META-ANALYSIS

Irene Bighelli*, Stefan Leucht

F215. EARLY SIGNS ACTION PLAN: EXPERIENCES OF RELATIVES

Nils Sjöström*, David Berg, Sofia Johansson, Eva Andreasson, Marda Waern

F216. SLEEP QUALITY AND CLINICAL IMPROVEMENT IN FIRST EPISODE PSYCHOSIS

L. Prayosha Villa, Lyndsay Schmidt, Tyler M. Moore, Monica Calkins*, Christian G. Kohler



F217. BASIC SELF-DISTURBANCE IN ADOLESCENCE AND SCHIZOPHRENIA-SPECTRUM DISORDERS IN YOUNG ADULTHOOD: A 7-YEAR FOLLOW-UP STUDY AMONG TREATMENT-SEEKING ADOLESCENTS

Dan Koren*, Yair Tzivoni, Liat Schalit, Noa Reznik, Merav Adres, Josef Parnas

F218. REAL-TIME ASSESSMENT OF AUDITORY HALLUCINATIONS USING A SMARTPHONE APPLICATION: RESULTS FROM A PILOT STUDY

Josef Bless*, Runar Smelror, Ingrid Agartz, Kenneth Hugdahl

F219. NOVEL OBJECTIVE ASSESSMENT OF ACTIVITY ENGAGEMENT IN SCHIZOPHRENIA USING WIRELESS MOTION CAPTURE

Ishraq Siddiqui*, Gary Remington, Gagan Fervaha, Paul Fletcher, Aristotle Voineskos, Sarah Saperia, Konstantine Zakzanis, George Foussias

F220. THREAT ANTICIPATION AND NEGATIVE AFFECT IN EARLY PSYCHOSIS

UnYoung Chavez-Baldini*, Inez Myin-Germeys, Charlotte Gayer-Anderson, Matthew Kempton, Lucia Valmaggia, Philip McGuire, Til Wykes, Craig Morgan, Ulrich Reininghaus

F221. SELECTIVE ATTENTION BIAS FOR FEAR STIMULI AND HALLUCINATION IN PATIENTS WITH SCHIZOPHRENIA: A PRELIMINARY STUDY

Jiyun Yum, Han-Suk Kim, Ho Jun Seo*

F222. CONCRETE THINKING PATTERN IN DAILY DECISION-MAKING PROCESS OF PATIENTS WITH SCHIZOPHRENIA: THROUGH EYE-TRACKING

Soo-Jeong Kim*, Yeon-Ju Hong, Min-Woo Kim, Young-Hoon Jung, Jae-Jin Kim

F223. COMPARATIVE STUDY OF HEART RATE VARIABILITY AND EMOTIONAL RESPONSE TO POSITIVE AND NEGATIVE AUDIOVISUAL STIMULATION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA AND HEALTHY CONTROL

Sang-Yeol Lee*, Won-Myong Bahk, Young-Joon Kwon, Duk-In Jon, Moon Doo Kim, Beomboo Nam, Sung-Yong Park, Min-Kyu Song

F224. UTILITY OF SALIVA FOR MONITORING OF CLOZAPINE LEVELS

Jimmy Lee*, Jie Yin Yee, Yuen Mei See, Charmaine Tang, Boon Tat Ng, Gary Remington, Balram Chowbay

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

George Foussias*, Naren Rao, Gagan Fervaha, Carol Borlido, Lillian Haber, Hiroyoshi Takeuchi, Romina Mizrahi, Gary Remington

F226. CLINICAL FACTORS ASSOCIATED WITH CONTINUATION OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATION: RETROSPECTIVE CHART REVIEW

Shi Hyun Kang*, Jong Il Lee



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F227. PSYCHOLOGICAL TRAUMA OCCURRING DURING ADOLESCENCE IS ASSOCIATED WITH AN INCREASED RISK OF GREATER WAIST CIRCUMFERENCE IN EARLY PSYCHOSIS PATIENTS INDEPENDENTLY OF MEDICATION

Luis Alameda*, Axel Levier, Philippe Golay, Mehdi Gholam-Rezaee, Frederik Vandenberghe, Aurélie Delacretaz, Anaïs Glatard, Céline Dubath, Kim Q. Do, Chin B. Eap, Philippe Conus

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY

Rashmi Patel*, Edward Chesney, Matthew Taylor, David Taylor, Philip McGuire

F229. THE BIOLOGICAL UNDERPINNINGS OF TREATMENT RESPONSE IN DELUSIONAL DISORDER: A SYSTEMATIC REVIEW OF QUALITATIVE EVIDENCE-TO-DATE

Alexandre González-Rodríguez*, Francesc Estrada, Itziar Montalvo, José Antonio Monreal, Diego Palao, Javier Labad

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY

Maju Mathews, Srihari Gopal*, Arun Singh, Jagadish Gogate, Edward Kim, Katalin Pungor

F231. GYM RATS: EXERCISE REVERSES COGNITIVE IMPAIRMENT IN THE PHENCYCLIDINE RAT MODEL OF SCHIZOPHRENIA

Lisa Heaney*, Joanna Neill, Antonio Gonzales, Alison Yung, Stuart Allan, Michael Harte

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA

David McDonnell*, Steven G. Potkin, Adam Simmons, Ying Jiang, Lauren DiPetrillo, Bernard Silverman

F233. NEGATIVE SYMPTOMS ARE INDEPENDENT MODERATOR FACTORS OF TREATMENT RESISTANT SCHIZOPHRENIA EFFECTS ON MULTIPLE CLINICAL, PSYCHOPATHOLOGICAL, COGNITIVE AND PSYCHOSOCIAL VARIABLES

Felice Iasevoli*, Benedetta Altavilla, Camilla Avagliano, Annarita Barone, Luigi D'Ambrosio, Marta Matrone, Danilo Notar Francesco, Eugenio Razzino, Andrea de Bartolomeis

F234. TYPICAL AND ATYPICAL ANTIPSYCHOTICS' D2R AFFINITY AND DOSES INFLUENCES POSTSYNAPTIC DENSITY BY MODULATING THE SPATIAL EXPRESSION OF HOMER1A A GENE HIGHLY IMPLICATED IN SYNAPTIC PLASTICITY AND PSYCHOSIS

Avagliano Camilla*, Elisabetta Buonaguro, Carmine Tomasetti, Federica Marmo, Licia Vellucci, Felice Iasevoli, Andrea de Bartolomeis

F235. DIFFERENTIAL EFFECTS OF ANTIPSYCHOTICS ON NEUROINFLAMMATION AND ENERGY SENSING IN A HYPOTHALAMIC CELL LINE

Chantel Kowalchuk*, Pruntha Kanagasundaram, Gary Remington, Denise Belsham, Margaret Hahn

F236. CLONIDINE NORMALIZES MMN IN SCHIZOPHRENIA PATIENTS ON STABLE MEDICATION

Caitlyn Kruiper*, Birte Glenthøj, Bob Oranje



F237. DOPAMINERGIC EFFECTS ON HIERARCHICAL PREDICTION ERRORS AND CONNECTIVITY DURING SOCIAL LEARNING

Daniel Hauke*, Andreea Diaconescu, Katharina Wellstein, Sara Tomiello, Lionel Rigoux, Jakob Heinzle, Klaas Enno Stephan

F238. COMPETENCE-PERFORMANCE DISCREPANCY IN SOCIAL FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA: THE IMPACT OF SOCIAL ANXIETY

Takahiro Nemoto*, Takashi Uchino, Sayaka Aikawa, Tomoyuki Funatogawa, Hiroshi Matsumoto, Taiju Yamaguchi, Naoyuki Katagiri, Naohisa Tsujino, Kei Sakuma, Masafumi Mizuno

F239. THE ROLE OF DANCE/MOVEMENT THERAPY IN THE TREATMENT OF NEGATIVE SYNDROME AND PSYCHOSOCIAL FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: RESULT FROM A PILOT MIXED METHODS INTERVENTION STUDY WITH EXPLANATORY INTENT

Karolina Bryl*

F240. MULTI-MODAL PREDICTION OF GLOBAL FUNCTION FROM NEUROCOGNITIVE AND NEUROIMAGING MEASURES: OUTCOMES FROM THE PRONIA STUDY

John Gillam, Dominic Dwyer, Anne Ruef, Nikolaos Koutsouleris, Stephen Wood, Dominic Dwyer*

F241. DEVELOPMENT AND VALIDATION OF THE SOCIAL FUNCTIONING ASSESSMENT SCALE (SFAS) FOR PEOPLE WITH SCHIZOPHRENIA IN TURKEY

Mustafa Yildiz*, Fatma Kiras, Aysel İncedere, Duygu Esen, Mehmet Buğrahan Gürcan, Betül Abut, Kübra İpçi, Güzide Örum, Ümit Tural, Güliz Özgen

F242. CHILDHOOD ADVERSITY AND PSYCHOTIC EXPERIENCES IN THE GENERAL POPULATION: WHAT IS THE PREDICTIVE ROLE OF RESILIENCE, COPING STYLE AND SOCIAL SUPPORT?

David Mongan*, Ciaran Shannon, Donncha Hanna, Adrian Boyd, Ciaran Mulholland

F243. INFLUENCE OF METACOGNITION AND IRRATIONAL BELIEFS ON SOCIAL FUNCTIONING IN PSYCHOSIS OF RECENT ONSET

Helena García-Mieres*, Raquel López-Carrilero, Jordi Cid, Esther Pousa, Ana Barajas, Eva Grasa, Maria Luisa Barrigon, Isabel Ruiz-Delgado, Ana de Apraiz, Fermín González-Higuera, Esther Lorente Rovira, The Spanish Metacognition Study Group, Susana Ochoa

F244. CHILDHOOD PSYCHOTIC EXPERIENCES ARE ASSOCIATED WITH PERSISTENTLY POORER FUNCTIONING INTO YOUNG ADULTHOOD: A 9-YEAR FOLLOW-UP STUDY

Dónal Campbell*, Colm Healy, Mary Cannon

F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS

Silvia Amoretti*, Bibiana Cabrera Llorca, Gisela Mezquida, Manuel J. Cuesta, Mara Parellada, Ana Gonzalez-Pinto, Iluminada Corripio, Eduard Vieta, Miquel Bernardo

F246. A SYSTEMATIC REVIEW COMPARING THE NEURAL CORRELATES OF EMPATHY ASSOCIATED WITH THE ONSET AND PROGRESSION OF SCHIZOPHRENIA

Meneshka Ponnampalam*



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

F247. INTERNALIZED STIGMA HAS A STRONGER RELATIONSHIP WITH INTRINSIC MOTIVATION COMPARED TO AMOTIVATION IN EARLY PHASE AND PROLONGED SCHIZOPHRENIA

Ruth Firmin*, Lauren Luther, Paul Lysaker, Jennifer Vohs

F248. COMMUNICATIVE-PRAGMATIC IMPAIRMENT IN SCHIZOPHRENIA: THE ROLE OF EXECUTIVE FUNCTION AND THEORY OF MIND

Alberto Parola*, Laura Berardinelli, Francesca M. Bosco

F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS

Shirley Glynn*, Susan Gingerich, Piper Meyer-Kalos, Kim Mueser, Alec Chan-Golston, Catherine Sugar, Nina Schooler, Robert Rosenheck, John Kane

F250. DEPRESSION IN SCHIZOPHRENIA: CORRELATIONS WITH OBJECTIVE AND SUBJECTIVE QUALITY OF LIFE OUTCOMES

Philip Harvey*, Kimberly Vanover, Robert Davis, David Penn, Amy Pinkham

F251. REVISITING THE RELATIONSHIP BETWEEN NEUROCOGNITION AND SUBJECTIVE QUALITY OF LIFE IN SCHIZOPHRENIA

Eric Tan*, Stuart Lee, Susan Rossell

F252. SERVICE PROVISION FOR ULTRA-HIGH RISK FOR PSYCHOSIS: IMPLEMENTATION OF CLINICAL GUIDELINES IN ENGLAND

Helen Stain*, Lauren Mawn, Stephanie Common, Marie Pilton, Andrew Thompson

F253. A FIDELITY TOOL FOR THE AUSTRALIAN EARLY PSYCHOSIS SYSTEM

Eoin Killackey*, Kristi van der El, Heather Stavely

F254. EXPANDING THE REACH OF NAVIGATE CSC PROGRAMS ACROSS THE US: WHAT DO WE KNOW?

Piper Meyer-Kalos*, Shaunequa James, Jillian Wright-Martin, Susan Gingerich, Shirley Glynn

F255. FACTORS RESPONSIBLE FOR DELAY IN TREATMENT SEEKING IN PATIENTS WITH PSYCHOSIS- A QUALITATIVE STUDY FROM CENTRAL INDIA

Mamidipalli Spoorthy*

F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?

Dominic Oliver*, Cathy Davies, Georgia Crossland, Steffiany Lim, George Gifford, Philip McGuire, Paolo Fusar-Poli

F257. PROSPECTIVE AND LONGITUDINAL ASSOCIATIONS BETWEEN WHITE MATTER DENSITY AND PSYCHOSIS ONSET

Rachael Grazioplene*, Tyrone Cannon



F258. ENACT: INVESTIGATING THE EFFICACY AND MECHANISMS OF ACTION OF N-ACETYLCYSTEINE AS AN ADJUNCTIVE TREATMENT FOR FIRST EPISODE PSYCHOSIS
Susan Cotton*, Stephen Wood, Aswin Ratheesh, Brian O'Donoghue, Kelly Allott, Cali Bartholomeusz, Chiara Bortolasci, Ken Walder, Andrew Chanen, Olivia Dean, Amity Watson, Kate Fila, Seetal Dodd

F259. SHARED DECISION MAKING IN ACUTE SCHIZOPHRENIA TREATMENT
Stephen Heres*, Johannes Hamann, Fabian Holzhüter

F260. POOR PREMORBID ADJUSTMENT PREDICTS POOR SOCIAL FUNCTIONING AND CHILDHOOD ADVERSE EXPERIENCES SUICIDAL THOUGHTS IN HELP-SEEKERS WITH PSYCHOSIS, CLINICAL HIGH RISK OF PSYCHOSIS AND DEPRESSION: RESULTS OF THE PRONIA PROJECT

Raimo Salokangas*, Tiina From, Stephan Ruhrmann, Marlene Rosen, Paolo Brambilla, Carla Bonivento, Stefan Borgwardt, Stephen Wood, Rachel Upthegrove, Eva Meisenzahl, Nikolaos Koutsouleris

F261. A SIMPLE TASK USING IMMERSIVE VIRTUAL REALITY CAN DISTINGUISH GLOBAL FUNCTIONING CLUSTERS IN PATIENTS WITH SCHIZOPHRENIA: A FEASIBILITY AND PROOF-OF-CONCEPT STUDY

Philippe Nuss*, Leo Malandain, Paul Rudelle, Jean-Victor Blanc, Théo Larrousse, Florian Ferreri, Nathanael Lapidus, Cedric Tessier, Julien Lalayaux, Sébastien Jousset

F262. A META-ANALYSIS OF AUDITORY P50 SENSORY GATING IN SCHIZOPHRENIA AND BIPOLAR DISORDER

Murat Atagun, Marjan Drukker, Mei-Hua Hall*, Ilkay Keles Altun, Zeynep Tatli, Sinan Guloksuz, Jim Van Os

F263. CLOZAPINE RELATED SUDDEN DEATH: A CASE REPORT AND LITERATURE REVIEW
Kevin Li, Ronald Gurrera, Lynn DeLisi*

F264. DATA-DRIVEN SELECTION OF PARENTAL AND DEMOGRAPHIC RISK FACTORS FOR SCHIZOPHRENIA IN A NATIONAL BIRTH COHORT – INFERENCE AND REPLICABILITY
David Gyllenberg*, Ian McKeague, Andre Sourander, Alan Brown



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

POSTERS, SATURDAY 7 APRIL

12:00 P.M. - 2:00 P.M.

Cavaniglia

Travel Awardee Posters are Circled

S1. THE ASSOCIATION BETWEEN WAR-RELATED STRESS, PTSD SYMPTOMS, AND SUBCLINICAL PSYCHOSIS: A CROSS-CULTURAL POPULATION-BASED STUDY AMONG PALESTINIAN AND ISRAELI YOUNG ADULTS

Amjad Mussa, Meirav Blizovski, Dan Koren*

S2. CHILDHOOD TRAUMA IS ASSOCIATED WITH SEVERITY OF AT-RISK MENTAL STATE AND PSYCHOSIS IN UHR INDIVIDUALS AND PATIENTS WITH SCHIZOPHRENIA

Attilio Rapisarda*, Oon Him Peh, Kang Sim, Jimmy Lee

S3. CHILDHOOD TRAUMA AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS: EFFECT OF FREQUENCY AND TYPE OF CHILDHOOD TRAUMA

Nina Morkved*, Erik Johnsen, Rune Kroken, Rolf Gjestad, Dagfinn Winje, Jens Thimm, Farivar Fathian, Else-Marie Løberg

S4. ASYMMETRIC DRUG-INDUCED PARKINSONISM IS RELATED TO PSYCHOPATHOLOGY

Lydia Pieters*, P. Roberto Bakker, Peter N. Van Harten

S5. EFFECTS OF EARLY LIFE ADVERSITY ON IMMUNE FUNCTION AND COGNITIVE PERFORMANCE IN YOUTHS WITH AND WITHOUT EXPERIENCE OF PSYCHOTIC SYMPTOMS

Jessica Holland*, Maria Dauvermann, Derek Morris, Stan Zammit, Golam Khandaker, Gary Donohoe

S6. EARLY LIFE ADVERSITIES AND SOCIAL COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA AND OTHER MAJOR PSYCHIATRIC DISORDERS: A SYSTEMATIC REVIEW

Karolina Rokita*, Maria M. Dauvermann, Gary Donohoe

S7. NEOSENSITIZATION TO MULTIPLE DRUGS FOLLOWING DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS SYNDROME(DRESS)

Moon Doo Kim*, Won-Myong Bahk, Young Joon Kwon, Bo-Hyun Yoon, Kwanghun Lee, Beomwoo Nam, Eunsung Lim, Min-Kyu Song

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS

Maximus Berger, Suzie Lavoie, Patrick D. McGorry, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam Schaefer, Zoltan Sarnyai, G. Paul Amminger*

S9. RESTING EEG CHANGES IN SCHIZOPHRENIA

Leonhardt Unruh, Rick Adams*, Alan Anticevic, L. Elliot Hong

S10. ASTROGLIAL PATHOLOGY IN SCHIZOPHRENIA: A META-ANALYSIS OF MRS STUDIES OF ANTERIOR CINGULATE MYOINOSITOL

Ayyarthana Dey, Priyadarshini Sabesan, Jean Theberge, Joaquim Radua, Lena Palaniyappan*



S11. BRAIN ABNORMALITIES ASSOCIATED WITH DISEASE-SPECIFIC AND GENETIC RISK FACTORS FOR SCHIZOPHRENIA

Vina Goghari*

S12. THE 'AUTOANTIBODYOME' IN PSYCHOSIS: A PILOT STUDY AND BLUEPRINT FOR BIOMARKER DISCOVERY

Thomas Pollak*, Cassandra DeMarshall, Abhirup Sarkar, Timothy Nicholson, Philip McGuire, James Stone, Anthony David, Robin Murray, Robert Nagele

S13. DO PATIENTS WITH RECENT-ONSET DEPRESSION DIFFER CLINICALLY AND NEUROBIOLOGICALLY FROM DEPRESSED PATIENTS WITH A CLINICAL HIGH-RISK STATE FOR PSYCHOSIS?

Rachel Upthegrove*, Renate Reniers, Pavan Mallikarjun, Eva Meisenzahl, Katharine Chisholm, Stefan Borgwardt, Stephan Ruhrmann, Raimo Salokangas, Paolo Brambilla, Stephen Wood, Nikolaos Koutsouleris

S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA

Helene Fachim*, Camila Loureiro, Fabiana Corsi-Zueli, Paulo Rossi Menezes, Paulo Louzada-Jr, Caroline Dalton, Cristina Marta Del-Ben, Gavin Reynolds

S15. ABNORMAL EYE TRACKING IN PATIENTS WITH SCHIZOPHRENIA UNDER THE SOCIAL SCENE

Qijing Bo*, Xianbin Li, Wenlong Jiang, Changming Wang, Chuanyue Wang

(S16) GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY

Yusuke Iwata*, Shinichiro Nakajima, Eric Plitman, Jun Ku Chung, Fernando Caravaggio, Julia Kim, Eric Brown, Nathan Chan, Parita Shah, Sofia Chavez, Philip Gerretsen, Masaru Mimura, Gary Remington, Ariel Graff-Guerrero

S17. ZNF804A GENE AND CANNABIS USE: INTERACTION ON THE RISK FOR PSYCHOSIS IN A NON-CLINICAL SAMPLE

Jordi Soler Garcia*, Barbara Arias, Jorge Moya, Manuel Ignacio Ibañez, Generós Ortet, Lourdes Fañanás, Mar Fatjó-Vilas

(S18) PREDICTING PROGNOSIS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS USING AUDITORY P300: A 1-YEAR FOLLOW-UP STUDY

Kim Minah*, Lho Kyung-jin, Lee Tak Hyung, Kwak Yoo Bin, Kwon Jun Soo

(S19) EVIDENCE OF THE LIPID PARADOX IN PSYCHOSIS: A META-ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN FIRST EPISODE PSYCHOSIS

Toby Pillingham*, Katherine Beck, Brendon Stubbs, Oliver Howes

(S20) PARAHIPPOCAMPAL THICKNESS PREDICTS TREATMENT IMPROVEMENT IN EARLY AND CHRONIC SCHIZOPHRENIA

Philipp Homan*, Miklos Argyelan, Delbert Robinson, Todd Lencz, Anil Malhotra



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S21. EVENT-RELATED REPETITIVE TMS TO RIGHT POSTERIOR STS (BUT NOT OCCIPITAL FACE AREA) IN HEALTHY VOLUNTEERS (HV) BRIEFLY RECAPITULATES FACE EMOTION RECOGNITION (FER) DEFICITS OF SCHIZOPHRENIA (SZ)

Cheryl Corcoran*, Jack Grinband, Jaimie Gowatsky, Casimir Klim, Matthew Hoptman, Daniel Javitt

S22. A TRANSDIAGNOSTIC NEUROANATOMICAL SIGNATURE OF PSYCHIATRIC ILLNESS

Gong Qiyong, Cristina Scarpazza*, Jing Dai, Manxi He, Xin Xu, Yan Shi, Baiwan Zhou, Sandra Vreira, Eamon McCrory, Cheng Yang, Feifei Zang, Su Lui, Andrea Mechelli

S23. INTRODUCING COMPASS: COMPARING BRAIN ACTIVITY ACROSS PATIENTS WITH DIFFERENTIAL TREATMENT RESPONSE IN SCHIZOPHRENIA – AN OBSERVATIONAL STUDY

Sandra Iglesias*, Jakob Siemerus, Martin Bischof, Sara Tomiello, Dario Schöbi, Lilian Weber, Jakob Heinzle, Julian Möller, Stephan Egger, Wolfgang Gerke, Markus Baumgartner, Wolfram Kawohl, Stefan Borgwardt, Stefan Kaiser, Helene Haker, Klaas Enno Stephan

S24. IS IT FEASIBLE TO PREDICT LONG-TERM METABOLIC OUTCOMES IN PSYCHOSIS USING BIOLOGICAL PROFILING AT BASELINE?

Conrad Iyegbe*, Lauren Allen, John Lally, Marta DiForti, Robin Murray, Fiona Gaughran

S25. COGNITIVE REMEDIATION THERAPY AND ITS EFFECTS ON BDNF SERUM LEVELS

Rafael Penades*, Irene López-Vilchez, Rosa Catalán, Barbara Arias, Clemente García-Rizo, Guillem Masana, Miquel Bernardo

S26. HERITABILITY OF SOCIAL MISTRUST IN CHILD AND ADOLESCENT NON-CLINICAL SAMPLES: A HEALTHY TWINS STUDY

Han-Yu Zhou, Keri Wong, Li-Juan Shi, Xi-Long Cui, Yun Qian, Ya-Song Du, Simon S.Y. Lui, Xue-Rong Luo, Eric F.C. Cheung, Anna Docherty, Raymond Chan*

S27. RELIABILITY OF SCHIZOPHRENIA DIAGNOSES IN CHILDREN AND ADOLESCENTS IN DENMARK

Ditte Lammers Vernal*, Anne Dorte Stenstrøm, Nina Staal, Anne Marie Raabjerg Christensen, Christine Ebbesen, Anne Katrine Pagsberg, Christoph Correll, René Ernst Nielsen, Marlene Briciet Lauritsen

S28. THE ROLE OF COPING IN THE ASSOCIATION BETWEEN SUBCLINICAL PSYCHOTIC EXPERIENCES AND DAILY FUNCTIONING: EVIDENCE FROM TWO INDEPENDENT ADOLESCENT SAMPLES FROM THE GENERAL POPULATION

Katharine Chisholm*, Johanna Wigman, Danielle Hallett, Tamara Woodall, Simone Mahfouda, Renate Reniers, Eoin Killackey, Alison Yung, Stephen Wood, Ashleigh Lin

S29. CONCORDANCE BETWEEN SELF-REPORT AT INTERVIEW-BASED RATINGS OF PSYCHOTIC EXPERIENCES IN PRE-ADOLESCENCE AND ASSOCIATED PSYCHOPATHOLOGY

Martin K. Rimvall*, Steffie Gundersen, Lars Clemmensen, Charlotte Ulrikka Rask, Anne Mette Skovgaard, Frank Verhulst, Jim Van Os, Pia Jeppesen

S30. UNDERSTANDING THE NATURE OF CHILDHOOD SUSPICIOUSNESS: A QUALITATIVE STUDY

Keri Wong*



S31. BASIC SENSE OF SELF IN YOUTH AT HIGH RISK FOR DEVELOPING SCHIZOPHRENIA
Hadar Hazan*, Richard Linscott, Elaine Reese

S32. ANXIETY IN THE DEVELOPMENT OF PSYCHOTIC EXPERIENCES IN CHILDREN AND ADOLESCENTS: A SYSTEMATIC REVIEW
Jessica Bird*, Felicity Waite, Daniel Freeman

S33. ETRO - A PROSPECTIVE FOLLOW-UP STUDY OF THE COMBINED TREATMENT APPROACH "ROBIN" FOR ADOLESCENTS WITH HIGH RISK FOR DEVELOPING A PSYCHOTIC DISORDER: THERAPY MODULES ENHANCED BY A SMARTPHONE APPLICATION
Maurizia Francini*, Nina Traber-Walker, Miriam Gerstenberg, Sibylle Metzler, Susanne Walitza

S34. DEVELOPMENTAL TRAJECTORIES OF PSYCHOTIC EXPERIENCES AND THEORY OF MIND IN 11-YEAR-OLD OFFSPRING OF PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
Maja Gregersen*, Lars Clemmensen, Anne Søndergaard, Camilla Jerlang Christiani, Nicoline Hemager, Ditte Ellersgaard, Katrine Søborg Spang, Aja Greve, Ditte Lou Gantriis, Christina Bruun Knudsen, Anna Krogh Andreassen, Lotte Vedum, Henriette Brockdorff Stadsgaard, Vibeke Fuglsang Bliksted, Ole Mors, Kerstin J. Plessen, Merete Nordentoft, Jens Richardt Møllegaard Jepsen, Anne A.E. Thorup

S35. NEURORADIOLOGICAL FINDINGS IN CHILD AND ADOLESCENT PATIENTS WITH PSYCHOTIC DISORDERS
Justo Pinzón Espinosa*, Adriana Fortea, Laura Espinosa, Anna Giménez, Gerard Anmella, Immaculada Baeza, Gisela Sugranyes

S36. DIFFERENTIAL ENCODING OF SENSITIZATION AND CROSS SENSITIZATION TO PSYCHOSTIMULANTS AND ANTIPSYCHOTICS IN NUCLEUS ACCUMBENS D1- AND D2-RECEPTOR EXPRESSING MEDIUM SPINY NEURONS
Davide Amato*, Jasper Heinsbroek, Peter W. Kalivas

S37. STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
Susan Sonnenschein*, Kathryn Gill, Anthony Grace

S38. CHARACTERISING THE COGNITIVE CONSEQUENCES OF DISRUPTED BDNF-TRKB SIGNALLING AT PARVALBUMIN-EXPRESSING INTERNEURONS
Adrienne Grech*, Xin Du, Rachel Hill

S39. GPR139 AN OPHAN GPCR AFFECTING NEGATIVE DOMAINS OF SCHIZOPHRENIA
Atienza Joy*, Holly Reichard, Victoria Mulligan, Jackie Cilia, Holger Monenschein, Deanna Colliia, Jim Ray, Gavin Kilpatrick, Nicola Brice, Mark Carlton, Steve Hitchcock, Ged Corbett

S40. MEDIAL SEPTUM ACTIVATION PRODUCES OPPOSITE EFFECTS ON DOPAMINE NEURON ACTIVITY IN THE VENTRAL TEGMENTAL AREA AND SUBSTANTIA NIGRA PARS COMPACTA IN MAM VERSUS NORMAL RATS
David Bortz*, Anthony Grace



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S41. SHORT- AND LONG-TERM OUTCOMES OF VITAMIN D SUPPLEMENTATION IN CLOZAPINE TREATED CHRONIC SCHIZOPHRENIA PATIENTS

Amir Krivoy*, Roy Onn, Yael Vilner, Zvika Friedman, Weizman Abraham

S42. KETAMINE DYSREGULATES TASK-RELATED NEURAL OSCILLATIONS IN THALAMO-CORTICAL CIRCUITS: IMPLICATIONS FOR PATHOPHYSIOLOGICAL THEORIES OF VISUAL-PERCEPTUAL DEFICITS IN SCHIZOPHRENIA

Tineke Grent-'t-Jong*, Davide Rivolta, Joachim Gross, Ruchika Gajwani, Stephen Lawrie, Matthias Schwannauer, Tonio Heidegger, Michael Wibrál, Wolf Singer, Andreas Sauer, Bertram Scheller, Peter Uhlhaas

S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH SCHIZOPHRENIA AND NEGATIVE SYMPTOMS PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES

Daniel Umbricht*, Jürgen Dukart, Markus Abt, Paul Tamburri, Chris Chatham, Michael Frank, Anne Collins, David Walling, Rick Mofsen, Daniel Gruener, Lev Gertsik, Jeffrey Sevigny

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

Kimberly Vanover*, Alex Dmitrienko, Steven Glass, Susan Kozauer, Jelena Saillard, Michal Weingart, Andrew Satlin, Sharon Mates, Christoph Correll, Robert Davis

S45. MENTALIZATION BASED TREATMENT FOR NON-AFFECTIVE PSYCHOTIC DISORDER

Jonas Weijers*, Corine ten Kate, Elisabeth Eurelings-Bontekoe, Wolfgang Viechtbauer, Jean-Paul Selten

S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA

Soren Dinesen Ostergaard*, Leslie Foldager, Ole Mors, Per Bech, Christoph U. Correll

S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT)

Astrid Roeh*, Stefan Leucht, Peter Falkai, Berthold Langguth, Irina Papazova, Alkomiet Hasan

S48. INTER-RATER RELIABILITY OF PANSS-6 SCHIZOPHRENIA SEVERITY RATINGS OBTAINED USING THE SIMPLIFIED NEGATIVE AND POSITIVE SYMPTOMS INTERVIEW (SNAPSI)

Pernille Kølbaek*, Per Bech, Ole Mors, Christoph U. Correll, Soren D. Østergaard

S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS – RESULTS FROM AN EXPLORATORY RE-ANALYSIS

Maximilian Hansbauer*, Thomas Wobrock, Birgit Kunze, Berthold Langguth, Michael Landgrebe, Joachim Cordes, Wolfgang Wölwer, Georg Winterer, Wolfgang Gaebel, Göran Hajak, Christian Ohmann, Pablo Verde, Marcella Rietschel, Raees Ahmed, William Honer, Berend Malchow, Wolfgang Strube, Thomas Schneider-Axmann, Peter Falkai, Alkomiet Hasan

S50. EMPLOYING TEXT-MESSAGES TO IMPROVE MOTIVATION: MOBILE ENHANCEMENT OF MOTIVATION IN SCHIZOPHRENIA

Lauren Luther*, Melanie Watkins, Annalee Johnson-Kwochka, Michelle Salyers



S51. MOTIVATIONAL ENHANCEMENT IMPROVES TREATMENT OUTCOMES OF MOBILE-BASED COGNITIVE REMEDIATION IN INDIVIDUALS WITH SCHIZOPHRENIA

Eun Jin Kim*, YongChun Bahk, Kee-Hong Choi

S52. WORKING MECHANISMS OF VIRTUAL REALITY BASED CBT FOR PARANOIA: A RANDOMIZED CONTROLLED TRIAL EXAMINING COGNITIVE BIASES, SCHEMATIC BELIEFS AND SAFETY BEHAVIOR

Chris Geraets*, Marije Van Beilen, Roos Pot-Kolder, Mark Van der Gaag, Wim Veling

S53. COMPARISON OF RALOXIFENE AND ISRADIPINE AS AN ADJUNCTIVE TREATMENT IN COGNITIVE DEFICITS OF PATIENTS WITH SCHIZOPHRENIA

Bitva Vahdani*, Alireza Armani kian, Abdolreza Esmaeilzadeh, Saeedeh Zenoozian, Vida Yousefi, Saeedeh Mazloomzadeh

S54. THE ROLE OF THE CLINICAL PHARMACIST IN DRUG EDUCATION FOR INCREASING COMPLIANCE WITH DRUG THERAPY IN THE PERIOD OF DISCHARGE WITH THE DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS

Nadir Yalcin*, Ayce Celiker, Seref Can Gurel, Sertac Ak, Mumin Kazim Yazici

S55. MECHANISTIC BASIS OF FRONTO-TEMPORAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON AUDITORY VERBAL HALLUCINATION IN SCHIZOPHRENIA: A MEDIATION ANALYSIS OF COROLLARY DISCHARGE

Anushree Bose*, Hema Nawani, Sri Mahavir Agarwal, Venkataram Shivakumar, Janardhanan C. Narayanaswamy, Devvarta Kumar, Ganesan Venkatasubramanian

S56. PHOENIX GROUP: A PROJECT TO PREVENT RELAPSES IN SCHIZOPHRENIA

Marcelo Chiramberro*, Tuula Kiesepää, Asko Wegelius, Tuomo Töhönen, Jenna Ilvonen, Heli Väisänen, Katja Sarkkinen, Jenni Tikkala, Marita Leiponen, Markku Ruppä, Matias Hyytiäinen, Ira Hynninen-Sundelin, Esa Anttonen

S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAÏVE AND PREVIOUSLY MEDICATED PATIENTS

Lena Stabell*, Rolf Gjestad, Rune Kroken, Else-Marie Løberg, Hugo A Jørgensen, Erik Johnsen

S58. A RANDOMIZED CONTROLLED TRIAL COMPARING VIRTUAL REALITY THERAPY TO COGNITIVE BEHAVIORAL THERAPY IN SCHIZOPHRENIA WITH TREATMENT REFRACTORY HALLUCINATIONS: PRELIMINARY RESULTS

Laura Dellazizzo, Stéphane Potvin, Kieron O'Connor, Alexandre Dumais*

S59. CHILDHOOD TRAUMA IS ASSOCIATED WITH SOCIAL COGNITION AND SCHIZOTYPAL PERSONALITY TRAITS IN PSYCHOTIC AND HEALTHY POPULATIONS

Yann Quide, Sarah Cohen-Woods, Nicole O'Reilly, Vaughan Carr, Bernet Elzinga, Melissa Green*

S60. SPANISH ADAPTATION AND VALIDATION OF THE SFRT-2 IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS

Ainara Gómez-Gastiasoro, Javier Peña, Leire Zubiaurre-Elorza, Naroa Ibarretxe-Bilbao, Natalia Ojeda*



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S61. THE ASSOCIATION OF VERBAL LEARNING DEFICITS WITH AGE AND SYMPTOMS IN SCHIZOPHRENIA

Dimitrios Kontis*, Alexandra Giannakopoulou, Eirini Theochari, Angeliki Andreopoulou, Spyridoula Vassiloulou, Dimitra Giannakopoulou, Eleni Sietto, Eleftheria Tsalas

S62. OPEN BOARD

S63. WHICH CLINICAL AND COGNITIVE FACTORS ARE RELATED WITH CHANGES IN JUMPING TO CONCLUSIONS IN FIRST-EPISODE PSYCHOSIS?

Susana Ochoa*, Raquel Lopez-Carrilero, Eva Grasa, Maria Luisa Barrigón, Esther Pousa, Ana Barajas, Esther Lorente, Jordi Cid, Fermin González, Isabel Ruiz, Trinidad Pélaez

S64. EXECUTIVE FUNCTION OF CHRONIC SCHIZOPHRENIA PATIENTS IN A SEVEN-YEAR FOLLOW-UP

Thalita Fernandes, Thais Martins, Gustavo Mustafé, Diego Mendes, Luiz Fernando Pegoraro, Clarissa De Rosalmei Dantas*

S65. INDEPENDENT COMPUTERISED COGNITIVE REMEDIATION FOR PSYCHOSIS: AN INVESTIGATION OF PATIENT EXPERIENCES

April Hargreaves*, Niamh Daly-Ryan, Rachael Dillon, Gary Donohoe

S66. THEORY OF MIND IN A FIRST-EPISODE PSYCHOSIS POPULATION USING THE HINTING TASK

Maija Lindgren*, Minna Torniainen-Holm, Inkeri Heiskanen, Greta Voutilainen, Ulla Pulkkinen, Tuukka Mehtälä, Markus Jokela, Tuula Kiesepä, Jaana Suvisaari, Sebastian Therman

S67. INTEGRATION OF SENSORY AND SOCIAL INFORMATION DURING DECISION MAKING IN SCHIZOPHRENIA

Arndis Simonsen*, Riccardo Fusaroli, Vibeke Bliksted, Ole Mors, Andreas Roepstorff, Daniel Campbell-Meiklejohn

S68. SYMPTOMS, NEUROCOGNITION, SOCIAL COGNITION AND METACOGNITION IN SCHIZOPHRENIA: A NETWORK ANALYSIS

Ilanit Hasson-Ohayon*, Gil Goldzweig, Adi Lavie, Lauren Luther, Paul Lysaker

S69. A CASE STUDY OF CLOZAPINE AND COGNITION: FRIEND OR FOE?

Gisela Mezquida*, George Savulich, Samuel Atkinson, Miguel Bernardo, Emilio Fernandez-Egea

S70. ABERRANT SALIENCE: A COMPARISON OF DIFFERENT MEASURES IN ANXIETY AND SCHIZOPHRENIA

Suzanne Neumann*, Richard Linscott

S71. ABERRANT TIMING AND SALIENCE NETWORK IN SCHIZOPHRENIA: FINDINGS FROM A META-ANALYSIS

Irene Alústiza*, María Sol Garcés, Marta Ortuño, Patricio Molero, Felipe Ortuño



S72. PRO-SOCIAL PROSPECTIVE MEMORY PERFORMANCE IS ASSOCIATED WITH PLASMA OXYTOCIN LEVEL IN SEXUALLY DIMORPHIC WAY IN FIRST-DEGREE RELATIVES OF SCHIZOPHRENIA

Fuchun Zhou*, Lan Xiong, Ping Zhou, Yu-Tao Xiang, Chuan-Yue Wang

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY

Philip D. Harvey, Robert Goldman, Michael Tocco*, Ling Deng, Josephine Cucchiaro, Antony Loebel

S74. EXPLORING PARTICIPANT-LEVEL TRAJECTORIES OF COGNITIVE PERFORMANCE AMONG PATIENTS WITH SCHIZOPHRENIA IN A MULTI-NATIONAL TRIAL

Kiri Granger*, Jack Cotter, Elizabeth Baker, John Evenden, Jennifer Barnett, Michael Sand

S75. MALADAPTIVE SOCIAL-EVALUATIVE AND SELF-BELIEFS INFORMING THE RELATION BETWEEN PARANOIA AND SOCIAL ANXIETY

Alexandra Andrea*, LeeAnn Shan, Cristina Garcia, Christina Savage, Melanie Bennett, Jack Blanchard

S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA

Gagan Fervaha*, Ofer Agid, George Foussias, Hiroyoshi Takeuchi, Konstantine Zakzanis, Ariel Graff-Guerrero, Gary Remington

S77. JUMPING TO CONCLUSIONS AND FACIAL EMOTION RECOGNITION IMPAIRMENT IN FIRST EPISODE PSYCHOSIS ACROSS EUROPE

Giada Tripoli*, Diego Quattrone, Charlotte Gayer-Anderson, Victoria Rodriguez, Natasha Benzian-Olsson, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Lucia Sideli, Fabio Seminerio, Daniele La Barbera, Craig Morgan, Pak Sham, Marta Di Forti, Robin Murray

S78. EXAMINING SEMANTIC AND EPISODIC MEMORY IN SCHIZOPHRENIA USING THE HOPKINS VERBAL LEARNING TASK

Erica Neill*, Susan Rossell

S79. ENHANCING WORKING MEMORY IN SCHIZOPHRENIA USING 1MA AND 2MA TRANSCRANIAL DIRECT STIMULATION TO THE LEFT DORSOLATERAL PREFRONTAL CORTEX

Irina Papazova*, Wolfgang Strube, Benedikt Becker, Bettina Henning, Tobias Schwippel, Andreas Fallgatter, Frank Padberg, Ulrich Palm, Peter Falkai, Christian Plewnia, Alkomiet Hasan

S80. NEUROCOGNITIVE FUNCTIONING IN YOUTH AT RISK OF SERIOUS MENTAL ILLNESS

Sylvia Romanowska*, Glenda MacQueen, Benjamin I. Goldstein, JianLi Wang, Sidney H. Kennedy, Signe Bray, Catherine Lebel, Jean Addington

S81. NEUROCOGNITIVE FUNCTIONING IN SCHIZOPHRENIA AND BIPOLAR DISORDER DURING THE REMISSION AND THE PSYCHOTIC STATES

Deniz Ceylan*, Berna Binnur Akdede, Emre Bora, Ceren Hıdıroğlu, Zeliha Tunca, Köksal Alptekin, Ayşegül Özerdem



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S82. GOAL MANAGEMENT TRAINING OF EXECUTIVE FUNCTIONS FOR PATIENTS WITH SCHIZOPHRENIA OR HIGH RISK OF SCHIZOPHRENIA: BASELINE CHARACTERISTICS AND PRELIMINARY RESULTS FROM AN RCT

Ingvild Haugen*, Elisabeth Haug, Torill Ueland, Jan Stubberud, Merete Øie

S83. THE IMPACT OF COENZYME Q10 ON THE COGNITIVE DEFICITS AND SYMPTOMS OF SCHIZOPHRENIA: PROTOCOL AND BASELINE DATA OF A RANDOMISED, PLACEBO-CONTROLLED STUDY

Áine Maguire*, April Hargreaves, Michael Gill

S84. NEUROPSYCHOLOGICAL FUNCTIONING AS A PREDICTOR OF PSYCHOLOGICAL RESILIENCE: PRELIMINARY RESULTS FROM THE PRONIA STUDY

Alexandra Stainton*, Katharine Chisholm, Rachel Upthegrove, Stephen Wood, The PRONIA Study Group

S85. THE EFFECT OF LONG-TERM SOCIAL DEPRIVATION ON EFFORT ALLOCATION PATTERN IN PATIENTS WITH SCHIZOPHRENIA

Min-Yi Chu*, Hui-Xin Hu, Hua Ni, Wei-Hong Lu, Simon S.Y. Lui, Eric F.C. Cheung, Zhen-Hui Yi, Raymond C. K. Chan

S86. EXAMINING REASONING BIASES IN SCHIZOPHRENIA USING A MODIFIED “JUMPING TO CONCLUSIONS” TASK

Hans Klein*, Amy Pinkham

S87. THE INITIAL CHANGE IN THE SERUM LEVEL OF C-REACTIVE PROTEIN IN ACUTE PSYCHOSIS IS ASSOCIATED WITH COGNITIVE PERFORMANCE IN LATER PHASES

Farivar Fathian*, Else-Marie Løberg, Rolf Gjestad, Vidar Martin Steen, Rune Kroken, Hugo A. Jørgensen, Erik Johnsen

S88. GRANDIOSE IDEAS IN SCHIZOPHRENIA: THE ROLE OF OPTIMISM BIAS AND HALLUCINATIONS

Catherine Bortolon*, Delphine Capdevielle, Hanan Yazbek, Joanna Norton, Stéphane Raffard

S89. THE IMPACT OF COGNITIVE REMEDIATION ON COGNITIVE AND PSYCHOSOCIAL OUTCOMES IN SCHIZOPHRENIA AND THE ROLE OF INTRINSIC MOTIVATION

Shayden Bryce*, Jennie Ponsford, Stuart Lee, Eric Tan, Sean Carruthers, Richard Lawrence, Susan Rossell

S90. IMPLICIT PROCESSING OF BODILY EMOTIONS IN SCHIZOPHRENIA

Michal Hajdúk*, Hans Klein, Emily Bass, Amy Pinkham

S91. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA

Joonho Choi*, Han-Yong Jung, Joo Eon Park, Hoseon Lee, Seon-Cheol Park

S92. DISTINCT RISK FACTORS FOR OBSESSIVE AND COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA

Emilio Fernandez-Egea*, Yulia Worbe, Miguel Bernardo, Trevor W. Robbins

S93. DIETARY PATTERNS AND PHYSICAL ACTIVITY IN PEOPLE WITH SCHIZOPHRENIA

Ane Jakobsen*



S94. INTEGRATED DIABETES MANAGEMENT FOR INDIVIDUALS WITH SERIOUS MENTAL ILLNESS

Kristina Cieslak*, Corinne Cather, Sarah Maclaurin, Deborah Wexler, Anne Thorndike, Trina Chang, Gladys Pachas, Mike Vilme, Oliver Freudenreich, Anne Eden Evins

S95. PREVALENCE AND CLINICAL CORRELATES OF COMORBID OBSESSIVE-COMPULSIVE DISORDER IN PATIENTS WITH SCHIZOPHRENIA

Lee Bora*, Kyung Sue Hong, Ji Hyun Baek, So Yung Yang

S96. CARDIOVASCULAR DISEASE RISK IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER

Linn Rødevand*, Nils Eiel Steen, Daniel Quintana, Elina Johanna Reponen, Ragni Helene Mørch, Synve Hoffart Lunding, Trude Iversen, Trine V. Lagerberg, Ingrid Melle, Ole A. Andreassen

S97. SOCIAL ANXIETY IN SCHIZOPHRENIA: THE IMPACT OF HALLUCINATIONS AND SELF-ESTEEM SUPPORT

Laura Faith*, Elise Racette, Amber Grove, Melisa Rempfer

S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Katsuhiko Hagi*, Tadashi Nosaka, Christoph Correll

S99. CANNABIS USE, PSYCHOTIC-LIKE EXPERIENCES AND ABERRANT SALIENCE IN A SAMPLE OF BELGIAN STUDENTS

Francesco Bernardini*, Chiara Gobbicchi, Luigi Attademo, Severin Puchalski, Patrizia Moretti, Alfonso Tortorella, Gwenole Loas

S100. EFFECTS OF CANNABIS USE ON BODY MASS, FASTING GLUCOSE AND LIPIDS DURING THE FIRST 12 MONTHS OF TREATMENT IN SCHIZOPHRENIA SPECTRUM DISORDERS

Frederika Scheffler*, Sanja Kilian, Bonga Chiliza, Laila Asmal, Lebogang Phahladira, Stefan du Plessis, Martin Kidd, Robin Murray, Marta Di Forti, Soraya Seedat, Robin Emsley

S101. CLINICAL FACTORS ASSOCIATED WITH CANNABIS USE IN A CHILEAN SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS

Barbara Iruretagoyena*, Nicolas Crossley, Alfonso Gonzalez-Valderrama, Cristian Mena, Carmen Castañeda, Camila Diaz, Juan Undurraga

S102. CANNABIS MAY PROTECT AGAINST CERTAIN DISORDERS OF THE DIGESTIVE ORGANS IN PATIENTS WITH SCHIZOPHRENIA BUT NOT IN HEALTHY CONTROLS

Julie Aamand Olesen, Christine Merrild Posselt, Merete Nordentoft, Carsten Hjorthøj*

S103. IS CANNABIS A RISK FACTOR FOR SUICIDE ATTEMPTS IN MEN AND WOMEN WITH PSYCHOTIC ILLNESS?

Anna Waterreus*, Patricia Di Prinzio, Johanna Badcock, Mat Martin-Iverson, Assen Jablensky, Vera Morgan



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S104. THE RELIABILITY AND VALIDITY OF THE CORE SCHIZOPHRENIA SYMPTOMS SCALE OF THE STANDARD FOR CLINICIANS' INTERVIEW IN PSYCHIATRY

Ahmed Aboraya*

S105. VALIDATING THE PREDICTIVE ACCURACY OF THE NAPLS-2 PSYCHOSIS RISK CALCULATOR IN A CLINICAL HIGH-RISK SAMPLE FROM THE SHARP (SHANGHAI AT RISK FOR PSYCHOSIS) PROGRAM

TianHong Zhang*, HuiJun Li, LiHua Xu, YingYing Tang, HuiRu Cui, Junjie Wang, Chunbo Li, Kristen Woodberry, Daniel I. Shapiro, Margaret Niznikiewicz, Martha E. Shenton, Matcheri S. Keshavan, William S. Stone, Jijun Wang, Robert W. McCarley, Larry J. Seidman

S106. OPEN BOARD

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES

Mallik Greene, Tingjian Yan, Eunice Chang, Ann Hartry*, Jennifer Munday, Michael S. Broder

S108. ASSOCIATIONS BETWEEN GLOBAL BRAIN MEASURES AND STATE- AND TRAIT- RELATED SYMPTOM EXPRESSION OF SCHIZOPHRENIA

Laila Asmal, Stéfan Du Plessis*, Bonginkosi Chiliza, Sanja Kilian, Riaan Olivier, Freda Scheffler, Lebogang Phahladira, Paola Dazzan, Robin Emsley

S109. SYMPTOM NETWORK MODELS OF PSYCHOSIS

Adela-Maria Isvoranu*

S110. THE CLINICAL IMPLICATION OF CLINICIAN-RATED DIMENSIONS OF PSYCHOSIS SYMPTOM SEVERITY (CRDPSS) FOR DIAGNOSIS BY DSM-5

Beomwoo Nam*, Won-Myong Bahk, Sang-Yeol Lee, Kwanghun Lee, Duk-In Jon, Eunsung Lim, Sung-Yong Park, Min-Kyu Song, Seongwoo Jo, Youngsoon Jeon

S111. ARE SCHIZOPHRENIA AND SCHIZO-AFFECTIVE DISORDER SEPARABLE?

Walter Heinrichs, Leah Hartman, Farena Pinnock*, Farzaneh Mashhadi, Sarah Ciantar

S112. RELATION BETWEEN EARLY-ONSET PSYCHOSIS AND FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA

Koksal Alptekin*, Simge Altinok, Halis Ulas, Banu Degirmencioglu, Berna Akded

S113. THE ASSOCIATION BETWEEN SCHIZOTYPAL COMPONENTS AND CONSPIRACIST BELIEFS THROUGH COGNITIVE MEDIATORS

David Barron*, Adrian Furnham, Laura Weis, Kevin Morgan, Tony Towell, Viren Swami

S114. ASSOCIATION BETWEEN APATHY AND DEPRESSION: SECONDARY OR REFLECTING UNDERLYING COMMON FEATURES?

Ann Faerden*, Siv Hege Lyngstad, Ingrid Melle

S115. SYMPTOM DOMAINS IN SCHIZOPHRENIA AND GENE POLYMORPHISMS

Vjekoslav Peitl*, Branka Vidrih, Draženka Ostojić, Tanja Frančeski, Milena Peitl, Dalibor Karlović



S116. THE IMPACT OF PSYCHOTIC EXPERIENCES IN THE EARLY STAGES OF MENTAL HEALTH PROBLEMS IN YOUNG PEOPLE

Karen Heinze*, Ashleigh Lin, Barnaby Nelson, Renate Reniers, Rachel Upthegrove, Latoya Clarke, Ayesha Roche, Lowrie Angelique, Stephen Wood

S117. MODELLING THE RELATIONSHIP BETWEEN INSIGHT, PSYCHOPATHOLOGY AND GENDER IN SCHIZOPHRENIA USING STRUCTURAL EQUATIONS

Jesus Cobo*, Javier Labad, Esther Pousa, Lourdes Nieto, Susana Ochoa, Judith Usall, Iris Baños, Beatriz González, Carmina Massons, Isabel Ruiz, Ada Ruiz

S118. CAN THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) DIFFERENTIATE REFRACTORY FROM NON-REFRACTORY SCHIZOPHRENIA? A FACTOR ANALYTIC INVESTIGATION BASED ON DATA FROM THE PATTERN COHORT STUDY

Rosana de Freitas*, Bernardo dos Santos, Carlo Altamura, Corrado Bernasconi, Ricardo Corral, Jonathan Evans, Ashok Malla, Marie-Odile Krebs, Anna-Lena Nordstroem, Mathias Zink, Josep Maria Haro, Helio Elkis

S119. MULTICULTURAL IDENTITY INTEGRATION AND SCHIZOTYPAL PERSONALITY DISORDER

Daisy Lopez*, Amy Weisman de Mamani

S120. FACTORS ASSOCIATED WITH SUICIDE ATTEMPTS AMONG PATIENTS WITH SCHIZOPHRENIA

Rahma Nefzi*, Amine Larnaout, Hanen Ben Ammar, Emira Khelifa, Amina Aissa, Zouhaier El Hechmi

S121. JUMPING TO CONCLUSIONS, SOCIAL COGNITION AND METACOGNITION IN PEOPLE WITH A RECENT-ONSET OF PSYCHOSIS

Raquel López-Carrilero*, Luciana Díaz, Esther Pousa, Eva Grasa, Ana Barajas, Maria Luisa Barrigon, Fermin Gonzalez Higuera, Esther Lorente, Jordi Cid, Isabel Ruiz, Irene Birules, Susana Ochoa

S122. 3-YEAR NEGATIVE SYMPTOM TRAJECTORY AND ITS RELATIONSHIP WITH SYMPTOM AND FUNCTIONAL OUTCOMES IN FIRST-EPIISODE NON-AFFECTIVE PSYCHOSIS: A PROSPECTIVE 13-YEAR FOLLOW-UP STUDY

Wui Hang Ho, Wing Chung Chang*, Yee Man Tang, Lai Ming Hui, Kit Wa Chan, Ho Ming Lee, Yi Nam Suen, Eric Chen

S123. TREATMENT RESISTANT SCHIZOPHRENIA AND GYRIFICATION-BASED CONNECTOME

Olesya Ajnakina*, Tushar Das, John Lally, Marta Di Forti, Robin Murray, Lena Palaniyappan

S124. RECOVERY TRAJECTORIES IN FIRST EPISODE PSYCHOSIS PATIENTS: THE ROLE OF TIMING

Rosa Ayesa-Arriola*, Jose Maria Pelayo-Teran, Esther Setien-Suero, Rocio Perez-Iglesias, Benedicto Crespo-Facorro

S125. THE DYNAMIC RELATIONSHIP BETWEEN INSIGHT AND SUICIDAL BEHAVIOUR IN FIRST EPISODE PSYCHOSIS PATIENTS OVER 3-YEAR FOLLOW-UP

Rosa Ayesa-Arriola*, Jose Maria Pelayo-Teran, Javier-David Lopez-Morinigo, Manuel Canal-Rivero, Esther Setien-Suero, Manuel J. Cuesta, Anthony David, Benedicto Crespo-Facorro



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY

Natalia Petros*, Andrea Mechelli, Paolo Fusar-Poli, Sandra Vieira, Emma Rowland, Philip McGuire

S127. "HOW COULD THIS HAPPEN?": PSYCHOSIS OR DEPRESSION AS A FACTOR IN DEATH BY SUICIDE

James Overholser*, Alison Athey, Eleanor Beale, Lesa Dieter, Craig Stockmeier

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA

Beatriz Yukie Elias, Gabriela Koga Tonsig, Bruno Bertolucci*, Cristiano Noto, Daniel Azevedo Cavalcante, Quirino Cordeiro, Rodrigo Bressan, Ary Gadelha

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?

Bruno Bertolucci*, José Cássio Pitta, Cinthia Higuchi, Cristiano Noto, Deyvis Rocha, Dan Joyce, Christoph Correll, Rodrigo Bressan, Ary Gadelha

S130. INCIDENCE OF FIRST EPISODE OF PSYCHOSIS IN AN AUSTRALIAN COHORT AND ASSOCIATIONS WITH NEIGHBOURHOOD CHARACTERISTICS

Scott Eaton, Linglee Downey, Kristen Thien, Meghan Bowtell, Melissa Bardell-Williams, Aswin Ratheesh, Patrick D. McGorry, Brian O'Donoghue*

S131. PERCEPTUAL ABNORMALITIES AND RELIGIOSITY IN ULTRA HIGH-RISK FOR PSYCHOSIS (UHR) INDIVIDUALS IN A LATIN AMERICAN POPULATIONAL SAMPLE RESULTS FROM THE SAO PAULO SSAPP COHORT

Alexandre Loch*, Camille Chianca, Elder Lanzani Freitas, Julio Cesar Andrade, Tania Maria Alves, Mauricio Henriques Serpa, Lucas Hortêncio, Martinus Theodorus van de Bilt, Wagner Gattaz, Wulf Rössler

S132. A NORMATIVE CHART FOR THE TRAJECTORY OF COGNITIVE FUNCTIONING IN INDIVIDUALS AT HIGH RISK FOR SCHIZOPHRENIA: LONGITUDINAL FINDINGS FROM THE INTERNATIONAL BRAIN AND BEHAVIOR CONSORTIUM ON 22Q11.2 DELETION SYNDROME

Fikinski Ania*, Jacob Vorstman, Anne Bassett, Elemei Breetvelt

S133. THE RELATIONSHIP BETWEEN EXPOSURE TO TRAUMA DURING CHILDHOOD AND ADOLESCENCE AND PSYCHOTIC EXPERIENCES AT 18 YEARS OLD IN A NON-CLINICAL POPULATION

Jazz Croft*, Stanley Zammit, Jon Heron, Christoph Teufel

S134. THE INCIDENCE OF PSYCHOSIS IN OLDER PEOPLE: A SWEDISH POPULATION-BASED COHORT STUDY

Jean Stafford*, Robert Howard, Christina Dalman, James Kirkbride

S135. THE PSYCHOSIS CONTINUUM IN ELDERLY NON DEMENTED PERSONS: EVIDENCE DERIVED FROM PSYCHOTIC SYMPTOMS IN OLDER PEOPLE WITHOUT DEMENTIA FROM A BRAZILIAN COMMUNITY-BASED SAMPLE: A SEVEN YEARS' FOLLOW-UP

Walter Soares*, Eriton dos Santos, Cassio Bottino, Helio Elkis



S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING

Hok Pan Yuen*, Andrew Mackinnon, Jessica Hartmann, Paul Amminger, Connie Markulev, Suzie Lavoie, Miriam Schafer, Andrea Polari, Nilufar Mossaheb, Monika Schlogelhofer, Stefan Smesny, Ian Hickie, Gregor Berger, Eric Chen, Lieuwe de Hann, Dorien Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Andrew Thompson, Alison Yung, Patrick D. McGorry, Barnaby Nelson

S137. DO HALLUCINATIONS PREDICT THE TRANSITION FROM SUICIDAL THOUGHTS TO ATTEMPTS? RESULTS FROM AN AUSTRALIAN LONGITUDINAL COHORT STUDY

Emily Hielscher*, Jordan DeVlyder, Melissa Connell, Penelope Hasking, Graham Martin, James Scott

S138. AN INVESTIGATION INTO THE ASSOCIATION BETWEEN EXPOSURE TO PRENATAL STRESS AND RISK OF PSYCHOSIS IN OFFSPRING

Ross Brannigan*, Antti Tanskanen, Matti O.Hunnunen, Mary Cannon, Finbarr Leacy, Mary Clarke

(S139.) INVESTIGATING THE GENETIC ARCHITECTURE OF GENERAL AND SPECIFIC PSYCHOPATHOLOGY IN ADOLESCENCE USING SCHIZOPHRENIA POLYGENIC SCORES

Hannah Jones*, Jon Heron, Gemma Hammerton, Jan Stochl, Peter B. Jones, Mary Cannon, George Davey Smith, Peter Holmans, Glyn Lewis, David E.J. Linden, Michael C. O'Donovan, Michael J. Owen, James Walters, Stanley Zammit

S140. VOICE-SELECTIVE FORWARD MODEL ABNORMALITIES IN NONCLINICAL VOICE HEARERS

Ana Pinheiro*, Michael Schwartz, Sonja Kotz

S141. TRANSGENIC OVEREXPRESSION OF THE TYPE III ISOFORM OF NEUREGULIN 1 IN MICE INDUCES ABNORMALITIES ON AUDITORY EVENT RELATED EEG BIOMARKERS RELATED TO SCHIZOPHRENIA

Holger Rosenbrock*, Wiebke Nissen, Roberto Arban, Rossner Moritz, Schwab Markus, Cornelia Dörner-Ciossek, Niklas Schülert

S142. RESTING STATE NETWORKS ALTERATION IN BIPOLAR DEPRESSION

Gianluca Mingoia*, Igor Nenadic

S143. NEURAL CORRELATES OF INTENTION AND BELIEF INFERENCE RELATIVE TO EMOTION ATTRIBUTION TO OTHERS IN SCHIZOPHRENIA AND PSYCHOSIS PRONENESS: ACTIVATION LIKELIHOOD ESTIMATION META-ANALYSIS

Ksenija Vucurovic*, Stéphanie Caillies, Arthur Kaladjian

S144. THE ASSOCIATION BETWEEN BRAIN ACTIVITY IN THE PREFRONTAL CORTEX AND DEMOGRAPHIC VARIABLES: A LARGE-SAMPLE FUNCTIONAL NEAR-INFRARED SPECTROSCOPY STUDY

Shinsuke Koike*, Eisuke Sakakibara, Yoshihiro Satomura, Hanako Sakurada, Mika Yamagishi, Jun Matsuoka, Naohiro Okada, Kiyoto Kasai



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S145. ANTIPSYCHOTIC DISCONTINUATION IN FIRST EPISODE PSYCHOSIS: [18F]DOPA AND [11C]RACLOPRIDE PET STUDY

Euitae Kim*

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA.

Kyra-Verena Sendt*, Grant McQueen, Amy Gillespie, James MacCabe, Fernando Zelaya, Alice Egerton

S147. ASSOCIATION BETWEEN SOCIAL ANHEDONIA AND TOPOLOGICAL PROFILE OF BRAIN NETWORK IN SCHIZOPHRENIA

Zhi Li*, Raymond Chan

S148. DIFFERENTIAL NEURAL REWARD MECHANISMS IN TREATMENT RESPONSIVE AND TREATMENT RESISTANT SCHIZOPHRENIA

Lucy Vanes*, Elias Mouchlianitis, Tracy Collier, Bruno Averbeck, Sukhi Shergill

S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS

Cathy Davies*, Grazia Rutigliano, Marco Cappucciati, Andrea De Micheli, Valentina Ramella-Cravaro, Umberto Provenzani, Andre Schmidt, Yannis Paloyelis, Philip McGuire, Paolo Fusar-Poli

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAÏVE FIRST EPISODE PSYCHOTIC PATIENTS

Anne Sigvard*, Karen Tangmose, Kirsten Borup Bojesen, Kasper Jessen, Mette Ødegaard Nielsen, Dan Fuglø, Lars Thorbjørn Jensen, Egill Rostrup, Birte Glenthøj

S151. DYNAMIC FUNCTIONAL CONNECTIVITY IN THOSE AT ULTRA HIGH RISK OF PSYCHOSIS VS CONTROLS

George Gifford*, Nicolas Crossley, Paola Dazzan, Kempton Matthew, Philip McGuire

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS

Aisling O'Neill*, Robin Wilson, Grace Blest-Hopley, Luciano Annibale, Marco Colizzi, Sagnik Bhattacharyya

S153. WHERE IS THE ABNORMAL BRAIN ACTIVITY IN FIRST EPISODE PSYCHOSIS?

Soldevila-Matias Pau*, González-Vivas Carlos, García-Martí Gracián, Soprano-Ros Olga, Martí-Bonmatí Luis, Crespo-Facorro Benedicto, Sanjuán Julio

S154. THE ROLE OF DOPAMINE IN PROCESSING THE MEANINGFUL INFORMATION OF OBSERVATIONS, AND IMPLICATIONS FOR THE ABERRANT SALIENCE HYPOTHESIS OF SCHIZOPHRENIA

Matthew Nour*, Tarik Dahoun, Philipp Schwartenbeck, Rick Adams, Thomas FitzGerald, Christopher Coello, Matthew Wall, Raymond Dolan, Oliver Howes



S155. SENSORY ATTENUATION DURING AUDITORY PROCESSING IN PARTICIPANTS AT CLINICAL-HIGH RISK FOR PSYCHOSIS: EVIDENCE FROM MAGNETOENCEPHALOGRAPHY
Lingling Hua*, Marc Recasens, Tineke Grent-'t-Jong, Emmi Mikanmaa, Hanna Thuné, Andrew Gumley, Matthis Schwannauer, Stephen Lawire, Ruchika Gajwan, Joachim Gross, Peter Uhlhaas

S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA
Seouyoung Kim*, Wi Hoon Jung, Euitae Kim, Jun Soo Kwon

S157. NEURAL CORRELATES OF SMOOTH PURSUIT EYE MOVEMENTS IN POSITIVE AND NEGATIVE SCHIZOTYPY
Eliana Faiola*, Maria F. Urquijo, Inga Meyhöfer, Anna Kasparbauer, Maria Steffens, Michael Wagner, Nikolaos Koutsouleris, Ulrich Ettinger

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAÏVE FIRST-EPIISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
Karen Tangmose*, Mette Ødegård Nielsen, Anne Sigvard, Kasper Jessen, Kirsten Bojesen, Marie Bjerregaard, Egill Rostrup, Birte Glenthøj

S159. REDUCED PROCESSING SPEED IN SCHIZOPHRENIA IS MEDIATED BY WHITE MATTER INTEGRITY
Saetbyeol Cha*, Woon Yoon, Seung-Hyun Shon, Jungsun Lee

S160. INTERACTIONS BETWEEN BOTTOM-UP AND TOP-DOWN ATTENTION DURING WORKING MEMORY ENCODING: EVALUATION OF AN FMRI PARADIGM FOR THE STUDY OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA
Mishal Qubad*, Catherine Barnes, Lara Rösler, Michael Schaum, Benjamin Peters, Michael Wibrall, Andreas Reif, Robert Bittner

(S161.) FUNCTIONAL BRAIN NETWORKS INVOLVED IN ATTENTIONAL BIASING IN SCHIZOPHRENIA
Paul Metzák*, Todd Woodward

S162. IMPACT OF THE PRESENCE OF A PEER WORKER IN AN EARLY INTERVENTION UNIT FOR YOUNG ADULTS WITH MENTAL ILLNESS (JADE)
Maryse Badan Ba*, Elisabeth Sturm, Laurent Bediat, Logos Curtis

S163. FEASIBILITY STUDY: MEASURES OF SLEEP AND PHYSICAL ACTIVITY IN PEOPLE WITH SCHIZOPHRENIA
Alexandra Berry*, Richard Drake, Roger Webb, Darren Ashcroft, Matthew Carr, Alison Yung

S164. "AT-RISK MENTAL STATES" PROGRAM IN LAUSANNE: INFLUENCE OF RECRUITMENT STRATEGIES ON THE RATE OF FALSE POSITIVES
Alessandra Solida*, Martine Cleusix, Carline Zorzi, Carina Ferrari, Kim Q. Do, Philippe Conus

(S165.) ALTERED ASSOCIATION BETWEEN PARIETAL GRAY-MATTER VOLUME AND DISSOCIATIVE SYMPTOMS IN SCHIZOPHRENIA: A VOXEL-BASED MORPHOMETRY STUDY
Huai-Hsuan Tseng*, Chui-de Chiu, Kao Chin Chen, I. Hui Lee, Po See Chen, Yen Kuang Yang



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S166. OPEN BOARD

S167. ANATOMICAL CONNECTIVITY OF THE VISUOSPATIAL ATTENTIONAL NETWORK IN SCHIZOPHRENIA: A DTI-BASED TRACTOGRAPHY STUDY

Leroux Elise*, Poirel Nicolas, Sonia Dollfus

S168. AUDITORY TRANSCALLOSAL FIBERS AND AUDITORY HALLUCINATIONS

Dean Salisbury*, Yiming Wang, Brian Coffman

S169. MICROGLIAL ACTIVATION AND MORPHOLOGICAL BRAIN ALTERATIONS IN PSYCHOSIS AND PSYCHOSIS RISK

Sina Hafizi*, Elisa Guma, Alex Koppel, Tania Da Silva, Michael Kiang, Sylvain Houle, Alan Wilson, Pablo Rusjan, Mallar Chakravarty, Romina Mizrahi

S170. AMYGDALA SUBNUCLEI VOLUMES IN FIRST-EPISODE PSYCHOSIS: ASSOCIATION WITH CHILDHOOD ADVERSITY

Reetta-Liina Armio*, Heikki Laurikainen, Raimo Salokangas, Lauri Tuominen, Jarmo Hietala

S171. ALTERED WHITE MATTER CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA USING PUBLIC NEUROIMAGING DATA FROM SCHIZCONNECT

Sung Woo Joo, Woon Yoon, Seung-Hyun Shon, Saetbyeol Chat, JungSun Lee*

S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY

Claudia Vingerhoets*, Geor Bakker, Marieke van der Pluijm, Oswald Bloemen, Liesbeth Reneman, Matthan Caan, Jan Booij, Therese van Amelsvoort

S173. GREY MATTER VOLUME DEFICITS IN PATIENTS WITH A FIRST EPISODE NON-AFFECTIVE PSYCHOSIS AND SUICIDE RELATED BEHAVIOUR

Diana Tordesillas-Gutiérrez*, Manuel Canal-Rivero, Esther Setien-Suero, Rosa Ayesa-Arriola, Manuel Delgado-Alvarado, Benedicto Crespo-Facorro

S174. ABNORMAL SOCIAL COGNITION RELATED TO STRUCTURAL DISCONNECTIVITY IN SCHIZOPHRENIA

Molina Vicente*, Alba Lubeiro Juárez, Eva Sotelo, Mercedes Vaquero, Rodrigo de Luis-García

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA

Fernando Caravaggio*, Gagan Fervaha, Yusuke Iwata, Eric Plitman, Jun Ku Chung, Shinichiro Nakajima, Wanna Mar, Philip Gerretsen, Julia Kim, Mallar Chakravarty, Benoit Mulsant, Bruce Pollock, David Mamo, Gary Remington, Ariel Graff-Guerrero

S176. SYSTEMATIC REVIEW AND META-ANALYSIS OF MAGNETIC RESONANCE IMAGING FINDINGS IN 22Q11.2 DELETION SYNDROME

Guido Maria Lattanzi*, Cristina Scarpazza, Fabio Di Fabio, Philip McGuire, Giuseppe Sartori, Simon B. Eickhoff, Stefania Tognin



S177. FRONTAL CORTICAL PLASTICITY IN SCHIZOPHRENIA PATIENTS EXAMINED BY LTP-INDUCING ANODAL TDCS AND REPETITIVE EEG

Benjamin Pross*, Melina Siamouli, Oliver Pogarell, Peter Falkai, Alkomiet Hasan, Wolfgang Strube

S178. ALTERED GYRIFICATION IN THE SCHIZOPHRENIA SPECTRUM

Daiki Sasabayashi*, Yoichiro Takayanagi, Tsutomu Takahashi, Yusuke Takegoshi, Tokio Matsuda, Atsushi Furuichi, Mikio Kido, Yumiko Nishikawa, Mihoko Nakamura, Kyo Noguchi, Michio Suzuki

S179. PROGNOSTIC UTILITY OF MULTIVARIATE MORPHOMETRY IN SCHIZOPHRENIA

Mingli Li*, Xiaojing Li, Deng Wei, Yinfei Li, Liansheng Zhao, Xiaohong Ma, Yingcheng Wang, Hua Yu, Ya-jing Meng, Qiang Wang, Lena Palaniyappan, Tao Li

S180. MICROSTRUCTURE COMPLEXITY OF THE THALAMUS IN SCHIZOPHRENIA: A NODDI STUDY

Yasser Alemán-Gómez, Timo Roine, Elena Najdenovska, Philippe Golay, Zita Rovó, Raoul Jenni, Martine Cleusix, Philippe Conus, Kim Q. Do, Pascal Steullet, Meritxell Bach Cuadra, Philipp Baumann*

S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION

Maria Rogdaki*, Mattia Veronese, Pamela Hathway, Sameer Jauhar, Maria Gudbrandsen, Eileen Daly, Oliver Howes

S182. CHANGE IN CORTICAL MORPHOMETRY IN INDIVIDUALS WITH PERSISTING PSYCHOTIC EXPERIENCES: A LONGITUDINAL PILOT STUDY

Leon Fonville*, Mark Drakesmith, Avi Reichenberg, Derek Jones, David Linden, Anthony David

S183. ABNORMALITIES OF FRONTO-SUBCORTICAL PATHWAYS IN SCHIZOPHRENIA AND THE DIFFERENTIAL IMPACTS OF ANTIPSYCHOTIC TREATMENT: A DTI-BASED TRACTOGRAPHY STUDY

Anaïs Vandeveldel*, Elise Leroux, Maxime Tréhout, Sonia Dollfus

S184. MACHINE LEARNING REVEALS DEVIANCE IN NEUROANATOMICAL MATURITY PREDICTIVE OF FUTURE PSYCHOSIS IN YOUTH AT CLINICAL HIGH RISK

Yoonho Chung*, Jean Addington, Carrie Bearden, Kristen Cadenhead, Barbara Cornblatt, Daniel Mathalon, Thomas McGlashan, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Sarah McEwen, Theo van Erp, Tyrone Cannon

S185. DTNBP1 IS ASSOCIATED WITH THE AGE AT ONSET OF KOREAN PATIENTS WITH SCHIZOPHRENIA

Kyuyoung Lee*, Eun-Jeong Joo

S186. KCNH2 POLYMORPHISM ASSOCIATED TO ALTERED EEG FUNCTIONAL NETWORK MODULATION IN SCHIZOPHRENIA

Alba Lubeiro Juárez*, Vicente Molina Rodriguez, Maria Guardiola, Javier Gómez Pilar, Mar Fatjó-Vilas



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S187. SEARCHING FOR BRAIN CO-EXPRESSION MODULES THAT CONTRIBUTE DISPROPORTIONATELY TO THE COMMON POLYGENIC RISK FOR SCHIZOPHRENIA
Javier Costas*, Mario Paramo, Manuel Arrojo

S188. DYSREGULATION OF CIRCULAR RNA EXPRESSION IN SCHIZOPHRENIA OBSERVED IN POSTMORTEM DORSOLATERAL PREFRONTAL CORTEX
Ebrahim Mahmoudi*, Chantel Fitzsimmons, Michael Geaghan, Murray Cairns

S189. CARVING A MORE SPECIFIC SUBTYPE OF SCHIZOPHRENIA FOR GENETIC STUDIES: SPORADIC SCHIZOAFFECTIVE BIPOLAR TYPE
Nicolaas van der Merwe*, Maria Karayiorgou, René Ehlers, Johannes Roos

S190. SCHIZOTYPY & SUICIDALITY: A MENDELIAN RANDOMISATION ANALYSIS
Kirstie O'Hare*, Richard Linscott, Tony Merriman

S191. INVESTIGATION OF THE PREVALENCE OF COPY NUMBER VARIANT SYNDROMES IN A LARGE SCHIZOPHRENIA COHORT
Venuja Sriretnakumar*, Clement Zai, James Kennedy, Joyce So

S192. AKT-MTOR SIGNALING PATHWAY IS DOWNREGULATED IN SCHIZOPHRENIA
Radhika Chadha*, James Meador-Woodruff

S193. EX VIVO SIGNATURE OF PSYCHOSIS AND TREATMENT RESPONSE IN PATIENT-DERIVED NEURONS
Rakesh Karmacharya*, Bradley Watmuff, Annie Kathuria, Bangyan Liu

S194. INVESTIGATING PERIPHERAL MICRORNA-MRNA INTERACTIONS IN SCHIZOPHRENIA
Michael Geaghan*, Murray Cairns

S195. ELECTRORETINOGRAPHIC INDICES OF PHOTORECEPTOR, BIPOLAR, AND GANGLION CELL FUNCTIONING DIFFERENTIATE PEOPLE WITH SCHIZOPHRENIA FROM THOSE WITH MAJOR DEPRESSION AND HEALTHY CONTROLS
Docia Demmin*, Matthew Roché, Roni Netser, Steven Silverstein

S196. ASSOCIATION BETWEEN INTRACELLULAR INFECTIOUS AGENTS AND SCHIZOPHRENIA IN KOREA
Young-Joon Kwon*, Won-Myong Bahk, Bo-Hyun Yoon, Duk-In Jon, MoonDoo Kim, Beomwoo Nam, Eunsung Lim, Sung-Yong Park

S197. OBSTETRIC COMPLICATIONS, NEUROCOGNITION, AND SCHIZOPHRENIA
Bjorn Rund*, Charlotte Teigset, Christine Mohn

S198. PRE-ADOLESCENT BRAIN STRUCTURE: THE INTERPLAY BETWEEN GENETIC VULNERABILITY FOR SCHIZOPHRENIA AND CORTISOL LEVELS
Koen Bolhuis*, Philip R. Jansen, Hanan El Marroun, Manon H.J. Hillegers, Henning Tiemeier, Steven A. Kushner



S199. ENHANCED OLFATORY IDENTIFICATION IN ADOLESCENTS WITH PSYCHOTIC EXPERIENCES

Eleanor Carey*, Niamh Dooley, Erik O'Hanlon, Ian Kelleher, Mary Cannon

S200. HYPOVITAMINOSIS D IN SCHIZOPHRENIA: PREVALENCE AND ASSOCIATED CLINICAL CHARACTERISTICS.

Rahma Nefzi*, Amine Larnaout, Hanen Ben Ammar, Emira Khelifa, Amina Aissa, Zouhaier El Hechmi

S201. RELATION BETWEEN PSYCHOTROPIC DRUGS AND SEIZURE THRESHOLD IN ELECTROCONVULSIVE THERAPY

Seung Hyun Kim*, Jung-Seo Yi, Su-Hyuk Chi, Hyun-Ghang Jeong

S202. EFFICACY OF LONG-TERM RESIDENTIAL TREATMENT FOR PERSISTENT MENTAL ILLNESS

Michael Knable*

S203. COMPENSATORY COGNITIVE APPROACHES TO IMPROVING FUNCTIONING IN PSYCHOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS

Kelly Allott*, Kristi Van-Der-EL, Emma Parrish, Chris Bowie, Sean Kidd, Susan McGurk, Sarah Hetrick, Shayden Bryce, Matthew Hamilton, Eoin Killackey, Dawn Velligan

S204. NUTRITIONAL DEFICIENCIES AND CLINICAL CORRELATES IN FIRST-EPIISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Joseph Firth*, Rebekah Carney, Scott Teasdale, Brendon Stubbs, Philip Ward, Michael Berk, Jerome Sarris

S205. TRANSCRANIAL DIRECT CURRENT STIMULATION FOR SEVERE, PERSISTENT, TREATMENT-REFRACTORY AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA

Parth Goyal*, Lakhan Kataria, Chittaranjan Andrade, Priyal Desai

S206. KNOWLEDGE ABOUT CAUSES OF RELAPSE DURING PSYCHOEDUCATION IN PATIENTS LIVING WITH SCHIZOPHRENIA- A QUALITATIVE ANALYSIS

Anoop Gupta*, Mamidipalli Spoorthy, Bina Gurung, Robin Jha, Bishnu Acharya

S207. TDCS AS FUTURE TREATMENT OPTION FOR SCHIZOPHRENIA PATIENTS - A NEUROPHYSIOLOGICAL INVESTIGATION OF INDUCED PLASTICITY OVER MOTOR AND PREFRONTAL CORTEX USING SLORETA

Nina Filipova*, Alkomiet Hasan, Daniel Keeser, Wolfgang Strube

S208. PREDICTORS OF RESPONSE TO COGNITIVE REMEDIATION THERAPY: SYSTEMATIC REVIEW OF LITERATURE

Maree Reser*, Reneta Slikboer, Susan Rossell

S209. PATIENT EXPERIENCES OF THE EARLY SIGNS ACTION PLAN

Nils Sjöström*, Maria Genberg, Alexander Marteleur, Eva Andreasson, Margda Waern



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S210. MULTIDISCIPLINARY LIFESTYLE-ENHANCING TREATMENT FOR INPATIENTS WITH SEVERE MENTAL ILLNESS (MULTI-STUDY): EFFECTS ON PHYSICAL HEALTH, PSYCHOTIC SYMPTOMS, QUALITY OF LIFE AND FUNCTIONING

Jeroen Deenik*, Diederik Tenback, Ingrid Hendriksen, Erwin Tak, Peter van Harten

S211. SCHIZOTYPY IN PATIENTS FROM A CLINICAL HIGH RISK SERVICE: TRAIT OR STATE?

Frauke Schultze-Lutter*, Rahel Flückiger, Chantal Michel, Daniela Hubl

S212. CONVERSING WITH PEOPLE WITH THOUGHT DISORDER

Cherrie Galletly*, David Ash, Shaun Sweeney, Jonathan Crichton

S213. CAN PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA RELIABLY REPORT NEGATIVE SYMPTOMS? A PILOT STUDY USING THE SELF-EVALUATION OF NEGATIVE SYMPTOMS SCALE

Jean-Pierre Lindenmayer*, Abraham Goldring, Amanda Hefner, Anzalee Khan, Amod Thanju

S214. USING ONLINE-SCREENING TO DETECT PARTICIPANTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS

Mhairi McDonald, Andrew Gumley, Stephen Lawrie, Matthias Schwannauer, Ruchika Gajwani, Joachim Gross, Peter Uhlhaas*

S215. THE APROSODY OF SCHIZOPHRENIA: COMPUTATIONALLY DERIVED ACOUSTIC PHONETIC UNDERPINNINGS OF MONOTONE SPEECH

Michael Compton, Luca Pauselli*, Anya Lunden, Sean Cleary, Yazeed Alolayan, Brooke Halpern, Beth Broussard, Anthony Crisafio, Leslie Capulong, Pierfrancesco Balducci, Francesco Bernardini, Michael Covington

S216. REDUCED EMOTIONAL FACIAL EXPRESSION IN SCHIZOPHRENIA – A PROBE INTO THE PHENOMENOLOGY AND RELEVANCE OF EXPRESSIVE NEGATIVE SYMPTOMS

Marcel Riehle*, Stephanie Mehl, Tania M. Lincoln

S217. SELF-DISTURBANCES AND DIAGNOSTIC STABILITY IN FIRST EPISODE PSYCHOSIS: A SEVEN YEAR FOLLOW-UP STUDY

Ingrid Svendsen*, Merete Øie, Paul Møller, Barnaby Nelson, Ingrid Melle, Elisabeth Haug

S218. INSIGHT AND SUBJECTIVITY

Clara Monserrat*, Dolores Sanchez-Cabezudo, Carles Garcia-Ribera, Carmina Massons, Lourdes Nieto, Esther Pousa, Jesús Cobo, Ada Ruiz, Susana Ochoa, Judith Usall

S219. RISK FACTORS FOR LOW BONE MINERAL DENSITY IN PATIENTS TAKING ANTIPSYCHOTICS

Min Jhon, Ji-Eun Hong, Cheol Park, Ju-Yeon Lee, Anna Jo, Jae-Min Kim, Il-Seon Shin, Lana Williams, Michael Berk, Jin-Sang Yoon, Sung-Wan Kim*



S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION?: AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY

Won-Myong Bahk*, Young Joon Kwon, Bo-Hyun Yoon, Sang-Yeol Lee, Kwanghun Lee, Duk-In Jon, Moon Doo Kim, Eunsung Lim

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS. PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT

Hugo Geerts*, Athan Spiros, Giouliana Kadra, Robert Stewart, Richard Hayes, Hitesh Shetty, Ehtesham Iqbal

S222. CLINICAL UTILITY OF PHARMACOGENETIC TESTING IN SCHIZOPHRENIA TREATMENT

Daniel J. Mueller*, Arun Tiwari, Clement Zai, James Kennedy

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS

Kazunori Suzuki*, Akina Harada, Hirobumi Suzuki, Atsushi Nakatani, Clizia Capuani, Annarosa Ugolini, Mauro Corsi, Nidhi Kaushal, Konstantin Bobkov, John Vekich, Joseph Doyle, Haruhide Kimura

S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE

Marco Colizzi*, Philip McGuire, Vincent Giampietro, Steve Williams, Mick Brammer, Sagnik Bhattacharyya

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA

Sri Mahavir Agarwal*, Zohra Ahsan, Jonathan Lockwood, Marcus Duncan, Hiroyoshi Takeuchi, Tony Cohn, Valerie Taylor, Gary Remington, Guy Faulkner, Margaret Hahn

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER

Adam Simmons*, David McDonnell, Ying Jiang, Christine Graham, Bernard Silverman

S227. A PROPOSED ALTERNATIVE BETWEEN DISCONTINUATION AND MAINTENANCE OF ANTIPSYCHOTICS: A GUIDED DOSE REDUCTION TRIAL FOR PATIENTS WITH REMITTED PSYCHOSIS

Chen-Chung Liu*



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S228. TOWARD EARLY DETECTION OF TREATMENT RESISTANT SCHIZOPHRENIA. PREDICTIVE INFORMATION ON NON-RESPONSE TO ANTIPSYCHOTICS BY EVALUATION OF A FEW CLINICAL FACTORS: A STUDY BY ROC CURVE ANALYSIS AND CONFIRMATORY MULTIVARIATE ANALYSIS

Felice Iasevoli*, Camilla Avagliano, Benedetta Altavilla, Annarita Barone, Mariateresa Ciccarelli, Luigi D'Ambrosio, Danilo Notar Francesco, Eugenio Razzino, Andrea de Bartolomeis

S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS?

Robert Zipursky*, Helen Huynh, Ofer Agid, Michael Kiang, Gary Remington

S230. LONG-TERM ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA: BENEFITS, RISKS AND FOLLOW-UP: DATA FROM FINNISH COHORT STUDIES AND SYSTEMATIC REVIEW

Matti Isohanni*, Jouko Miettunen, Erika Jääskeläinen, Jani Moilanen, Anja Hulkko, Sanna Huhtaniska

(S231.) THE ROLE OF DOPAMINERGIC AND GLUTAMATERGIC NEUROTRANSMISSION IN DELUSIONAL IDEATION AND SENSORY INFORMATION PROCESSING OF PATIENTS WITH SCHIZOPHRENIA IN COMPARISON TO HEALTHY HUMAN PARTICIPANTS

Wolfgang Strube*, Graziella Quattrocchi, Simon Little, Louise Marshall, Alkomiet Hasan, Sven Bestmann

S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA

Gilda Neves*, Anthony Grace

S233. EVOLUTION OF THE FUNCTIONING AND ATTITUDES TO MEDICATION IN A SAMPLE WITH EARLY PSYCHOSIS IN TREATMENT WITH ARIPIPRAZOLE ONCE-MONTHLY

Marta Soto*, Adolfo Benito

S234. ONE-YEAR OUTCOME AND USE OF CLOZAPINE IN FIRST-EPISEDE SCHIZOPHRENIA

Petros Drosos*, Kolbjørn Brønnick, Rune Kroken, Inge Joa, Jan Olav Johannessen, Tor Ketil Larsen

S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Johannes Schneider-Thoma*, Stefan Leucht

S236. IS MAINTENANCE TREATMENT NEEDED WHEN THE FIRST EPISODE OF PSYCHOSIS IS NOT DUE TO SCHIZOPHRENIA?

Gbolahan Odejayi*, Robert Zipursky

S237. THE ACCEPTANCE, FEASIBILITY AND PRELIMINARY EFFECTS OF DYNAMIC INTERACTIVE SOCIAL COGNITION TRAINING IN VIRTUAL REALITY (DISCOVER): A PILOT STUDY

Saskia Nijman*, Wim Veling, Chris Geraets, Marieke Pijnenborg

S238. DEVELOPMENT OF SELF-STIGMA INVENTORY FOR THE RELATIVES OF THE PATIENTS WITH SCHIZOPHRENIA: RELIABILITY AND VALIDITY STUDY IN TURKEY

Mustafa Yildiz, Aysel İncedere*, Fatma Kiras, Fatma Betül Abut, Ayşe Kircali, Kübra İpçi



S239. PREDICTIVE ACCURACY FOR WORK OUTCOME IN PATIENTS WITH SCHIZOPHRENIA
Chika Sumiyoshi*, Haruo Fujino, Tomiki Sumiyoshi, Hidenaga Yamamori, Noriko Kudo, Hirotsugu Azechi, Michiko Fujimoto, Yuka Yasuda, Kazutaka Ohi, Ryota Hashimoto

S240. DETERMINANT FACTORS OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA
Leticia González-Blanco*, M. Paz Garcia-Portilla, Leticia Garcia-Alvarez, Lorena De La Fuente-Tomas, Pilar Saiz-Martinez, Celso Iglesias, Ana Coto, Julio Bobes

S241. COMBIMOD: A FRENCH INTEGRATIVE PROGRAMME IN PATIENTS WITH SCHIZOPHRENIA FOCUSING ON RECOVERY: PRELIMINARY RESULTS
Corentin Tarquis, Audrey Tanguy, Sarah-Lise Farhat, Christophe Hochard, Corinne Bismuth, Corinne Gautier, Thierry Lambert, Sandrine Orens, Trang Ton, Marie-Cécile Bralet*

S242. INTERNALIZED STIGMA AND ITS ASSOCIATION WITH CLINICAL SYMPTOMS AND PREMORBID ADJUSTMENT IN STABLE SCHIZOPHRENIA
Silvia Pardeller*, Beatrice Frajo-Apor, Georg Kemmler, Annasara Meola, Fabienne Wartelsteiner, Wolfgang Fleischhacker, Alex Hofer

S243. EFFECTS OF A VIRTUAL REALITY SOCIAL TRAINING INTERVENTION ON LONELINESS AND SOCIAL COGNITION IN PATIENTS WITH SCHIZOPHRENIA
Laura Hieber Adery*, Megan Ichinose, Lénie Torregrossa, Heathman Nichols, Dayi Bian, Joshua Wade, Eric Granholm, Nilanjan Sarkar, Sohee Park

S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING
Dana Allswede*, Tyrone Cannon, Jean Addington, Carrie Bearden, Kristin Cadenhead, Barbara Cornblatt, Daniel Mathalon, McGlashan Thomas, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods

S245. LOWER- AND HIGHER-LEVEL SOCIAL COGNITIVE FACTORS ACROSS INDIVIDUALS WITH SCHIZOPHRENIA SPECTRUM DISORDERS AND HEALTHY CONTROLS: RELATIONSHIP WITH NEUROCOGNITION AND FUNCTIONAL OUTCOME
Lindsay Oliver*, John Haltigan, James Gold, George Fousias, Pamela DeRosse, Robert Buchanan, Anil Malhotra, Aristotle Voineskos

S246. PSYCHOMETRIC PROPERTIES OF THE DANISH VERSION OF BNSS (BNSS-DA)
Johannes Gehr*, Birte Glenthoj, Mette Nielsen

S247. GENDER DIFFERENCES IN FUNCTIONALITY IN INPATIENT POPULATION AFFECTED WITH SCHIZOPHRENIA AND OTHER PSYCHOSIS
Siddarta Acebillo*, Rebeca García Collell, Lourdes Nieto, Carmina Massons, Noèlia Ortuño, Cristina Domènech, Jesus Cobo

S248. RELATION BETWEEN CHILDHOOD TRAUMA AND PSYCHOTIC SYMPTOMS IN SCHIZOPHRENIA
Amine Larnaout*, Rahma Nefzi, Amina Aissa, Rouaa Trabelsi, Zouhaier El Hechmi



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

S249. IS INTERNET HARMFUL FOR PSYCHOTIC PATIENTS?

Lucia Bonet, Blanca Llacer, Miguel Hernandez, David Arce, Ignacio Blanquer, Carlos Cañete, Maria Jose Escarti, Julio Sanjuan*

S250. RELATION BETWEEN PSYCHOPATHOLOGY AND QUALITY OF LIFE IN SCHIZOPHRENIA PATIENTS BEFORE AND AFTER FIRST ANTIPSYCHOTIC TREATMENT

Gitte Andersen*, Helle Schæbel, Sanne Wulff, Birte Glenthøj, Mette Ødegaard Nielsen

S251. QUALITY OF LIFE OF CHRONIC SCHIZOPHRENIA PATIENTS IN THE LONG TERM FOLLOW-UP

Diego Mendes*, Gustavo Mustafé, Thalita Fernandes, Thais Martins, Clarissa Dantas

S252. HEALTH CARE RESOURCE UTILISATION IS HIGHER IN PATIENTS PRIOR TO DIAGNOSIS WITH SCHIZOPHRENIA THAN NON-SCHIZOPHRENIA COMPARATORS IN A LARGE COMMERCIALY-INSURED POPULATION IN THE UNITED STATES

Anna Wallace, Keith Isenberg*, John Barron, Whitney York, Mayura Shinde, Matt Sidovar, Jessica Franchino-Elder, Michael Sand

S253. PERSON-CENTERED PSYCHOSIS CARE (PCPC) IN AN INPATIENT SETTING: PATIENT OUTCOMES

Anneli Goulding*, Katarina Allerby, Lilas Ali, Margda Waern

S254. IMPLEMENTATION OF A PROGRAM FOR EARLY INTERVENTION IN PSYCHOSIS ONSET: THE EXPERIENCE OF REGIONE EMILIA ROMAGNA, NORTHERN ITALY

Maria Ferrara*, Sinan Guloksuz, Shadie Burke, Flavia Baccari, Manuela Miselli, Alessio Saponaro, Mila Ferri, Vinod Srihari, Fabrizio Starace, Gruppo Regionale Esordi Psicotici

S255. METAPHORICAL CONCEPTUALIZATION OF SCHIZOPHRENIA AND THE CAREGIVING PROCESS FROM THE PERSPECTIVE OF PRIMARY FAMILY CAREGIVERS

Zhou De-Hui Ruth*, Chiu Yu-Lung Marcus, Lo Tak-Lam William, Lo Wai Fan Alison, Wong Siu Sing

S256. A META-ANALYSIS OF RECOVERY EDUCATIONAL AND AWARENESS INTERVENTIONS FOR MENTAL HEALTH PROFESSIONALS

Helena García-Mieres*, Francisco José Eiroa-Orosa

S257. EFFICACY OF CARIPRAZINE BY BASELINE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA: A POST HOC ANALYSIS OF 3 RANDOMIZED CONTROLLED TRIALS

Rick Mofsen*, Yan Zhong, György Németh, Ágota Barabássy, Willie Earley, Kelly Krogh

S258. THE FIRST EPISODE PSYCHOSIS OUTCOME STUDY: PRELIMINARY DATA ON THE LONG-TERM FOLLOW-UP OF FIRST EPISODE PSYCHOSIS PATIENTS WHO WERE TREATED AT THE EARLY PSYCHOSIS PREVENTION AND INTERVENTION CENTRE BETWEEN 1998-2000

Susan Cotton*, Andrew Mackinnon, John F Gleeson, Leanne Hides, Michael Berk, Helen Herrman, Kate Filia, Amity Watson, Aswin Ratheesh, Philippe Conus, Martin Lambert, Benno Schimmelmann, Patrick D. McGorry



S259. DOES EARLY INTERVENTION FOR PSYCHOSIS REDUCE HOSPITAL ADMISSIONS AND BED USAGE IN IRELAND?

Nuala Murray, Karen O'Connor*

S260. GENETIC LOADING FOR SCHIZOPHRENIA RISK INFLUENCES HIPPOCAMPAL SUBREGION VOLUMES

Lauri Tuominen*, Richard Vettermann, Tian Ge, Newfei Ho, Avram Holmes, Mert Sabuncu, Jordan Smoller, Phil Lee, Randy Buckner, Joshua Roffman, Daphne Holt

S261. ASSOCIATION BETWEEN FTO AND RDOC DIMENSIONS ACROSS TWO NEURODEVELOPMENTAL DISORDERS- ADHD AND PSYCHOTIC DISORDERS

Ridha Joober*, Sarogini Sengupta, Natalie Grizenko, Aurelie Labbe, Martin Lepage, Srividya Iyer, Ashok Malla, Rho Aldanie, Kathleen MacDonald

S262. STUDY OF NRN1 EXPRESSION IN BRAIN FROM SCHIZOPHRENIC PATIENTS

Marcos Moreno, Raúl Ortiz, Carmen Almodóvar*, Maria Guardiola, Luis F. Callado, Mar Fatjó-Vilas, Carme Gallego

S263. IMMUNE RESPONSE & SOCIAL COGNITION IN SCHIZOPHRENIA (IRELATE)

Caroline Cullen*, Niamh Daly-Ryan, Gary Donohoe, Michael Gill, Aiden Corvin



INDEX OF PRESENTERS AND AUTHORS*

Abdel-Baki, Amal	31	Ayesa-Arriola, Rosa	75, 107, 133
Abi-Dargham, Anissa	3, 42, 64	Azis, Matilda	94
Aboraya, Ahmed	132	Bachmann, Silke	68
Abrams, Daniel	92	Badan Ba, Maryse	137
Abut, Fatma Betül	92	Bahk, Won-Myong	90, 143
Acebillo, Siddarta	145	Bakker, P. Roberto	114
Adams, Rick	122	Barch, Deanna	4
Addington, Jean	5	Barnes, Catherine	103
Adery, Laura Hieber	145	Barron, David	132
Adorjan, Istvan	87	Basson, Wilna	89
Adrian Noviar, Galoeh	78	Batty, Rachel	74, 105
Agarwal, Sri Mahavir	143	Baumann, Philipp	73, 139
Ahmed, Anthony	83	Beasley, Clare	64
Ahuir Perez, Maria Isabel	116	Begemann, Marieke	13, 57
Ajnakina, Olesya	46, 81, 133	Benavides, Caridad	98
Akgul, Ozge	13, 115	Benros, Michael	53, 69
Alameda, Luis	38, 118	Bentea, Eduard	32, 115
Albert, Nikolai	60, 72	Bentsen, Havard	70
Al-Diwani, Adam	66	Beresniewicz, Justyna	114
Allott, Kelly	38, 58, 72, 141	Bernardini, Francesco	131
Allswede, Dana	13, 145	Berretta, Sabina	30
Almeida, Valéria	30, 115	Berry, Alexandra	78, 137
Almodóvar, Carmen	83, 147	Bertolino, Alessandro	4
Alptekin, Koksal	132	Bertolucci, Bruno	79, 107, 134
Altamirano, Olivia	107	Bhattacharyya, Sagnik	37
Alústiza, Irene	128	Bhavsar, Vishal	64
Alvarez Astorga, Aldara	102	Biedermann, Falko	73
Alvarez-Jimenez, Mario	4, 26	Bighelli, Irene	116
Amato, Davide	125	Bird, Jessica	125
Amminger, G. Paul	69, 97, 122	Birnbaum, Michael	59, 107
Amoretti, Silvia	119	Bittner, Robert	37
An, Suk Kyoan	86	Blackman, Graham	50
Anand, Ravi	73	Blackman, Rachael	101
Andersen, Gitte	146	Bless, Josef	68, 117
Anderson, Kelly	61, 108	Blest-Hopley, Grace	78
Andrea, Alexandra	129	Bloomfield, Michael	30
Ania, Fiksinski	102, 134	Bo, Qijing	123
Anna-Karin, Olsson	106	Bogers, Jan	100
Anne-Kathrin, Fett	40	Bojesen, Kirsten	96
Anticevic, Alan	37	Boks, Marco	53
Antonucci, Linda	13, 59	Bolhuis, Koen	98, 140
Arango, Celso	4, 5, 47	Bonivento, Carolina	75
Armio, Reetta-Liina	138	Bora, Lee	131
Austin, Stephen	80	Borgan, Faith	113

* The Index of Authors and Presenters includes only First Authors of Posters, Speakers of Plenary Sessions, Symposia, and Workshops.



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Bortolato, Marco	72	Chekroud, Adam	13, 78
Bortolon, Catherine	130	Chelini, Gabriele	99
Bortz, David	125	Chen, Eric	3, 5, 16, 58
Bose, Anushree	127	Chiramberro, Marcelo	127
Bowie, Christopher	5	Chisholm, Katharine	124
Boyette, Lindylou	108	Choi, Joonho	130
Braff, David	36	Chu, Min-yi	130
Bralet, Marie-Cécile	107, 145	Chung, Yoonho	139
Brannigan, Ross	135	Cieslak, Kristina	131
Breier, Alan	65	Clementz, Brett	31
Brennand, Kristen	36	Cobo, Jesus	133
Bressan, Rodrigo	4, 5	Colizzi, Marco	143
Bristow, Greg	99	Collin, Guusje	56
Bronstein, Michael	76	Conn, P. Jeffrey	64
Bryce, Shayden	130	Conus, Philippe	5, 38, 99
Bryl, Karolina	119	Cooper, Helen	42
Bubl, Emanuel	27	Corcoran, Cheryl	41, 124
Buchanan, Robert	3, 4	Correll, Christoph	4, 5
Buckley, Peter	3	Corsi-Zuelli, Fabiana	97
Burdick, Katherine	4, 5	Costas, Javier	140
Burrer, Achim	83	Cotel, Marie	87
Busatto, Geraldo	3	Cotter, David	47, 50
Cabrera Llorca, Bibiana	96	Cotter, Jack	76, 102
Cabungcal, Jan Harry	27	Cotton, Susan	55, 93, 121, 146
Calkins, Monica	48, 116	Coughlin, Jennifer	28
Calvo, Ana	51	Coutinho, Luccas	77
Camilla, Avagliano	118	Crippa, Jose Alexandre	37
Campbell, Alastair	14, 23	Croft, Jazz	134
Campbell, Dónal	119	Cropley, Vanessa	50, 83
Campos, Rosa Catalan	94	Crossley, Nicolas	90
Cannon, Mary	4, 5, 46	Cryan, John F.	14, 15, 63
Cannon, Tyrone	3, 5, 36	Cullen, Alexis	16, 59, 69
Cao, Hengyi	13, 52	Cullen, Caroline	147
Caravaggio, Fernando	13, 138	Czamara, Darina	38
Carey, Eleanor	141	Czepielewski, Leticia	13, 75
Carpenter, William T.	14, 15, 28, 39, 47	Daniel, David	73
Carruthers, Sean	75, 102	Dantas, Clarissa De Rosalmei	128
Carter, Cameron	4, 5, 71	Dark, Frances	100
Castle, David J.	4, 77	Datta, Dibyadeep	37, 72
Castro, Mariana	112	Daumit, Gail L.	14, 15, 29
Cavalcante, Daniel	58	David, Anthony	4
Cecchi, Guillermo	54	Davidson, Michael	26
Ceylan, Deniz	129	Davies, Cathy	136
Cha, Saetbyeol	137	Dawson, Neil	98
Chadha, Radhika	13, 140	Dazzan, Paola	3, 4, 5, 47
Chan, Raymond	5, 124	Deakin, Bill	48
Chang, Wing Chung	74, 93, 101, 133	Dean, Brian	64
Chavez-Baldini, UnYoung	117	Deenik, Jeroen	142

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



de Freitas, Rosana	133	Fazel, Seena	29
de Girolamo, Giovanni	4, 5	Ferchiou, Aziz	79
de Jong, Steven	100	Fernandez-Egea, Emilio	130
Del-Ben, Cristina	81	Ferrara, Maria	13, 108, 146
DeLisi, Lynn	3, 4, 5, 31, 36, 121	Ferraro, Laura	54, 105
Del Re, Elisabetta	4, 16, 51	Ferri, Francesca	40
Demmin, Docia	140	Fervaha, Gagan	13, 129
Dempster, Kara	91	Filipčić, Igor	105
Deshpande, Smita	4	Filipčić, Ivona Šimunović	105
Di Biase, Maria	51	Filipova, Nina	141
Dickerson, Faith	55, 65	Fioramonte, Mariana	47
Dickson, Hannah	75	Firmin, Ruth	120
Diez, Alvaro	86	Firth, Joseph	13, 141
Di Forti, Marta	30, 57, 71	Fisher, Helen	38, 57
Di Sarno, Elaine	92	Fleishhacker, Wolfgang	4
Do, Kim	3, 10, 27, 38	Flores, Cecilia	42
Dollfus, Sonia	4, 5	Föcking, Melanie	50
Dolmer, Signe	73	Fonseca, Lais	57
Dong, Fang	101	Fonville, Leon	139
Donohoe, Gary	48	Fortea, Adriana	85
Dorner-Ciossek, Cornelia	72	Foss-Feig, Jennifer	107
Draheim, Henning	75	Foussias, George	117
Drake, Richard	47	Fraguas, David	96
Drosos, Petros	144	Francis, Emma	53
D'Souza, Deepak	5, 37	Franco, Ana Luiza	104
Duan, Jubao	36	Francini, Maurizia	125
Dumais, Alexandre	127	Fu, Susie	103
Du Plessis, Stéfan	132	Fusar-Poli, Paolo	48
Dwyer, Dominic	78, 119	Gadelha, Ary	85
Eisner, Emily	89	Gaisler-Salomon, Inna	90
Elise, Leroux	138	Galderisi, Silvana	3
Elkis, Helio	106	Gallego, Juan	96
Emsley, Robin	4, 5	Galletly, Cherrie	74, 91, 93, 111, 142
Engelstad, Katharina	103	Galletti, Chiara	89
Engemann, Kristine	46	Galli, Aurelio	42
Espinosa, Justo Pinzón	125	Galling, Britta	61, 91
Estrada, Francesc	103	Gama, Clarissa	112
Evans-Lacko, Sara	46	Ganapathiraju, Madhavi	86, 115
Fachim, Helene	123	García-Carmona, Juan-Antonio	91
Faerden, Ann	132	García-Mieres, Helena	92, 119, 146
Faikai, Peter	3	Garcia-Rizo, Clemente	94
Faiola, Eliana	137	Garrett, Chantel	26
Faith, Laura	131	Garzitto, Marco	76
Falkai, Peter	4, 31	Gass, Peter	115
Falkenberg, Irina	88	Gaughran, Fiona	16, 55
Farhang, Sara	93	Gawne, Timothy	70
Farias de Sousa, Ana Elisa	88	Geaghan, Michael	140
Fathian, Farivar	130		



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Geerts, Hugo	114, 143	Hansbauer, Maximilian	126
Gehr, Johannes	145	Hargreaves, April	128
Geraets, Chris	127	Harris, Anthony	87
Giersch, Anne	27, 40	Harris, Kamelia	95
Gifford, George	136	Hartmann, Jessica A.	16, 56, 71
Gilbert, Elsa	75	Hartry, Ann	58, 102, 132
Gilleen, James	89	Harvey, Philip	40, 91, 120
Gilmore, John	56	Haselden, Morgan	61
Giordano, Annalisa	69	Hasson-Ohayon, Ilanit	128
Giordano, Giulia	106	Haugen, Ingvild	130
Gisela, Sugranyes	71	Hauke, Daniel	119
Glynn, Shirley	93, 120	Hawar, Moradi	79
Gohari, Vina	123	Hawco, Colin	83
Gohar, Sherif M.	97	Hazan, Hadar	125
González-Blanco, Leticia	70, 145	Healy, Colm	57
González-Rodríguez, Alexandre	90, 118	Heaney, Lisa	118
Gooding, Diane	89	Heckers, Stephan	3
Gopal, Srihari	72, 118	Heinz, Andreas	42
Goulding, Anneli	146	Heinz, Kareen	133
Goyal, Parth	141	Hemager, Nicoline	101
Grace, Anthony	5, 16, 50	Heres, Stephen	121
Granger, Kiri	129	Herold, Christina	75, 113
Grazioplene, Rachael	120	Hidalgo-Mazzei, Diego	26
Grech, Adrienne	125	Hielscher, Emily	135
Green, Melissa	97, 127	Hietala, Jarmo	66
Green, Michael	3	Hilker, Rikke	92
Greenwood, Kathy	82	Hirano, Yoji	13, 69
Gregersen, Maja	125	Hjelmervik, Helene	113
Grent-'t-Jong, Tineke	126	Hjorthoej, Carsten	59, 131
Greve, Aja	103	Hofer, Alex	5
Griffiths, Sian	58	Holland, Jessica	122
Grigoriou, Markella	79	Homan, Philipp	13, 123
Groc, Laurent	66	Hong, Kyung Sue	4
Groot, Christopher	89	Hopkins, Seth	79
Gruber, Oliver	109	Howes, Oliver	5, 31, 66
Guardiola, Maria	76	Hua, Lingling	137
Guimaraes, Francisco	30	Hughes, Rebecca	99
Guimond, Synthia	70	Hwang, Tzung-Jeng	86
Gupta, Anoop	141	Hwang, Wu Jeong	114
Gyllenberg, David	121	Hyötyläinen, Tuulia	66
Haas, Shalaila	102	Iasevoli, Felice	90, 118, 144
Hafizi, Sina	138	Ichinose, Megan	37, 88
Hagi, Katsuhiko	131	Iglesias, Sandra	124
Hahn, Margaret	56	Ilzarbe, Daniel	85
Haidl, Theresa	68	İncedere, Aysel	144
Hajdúk, Michal	103, 130	Irani, Sarosh	66
Hakala, Mika	60	Iruretagoyena, Barbara	108, 131
Hall, Mei-Hua	121	Isenberg, Keith	146



Isohanni, Matti	76, 144	Kim, Do-Won	86
Isvoranu, Adela-Maria	132	Kim, Euitae	136
Ithal, Dhruva	74	Kim, Eun Jin	127
Iversen, Trude	91	Kim, Moon Doo	122
Iwata, Yusuke	13, 123	Kim, Pitna	115
Iyegbe, Conrad	124	Kim, Seoyoung	137
Jacobs, Grace	97	Kim, Seung Hyun	141
Jakobsen, Ane	130	Kim, Soo-Jeong	117
Jauhar, Sameer	13, 52	Kim, Sung-Wan	5, 84, 142
Jessen, Kasper	113	Kim, Tae Yong	104
Ji, Ellen	82	Kim, Yong Sik	90
Johannessen, Jan Olav	5, 111	Kim, You-Na	94
Johansson, Viktoria	50	Kimhy, David	31
Jon, Duk-In	106	Kiras, Fatma	111
Jones-Brando, Lorraine	77	Kircher, Tilo	109
Jones, Hannah	13, 109, 135	Kirschner, Matthias	52, 111
Jones, Peter	5, 28	Klauser, Paul	30, 110
Jongsma, Hannah	46	Klein, Hans	130
Jooper, Ridha	147	Knable, Michael	109, 141
Joo, Yeon Ho	112	Koblan, Kenneth	26
Joy, Atienza	125	Koike, Shinsuke	135
Joyce, Dan	80	Kokkinou, Michelle	60
Jung, Sra	113	Kølbæk, Pernille	13, 126
Just, David	96	Kontis, Dimitrios	101, 128
Kahn, René	3, 5, 47	Koren, Dan	46, 89, 117, 122
Kane, John	64	Kotov, Roman	28
Kang, Shi Hyun	117	Kott, Alan	74
Kang, Yuree	95	Koutsouleris, Nikolaos	5
Kao, Amy	104	Kowalchuk, Chantel	118
Kapur, Shitij	3, 5	Kraguljac, Nina	51
Karmacharya, Rakesh	140	Krebs, Marie-Odile	5
Katthagen, Teresa	82	Krężolek, Martyna	76, 103
Kebir, Oussama	38	Krivoy, Amir	126
Keefe, Richard	3	Kruiper, Caitlyn	118
Kegeles, Lawrence	27	Krynicky, Carl	73
Keinänen, Jaakko	112	Krystal, John	14, 15, 25, 64
Kelleher, Eric	75	Ku, Benson	81
Kelleher, Ian	59	Kusztrits, Isabella	106
Kelly, Deanna	87	Kwon, Young-Joon	91, 140
Kennedy, James	4	Laezza, Fernanda	32
Kenney, Joanne	76	Lahti, Adrienne	41
Kepinska, Adrianna	87	Lalousis, Paris Alexandros	110
Keshavan, Matcheri	4, 36	Laloyaux, Julien	107
Ketharanathan, Tharini	96	Langbein, Kerstin	71, 97
Khan, Anzalee	79, 109	Laprevote, Vincent	82
Khandaker, Golam	48	Larnaout, Amine	80, 145
Kidd, Sean	38	Lasalvia, Antonio	46
Killackey, Eoin	4, 5, 120	Lattanzi, Guido Maria	138



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Leboyer, Marion	47	Malla, Ashok	5, 11
Lee, Eunbyeol	101	Mallikarjun, Pavan	111
Lee, Jimmy	117	Mansueto, Giovanni	54
Lee, Junghee	37	Mantyla, Teemu	82
Lee, Jung Suk	107	Maples, Natalie	38
Lee, JungSun	138	Margolis, Russell	113
Lee, Junhee	86	Marques, Tiago Reis	48
Lee, Kwanghun	79, 114	Martins-De-Souza, Daniel	41, 47
Lee, Kyuyoung	139	Martins, Thaís	76
Lee, Sang-Hyuk	114	Marzullo, Giovanni	88
Lee, Sang-Yeol	93, 117	Maziade, Michel	27
Lee, Tae Young	90	McCullumsmith, Robert	32, 47
Lee, Yu Sang	93	McDaid, David	14, 15, 49
Legind, Christian	53	McDonnell, David	118
Lemvigh, Cecilie	98	McGorry, Patrick D.	3, 5, 9, 41, 80
Lennox, Belinda	66	McGuire, Philip	4, 37, 48
Lepage, Martin	84	McQueen, Grant	52
Leucht, Claudia	60	Meador-Woodruff, James	47
Leucht, Stefan	16, 60	Mehtala, Tuukka	38
Lewis, Shon	4, 16, 61	Meier, Madeline	27
Li, Anna	87	Melau, Marianne	61
Li, Huijun	71, 95	Melle, Ingrid	5
Li, Mingli	51, 139	Mendes, Diego	146
Li, Zhi	13, 136	Menezes, Paulo	4
Liddle, Peter	82	Metzak, Paul	13, 137
Lim, Eunsung	116	Meunier-Cussac, Sophie	71
Lindenmayer, Jean-Pierre	72, 101, 142	Meyer-Kalos, Piper	120
Lindgren, Maija	128	Meyer-Lindenberg, Andreas	5, 46
Linscott, Richard	77, 104	Mezquida, Gisela	128
Liu, Chen-Chung	109, 143	Miettunen, Jouko	108
Liu, Chenxing	13, 114	Mikanmaa, Emmi	110
Liu, Siwei	110	Minah, Kim	13, 123
Loch, Alexandre	134	Mingoia, Gianluca	82, 109, 135
López-Carrilero, Raquel	133	Minichino, Amedeo	80
Lopez, Daisy	133	Minyaycheva, Maria	92
Louzada-Junir, Paulo	96	Mittal, Vijay	41
Lubeiro Juárez, Alba	139	Mizrahi, Romina	41
Luteijn, L.B.	104	Mizuno, Masafumi	5
Luther, Lauren	126	Modinos, Gemma	51
Lyall, Amanda	88	Mofsen, Rick	146
Lynn, Marquardt	116	Moghaddam, Bitá	5, 42
MacCabe, James	64	Mollon, Josephine	40, 102
Maguire, Áine	130	Mongan, David	119
Mahmoudi, Ebrahim	140	Monserat, Clara	142
Maj, Mario	5	Moreira, Fabricio	30
Mäki, Pirjo	80	Morgan, Craig	28, 48
Makowski, Carolina	13, 85	Morgan, Vera	4, 5
Malchow, Berend	31, 77	Morkved, Nina	122

FINAL PROGRAM

FLORENCE, ITALY

4 – 8 APRIL 2018



Morris, Crystal	93	Ohi, Kazutaka	102
Morrison, Sinead	53	Ojeda, Natalia	127
Mortensen, Preben	4, 5	Oliveira, Hianna	78
Mouchlianitis, Elias	51	Oliver, Dominic	120
Muckenhuber-Sternbauer, S.	113	Oliver, Lindsay	145
Mueller, Daniel J.	87, 95, 143	Olsson-Tall, Maivor	107
Mueller, Daniel R.	100	O'Neill, Aisling	136
Mueller, Toni	115	Ongur, Dost	30
Mulert, Christoph	28	Oresic, Matej	66
Müller, Bernhard	72	Orlov, Natasza	13, 83, 110
Müller, Flavia	99	Østefjells, Tiril	68
Murray, Robin	3, 28, 46	Ostergaard, Soren Dinesen	126
Mustafé, Gustavo	106	Overholser, James	134
Myin-Germeyms, Inez	5	Oviedo Salcedo, Tatiana	106
Nam, Beomwoo	132	Owen, Michael	31
Nascimento, Juliana	30	Paccalet, Thomas	71, 98
Nefzi, Rahma	77, 105, 133, 141	Palaniyappan, Lena	12, 52, 82, 84, 86, 88, 89, 95, 97, 122
Neill, Erica	129	Pan, Pedro	13, 80
Nelson, Barnaby	4, 5, 40	Pantelis, Christos	4, 5, 28
Nemoto, Takahiro	119	Papaleo, Francesco	42
Nenadic, Igor	5, 84, 112	Papazova, Irina	129
Neumann, Suzanne	128	Pardeller, Silvia	145
Neves, Gilda	144	Park, Kee Jeong	98
Nielsen, Anita Tønder	55	Park, Kiho	100
Nielsen, Mette	16, 52	Park, Sohee	3, 37, 40
Nieman, Dorien	5	Parola, Alberto	81, 120
Niendam, Tara	26	Pasternak, Ofer	28
Nijman, Henk	29	Patel, Maxine	5
Nijman, Saskia	144	Patel, Rashmi	78, 118
Nikita, Setiawan	96	Pauselli, Luca	84, 105, 142
Nilsson, Peter	47	Pau, Soldevila-Matias	136
Nilsson, Sandra Feodor	57	Pedersen, Carsten	81
Nimgaonkar, Vishwajit	65	Pedersen, Emilie	109
Noordsy, Douglas	4	Peitl, Vjekoslav	132
Nordentoft, Merete	3, 16, 57	Penades, Rafael	124
Notter, Tina	48	Penney, Danielle	77
Nour, Matthew	136	Penzel, Nora	114
Nuechterlein, Keith	31	Peredo Nunez de Arco, Rossana Katherca	77
Nunez, Daniel	58	Perez, Stephanie	59
Nuss, Philippe	121	Perez, Jesus	48
Ochoa, Susana	68, 91, 100, 128	Perez-Rodriguez, M. Mercedes	100
O'Connor, Karen	147	Perkins, Diana	5, 65
Odejayi, Gbolahan	144	Persson, Mats	70
O'Donnell, Patricio	4, 5	Peters, Emmanuelle	4
O'Donoghue, Brian	80, 108, 134	Petros, Natalia	134
O'Hanlon, Erik	85	Phahladira, Lebogang	106
O'Hare, Kirstie	140		
Oh, Hyeonju	105		



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Pieters, Lydia	122	Rolls, Asya	14, 15, 45
Pignon, Baptiste	13, 81	Romanowska, Sylvia	129
Pijnenborg, Marieke (Gerdina)	38	Rosenbrock, Holger	135
Pikalov, Andrei	101	Rosengard, Rachel	85
Pillinger, Toby	13, 96, 123	Rosen, Marlene	92
Pinheiro, Ana	135	Rossell, Susan	3, 4, 16, 54, 74, 116
Pinnock, Farena	77, 132	Roussos, Panos	86
Piontkewitz, Yael	87	Rowland, Laura	32
Plana Ripoll, Oleguer	55	Roy, Martin	104
Plitman, Eric	13, 113	Rubinstein, Katya	13, 81
Pollak, Thomas	66, 123	Rubio, Jose	13, 60, 91
Ponnampalam, Meneshka	119	Ruderfer, Douglas	36
Porffy, Lilla	103	Ruhrmann, Stephan	5
Pries, Lotta-Katrin	53	Rund, Bjorn	140
Pross, Benjamin	139	Russo, Manuela	58
Puig-Navarro, Olga	71, 98	Ruth, Zhou De-Hui	146
Pujol, Nuria	100	Salgado, Joao	30
Purves-Tyson, Tertia	65	Salisbury, Dean	112, 138
Quarto, Tiziana	69	Salokangas, Raimo	121
Quattrone, Diego	13, 28, 79	Sami, Musa	105
Qubad, Mishal	137	Sanchez-Gutierrez, Teresa	104
Raballo, Andrea	40	Sand, Michael	74
Raedler, Thomas	4	Sanfelici, Rachele	86
Ramsay, Hugh	108	Sanjuan, Julio	78, 109, 146
Ramsey, Amy	32	Santesteban-Echarri, Olga	77, 98
Ranganathan, Mohini	37	Sanz-Fuentenebro, Francisco J.	90
Rao, Naren	84	Sasabayashi, Daiki	139
Rapisarda, Attilio	71, 108, 122	Savage, Christina	106
Rapp, Alexander	74	Sawada, Ken	113
Rauschenberg, Christian	79, 95	Scarpazza, Cristina	13, 124
Reay, William	114	Schalbroeck, Rik	56
Reichenberg, Abraham	40, 54	Schäppi, Lea	88
Reinhart, Robert	116	Scheffler, Frederika	13, 131
Reininghaus, Ulrich	28	Schlagenhauf, Florian	110
Reniers, Renate	91	Schlögelhofer, Monika	73
Reser, Maree	116, 141	Schmidt, André	13, 56
Richard, Jean-Romain	78	Schmitt, Andrea	41
Richetto, Juliet	72	Schnack, Hugo	59, 112
Riecher-Rössler, Anita	4, 5	Schneider, Maude	42
Riehle, Marcel	142	Schneider-Thoma, Johannes	68, 144
Rikandi, Eva	52	Schofield, Peter	57
Rimvall, Martin K.	56, 124	Schooler, Nina	3
Riva, Marco Andrea	90	Schultze-Lutter, Frauke	61, 97, 142
Rødevand, Linn	131	Schwab, Sibylle	4
Rodriguez, Victoria	102	Scott, James	66
Roeh, Astrid	126	Seccomandi, Benedetta	88
Rogdaki, Maria	139	Seidman, Larry	4
Rokita, Karolina	122		



Selten, Iris	97	Sumner, Philip	110
Selvaggi, Pierluigi	53	Sun, Xiaoqi	79
Sendt, Kyra-Verena	13, 136	Surti, Toral	75
Seo, Ho Jun	117	Suvisaari, Jaana	66
Seo, Hye-Jin	89	Suzuki, Kazunori	143
Seppälä, Jussi	81	Svendsen, Ingrid	142
Serpa, Mauricio	88	Takao, Hensch	27
Setién-Suero, Esther	13, 103	Takeuchi, Hiroyoshi	107
Seves, Mauro	112	Talkowski, Michael	36
Shafner, Laura	73	Tamagnan, Gilles	83
Shah, Jai	48	Tan, Eric	13, 74, 120
Shang, Jing	111	Tandon, Rajiv	100
Siddiqui, Ishraq	117	Tangmose, Karen	137
Sigvard, Anne	136	Tang, Yingying	96
Silverstein, Steven	27	Teigset, Charlotte	101
Simmons, Adam	143	Thara, Rangaswamy	5
Simonsen, Arndis	128	Thorup, Anne Amalie	115
Sinkeviciute, Igne	60	Thuné, Hanna	111
Siskind, Dan	64, 84	Tian, Ye	111
Sjöström, Nils	92, 116, 141	Tianmei, Si	4
Smesny, Stefan	4, 70, 95	Tibbo, Philip	77, 114
Smith, Eleanor	116	Tiihonen, Jari	64
Smith, Thomas	61	Tocco, Michael	68, 100, 129
So, Joyce	114	Tognin, Stefania	94
Soares, Walter	134	Tomiello, Sara	50
Soler Garcia, Jordi	123	Tordesillas-Gutiérrez, Diana	85, 105, 138
Solida, Alessandra	137	Torgalsboen, Anne-Kari	75
Sommer, Iris	3, 4, 5	Torniainen-Holm, Minna	55
Song, Min-Kyu	95	Torregrossa, Lénie	40, 54, 88
Sonnenschein, Susan	125	Torretta, Silvia	87
Sormunen, Elina	108	Torrey, E. Fuller	29
Soto, Marta	144	Tortelli, Andrea	81
Sparano, Olga	89	Tost Bonet, Meritxell	104
Spoorthy, Mamidipalli	13, 120	Toutountzidis, Diamantis	95
Sportel, Bouwina	105	Traber-Walker, Nina	98
Srihari, Vinod	5	Tripoli, Giada	129
Sriretnakumar, Venuja	140	Trotta, Antonella	58
Srivastava, Deepak	56	Tseng, Huai-Hsuan	13, 137
Stabell, Lena	127	Tully, Laura	26
Stafford, Jean	13, 134	Tuominen, Lauri	147
Stain, Helen	120	Uhlhaas, Peter	27, 142
Stainton, Alexandra	130	Umbricht, Daniel	26, 126
Stansley, Branden	13, 72	Upthegrove, Rachel	48, 123
Stegmayer, Katharina	13, 83	Uranova, Natalya	41
Steiner, Johann	30, 41	Urban, Alexander	36
Strube, Wolfgang	13, 144	Urquijo, Maria F.	70
Subramaniam, Karuna	13, 110	Ursini, Gianluca	13, 16, 53
Sumiyoshi, Chika	145	Vahdani, Bitá	13, 127



6th Schizophrenia International Research Society Conference

Integrated Prevention and Treatment: Shifting the Way We Think

Valiengo, Leandro	73	Weber-Stadlbauer, Ulrike	65
van Amelsvoort, Therese	109	Webster, Maree	42
van der Leeuw, Christine	69	Weibell, Melissa	78
van der Merwe, Nicolaas	140	Weickert, Cynthia Shannon	14, 15, 35, 65
van der Ven, Els	93	Weickert, Thomas	5, 50
Van der Zalm, Yvonne	64	Weijers, Jonas	126
Vandavelde, Anaïs	139	Weiner, Ina	65
van Dijk, Floor	61	Weiser, Mark	3, 4, 29
Vanes, Lucy	136	Weiske, Johanna	81
Van Haren, Neeltje	5, 54, 101	Weiss, Catherine	73
van Os, Jim	5	Wellstein, Katharina	104
Vanover, Kimberly	99, 126	Wenneberg, Christina	69
Van Snellenberg, Jared	42	Wichers, Marieke	31
van Tol, Marie-José	83	Wong, Keri	124
van Zelst, Catherine	46	Woo, Tsung-Ung Wilson	99
Veijola, Juha	59	Wood, Stephen	4, 5
Veling, Wim	5, 108	Woodberry, Kristen	54, 71
Velligan, Dawn	3, 4, 5, 38	Woodward, Melissa	113
Velthorst, Eva	40	Wright, Abigail	92
Ventura, Joseph	74	Wunderink, Alexander	5
Ver Loren van Themaat, Anna Hester	115	Wykes, Til	3
Vermeulen, Jentien	55	Xiao, Lan	41, 115
Vernal, Ditte Lammers	124	Xu, Junzhe	86
Vernon, Anthony	65	Yalcin, Nadir	127
Vicente, Molina	138	Yang, Lawrence	46
Vieira, Sandra	51	Yildiz, Mustafa	119
Vignapiano, Ananrita	106	Yohn, Samantha	13, 90
Viher, Petra	85	Yolken, Robert	65
Vila-Badia, Regina	92	Yolland, Caitlin	103
Vingerhoets, Claudia	13, 85, 138	Yoon, Bo-Hyun	99
Vinogradov, Sophia	3	Young, Jared	98
Vita, Antonio	4	Yuen, Hok Pan	135
Voineskos, Aristotle	4, 5	Yung, Alison	4, 5
Volkow, Nora	42	Zai, Clement	68
Vucurovic, Ksenija	135	Zammit, Stanley	80, 108
Wakuda, Tomoyasu	110	Zaytseva, Yulia	82
Walker, Elaine	36	Zhand, Naista	109
Walther, Sebastian	89	Zhang, Chengcheng	70, 116
Waltz, James	41	Zhang, Landan	78
Wang, Yi	101	Zhang, TianHong	36, 132
Waterreus, Anna	131	Zhou, Fuchun	129
Watson, Andrew	76	Zhou, Juan	28
Weber, Lilian	111	Zipursky, Robert	4, 5, 29, 144
		Zugman, Andre	112

